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ABSTRACT 
Lantibiotics are ribosomally-synthesized and post-translationally modified peptides 
(RiPPs) characterized for exerting antimicrobial activity against bacterial strains resistant to 
commonly used antibiotics. During lantibiotic biosynthesis different enzymes install various 
post-translational modifications (PTMs) in a precursor peptide important for conferring their 
biological activity. Understanding how these biosynthetic enzymes catalyze their respective 
reactions is central to further develop these compounds for therapeutic applications. This 
dissertation presents the biochemical characterization of different lantibiotic biosynthetic 
enzymes responsible for the dehydration, decarboxylation, halogenation, and proteolysis of 
selected lantibiotics. 
During class I lantibiotic biosynthesis selected Ser/Thr residues in a precursor peptide are 
dehydrated by a lantibiotic dehydratase. Biochemical and structural studies in collaboration with 
the Nair Laboratory identified lantibiotic dehydratases to be glutamyl-tRNAGlu-dependent 
enzymes. The role of glutamyl-tRNAGlu in the dehydration process, the generality of glutamyl-
tRNAGlu usage by lantibiotic dehydratases, as well as identity elements within the tRNA needed 
for recognition by lantibiotic dehydratases were established. A co-crystal structure of a 
lantibiotic dehydratase in complex with its substrate peptide is discussed, providing the first 
insights into substrate recognition by these enzymes. In addition to dehydroamino acids, selected 
lantibiotics may contain additional unusual PTMs such as decarboxylations and halogenations. In 
this thesis, the substrate specificity of a lantibiotic cysteine decarboxylase and a lantibiotic 
tryptophan halogenase was characterized using mass spectrometry and bioinformatic approaches. 
In contrast to many other lantibiotic biosynthetic enzymes, which employ the use of a leader 
peptide for substrate recognition, both enzymes catalyzed their respective reactions in a leader 
peptide independent manner. The potential of both enzymes to be used as general tools for 
modifying non-cognate peptides for various applications was investigated and discussed.  
Finally, the last step in lantibiotic maturation involves the removal of an N-terminal 
leader peptide by a lantibiotic peptidase. Bioinformatic, kinetic and mass spectrometry analysis 
revealed a consensus motif within precursor peptides important for cleavage by these peptidases. 
The use of this enzyme as a general tool for leader peptide removal from other RiPPs is explored 
and discussed. Together this dissertation signifies fundamental advances in RiPP biosynthesis 
with direct implications in the bioengineering of such compounds for clinical uses. 
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Chapter 1. Ribosomally Synthesized and Post-Translationally Modified Peptides: 
An Untapped Source of Natural Products for Therapeutic Applications 	
1.1. Introduction 
The different biological activities together with the presence of many unique 
pharmacophores accounts for the profound impact natural products have on society (1-3). Within 
natural products, a class that has garnered recent attention is the ribosomally synthesized and 
post-translationally modified peptides (RiPPs). Unlike non-ribosomal peptides, which need large 
multimodular enzyme complexes to incorporate non-proteinogenic amino acids into a peptide 
backbone (4), RiPPs are capable of accessing a similar degree of chemical diversity through 
extensive post-translational modifications of a ribosomally synthesized precursor peptide 
(Figure 1.1a) (5). This diversification allows RiPPs to possess a wide variety of structural 
features (Figure 1.1b) endowing these peptides with different biological activities such as 
antifungal, antibacterial, allelopathic, and antiviral (6-8). The different biological activities 
associated with these compounds has sparked a growing interest in this class of peptides for their 
potential to be used for therapeutic purposes. In addition, the small genetic fingerprint associated 
with the RiPP biosynthetic machinery (Figure 1.1a) makes RiPPs attractive for combinatorial 
biosynthesis and synthetic biology applications. Collectively, RiPPs represent an untapped 
source of chemical moieties with a vast potential to benefit society in multiple ways that range 
from the identification of novel biologically active chemical scaffolds to the characterization of 
unique biochemistry useful for chemoenzymatic applications.  
RiPPs are classified into more than 15 different subfamilies based on the structural 
framework present in the mature compound and on the biosynthetic machinery responsible for 
installing such features (9). Irrespective of the subfamily, RiPPs share several commonalities 
within their biosynthetic pathways. RiPP biosynthesis commences with the ribosomal translation 
of a precursor peptide encoded within a genome. Two distinct structural features are typically 
present within this precursor peptide, namely an N-terminal leader peptide sequence and a C-
terminal core region harboring the different post-translational modification sites (Figure 1.1a). 
In some cases a C-terminal recognition sequence needed for biosynthesis is present in select 
RiPP subfamilies (9). The biosynthetic machinery, which is also generally encoded within the 
same genomic neighborhood as the precursor peptide, recognizes the leader peptide and installs a 
	 2 
	
Figure 1.1 Overview of RiPP biosynthesis. (a) General biosynthetic pathway employed during RiPP biosynthesis. 
Each gene color represents a distinct biosynthetic enzyme and is color-coded in association to the modification it 
catalyzes. Dotted circles represent amino acids within the leader peptide. Full circles represent amino acids within 
the core region. (b) Chemical structures of selected RiPP subfamily members. Structural features defining a 
particular RiPP subfamily are shown in blue. Additional post-translational modifications are shown in red. RiPP 
subfamily class is labeled in italics. 
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myriad of different post-translational modifications in the core region (Figure 1.1a). These post-
translational modifications allow the installation of structural motifs otherwise not accessible by 
the native ribosomal machinery (Figure 1.1b). Following modification of the core region, the 
leader peptide is removed by a peptidase to yield the mature active compound (Figure 1.1a). In 
some cases additional post-translational modifications occur in the core region following the 
cleavage of the leader peptide.  
A distinct feature among RiPPs is the presence of characteristic amino acid motifs within 
the RiPP biosynthetic machinery. These motifs can be used as query sequences for the 
identification of novel RiPP biosynthetic gene clusters through genome mining approaches (10, 
11). Sequencing efforts of the last decade together with the implementation of genome mining 
platforms for secondary metabolites like antiSMASH (12) or ClusterFinder (13) have made it 
clear that the RiPP biosynthetic machinery is widely distributed in all three domains of life. Such 
approaches have confirmed the view that the great structural diversity found within RiPPs is 
achieved with a limited number of biosynthetic enzymes. In fact, some previously characterized 
peptides, like the polytheonamides, were once thought to originate from a non-ribosomal 
biosynthetic pathway but are instead made through the action of a small number of enzymes 
using a post-ribosomal peptide modification strategy (14). This observation abolishes the once-
held notion that only organisms with a vast genetic complexity are capable of accessing 
structurally diverse chemical scaffolds. As a result, genomic analysis of previously neglected 
organisms has proven that indeed they too have the potential to be a reservoir of RiPPs (10, 15, 
16).  
To fully exploit the hidden potential behind RiPPs it is important to develop a clear 
understanding of their biosynthetic pathways. Only then, rationalized efforts could be undertaken 
to develop RiPPs for commercial and clinical applications. During my dissertational work I 
focused towards understanding the logic behind the biosynthesis of lantibiotics, a family of 
peptides within RiPPs. Despite being one of the most studied RiPPs, several aspects regarding 
the enzymatic mechanism by which lantibiotics obtain their characteristic post-translational 
modifications and how the biosynthetic machinery mediated recognition of the N-terminal leader 
peptide were considered enigmatic at the time.  
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1.2. Lantibiotics and their potential as clinical antibiotics  
The widespread and accelerating bacterial resistance to antibiotics is a major problem that 
faces our society and needs to be addressed. In United States alone, around 23,000 out of 2 
million patients die per year as a direct consequence of a bacterial infection caused by antibiotic 
resistant strains (17). Unfortunately, pharmaceutical companies have reduced or in most cases 
eliminated their antibiotic discovery programs, due to the low success rate and lower revenues 
associated with the development of antibiotics when compared to other pharmaceuticals (18, 19). 
To prevent bacterial outbreaks of multi-drug resistant pathogenic strains, new antibiotics capable 
of evading resistance are greatly needed. One promising class of compounds with such capability 
is the lantibiotics (20).  
Lantibiotics are antimicrobial polycyclic peptides that belong to the lanthipeptide 
subfamily of RiPPs (9). Lanthipeptides are characterized for the presence of thioether linkages 
containing the bis-amino acids (2S,6R)-lanthionine (DL-Lan) and (2S,3S,6R)-3-
methyllanthionine (DL-MeLan) (Figure 1.2) (21). Recently, the structural characterization of the 
cytolysin revealed for the first time that lanthipeptides can also contain the isomer (2R,6R)-
lanthionine (LL-Lan) and/or (2R,3R,6R)-3-methyllanthionine (LL-MeLan) (Figure 1.2) (22). In 
addition many lanthipeptides also have the α,β-unsaturated amino acids 2,3-didehydroalanine 
(Dha) and (Z)-2,3-didehydrobutyrine (Dhb) within their structures (Figure 1.2) (23). The number 
and arrangement of Lan/MeLan thioether crosslinkages varies among different members 
highlighting the structural diversity encompassed within this RiPP subfamily (Figure 1.2) (24). 
Besides being responsible for endowing lanthipeptides with their respective biological activities, 
the thioether rings also contribute to the increased metabolic and chemical stability of these 
peptides when compared to their linear counterparts (25-30).  
Different biological activities have been associated with lanthipeptides in recent years 
including antifungal and antinociceptive activities (6, 8, 31). However many members of this 
RiPP subfamily exert potent antimicrobial activity (thus the name lantibiotic for lanthionine-
containing antibiotic) against several Gram-positive drug resistant bacterial pathogens. For 
example the lantibiotic NAI-107 (also called microbisporicin) (Figure 1.2) showed promising 
activity against methicillin and vancomycin-intermediate resistant Staphylococcus aureus, 
vancomycin-resistant Enterococcus sp., and penicillin-resistant Streptococcus pneumoniae.  (32). 
In the cases studied against a panel of human pathogens, microbisporicin potency compared to 
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Figure 1.2 Representation of the structural topology of selected lanthipeptides. The common post-translational 
modifications present in lanthipeptides are colored. Each amino acid is represented by its three-letter code. The 
nisin-like and mersacidin-like lipid II binding motif is shown in an orange and brown circle respectively. Ring 
structures are labeled with alphabet letters. Figure adapted from ref. (24). 
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the activity of the antibiotic vancomycin and in most cases surpassed nisin’s bioactivity, the only 
lantibiotic currently used commercially in the food industry (32, 33). Microbisporicin was also 
able to inhibit the growth of several gram-negative bacterial strains including species from the 
genus Neisseria, Moraxella, and Haemophilus (32). Moreover, the potential of microbisporicin 
as a useful therapeutic agent came from its efficiency at reducing the bacterial load of multi-drug 
resistant pathogens from in vivo acute lethal infection mice models (34). The potential of 
lantibiotics to be used in the clinic is further underscored by the lantibiotics actagardine and 
cinnamycin, both in clinical development for the treatment of Clostridium difficile infections and 
cystic fibrosis, respectively (35-37). Alluring to the use of lantibiotics in a clinical setting is the 
observation that these polycyclic peptides appear to be relatively unaffected by the development 
of resistant bacteria. For instance, the lantibiotic nisin (Figure 1.1b and 1.2) has been used 
worldwide for over 40 years as a preservative to combat food-borne pathogens without 
significant development of bacterial resistance (33). This unique property is thought to be a 
consequence of nisin’s dual mode of action: pore formation in bacterial cell membranes and 
stalling of peptidoglycan biosynthesis by sequestering the cell wall precursor lipid II (38-40). 
Lipid II is a membrane-bound intermediate essential for bacterial cell wall biosynthesis. 
This precursor consists of a bactoprenol lipid carrier linked via a pyrophosphate moiety to a 
disaccharide unit of N-acetylglucosamine (GlcNac) and N-acetylmuramic acid (MurNac) further 
decorated with a pentapeptide chain (41-43) (Figure 1.3a). The main role of lipid II is to serve as 
a carrier of GlcNac/MurNac which is utilized by the peptidoglycan biosynthetic machinery to 
assemble the bacterial cell wall common to all eubacteria (Figure 1.3a) (44). Two main reactions 
are involved in the final steps of peptidoglycan assembly: the transglycosylation of the GlcNac-
MurNac disaccharide unit onto a growing lipid II-tethered glycan polymer followed by 
transpeptidation of the MurNac pentapeptide chain, crosslinking adjacent glycan polymers 
(Figure 1.3a) (45-47). Several peptidoglycan layers (~20) are used to build the cell wall 
characteristic of gram-positive bacteria. Each layer is composed of multiple glycan polymers that 
consist of 50 to 250 disaccharide units each. However it has been estimated that each bacterial 
cell only contains a limited pool of lipid II precursors (48-50). As a result peptidoglycan 
biosynthesis is a rapid and dynamic process. This ensures a high turnover rate of lipid II 
molecules guaranteeing the availability of this precursor through out cell wall biosynthesis (51). 
Any disturbance in this process results in cell death since the cell wall is vital and integral for 
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maintaining stability and viability of bacterial cells. Consequently the essentiality of lipid II for 
bacterial cell wall biosynthesis coupled to the inability of bacteria to synthesize an alternative 
carrier molecule for the peptidoglycan building blocks are believed to be possible reasons as to 
why nisin do not elicit a bacterial resistance response despite its widely use in the food industry.  
The N-terminal A and B rings of nisin are involved in binding to lipid II. Nuclear 
magnetic resonance (NMR) studies revealed that nisin utilize this motif as a cage to engage the 
lipid II pyrophosphate moiety. The spatial arrangement of nisin’s A and B rings into this 
pyrophosphate cage structure ensures a suitable conformation for the peptide backbone to 
mediate hydrogen interactions with the lipid II pyrophosphate head (52) (Figure 1.3b). Nisin 
binding to lipid II results in the delocalization of this cell wall precursor preventing it from 
delivering the peptidoglycan units and thus inhibiting cell wall biosynthesis (40). The second 
mode of action of nisin is exerted by its C-terminus. Upon docking of nisin to lipid II, the C-
terminus of this lantibiotic is inserted into bacterial membranes causing the formation of pore 
complexes (38, 53, 54). Pore formation results in membrane depolarization, which subsequently 
leads to bacterial cell death (55). Notably, other lanthipeptide members also contain the N-
Figure 1.3 Inhibition of peptidoglycan biosynthesis by the lantibiotic nisin. (a) Schematic representation of the 
final steps in peptidoglycan biosynthesis. Lipid II provides the peptidoglycan building blocks, which are linked via a 
transglycosylation reaction to a growing peptidoglycan chain tethered to the membrane. In a second reaction, 
transpeptidation of the pentapeptide unit crosslinks adjacent peptidoglycan layers. Blue diamonds (MurNac) white 
circles (pentapeptide chain), red diamonds (GlcNac), yellow circle (phosphate), zigzag line (bactoprenol lipid 
carrier). (b) NMR solution structure of a nisin analog bound to a lipid II variant. The pyrophosphate cage is 
composed of the peptide backbone of residues compromising rings A and B of nisin. For clarity only the 
pyrophosphate moiety of lipid II and the N-terminal portion of nisin are shown. (P1) phosphate linked to MurNAC, 
(P2) phosphate linked to the bactoprenol lipid, (A) ring A in nisin, (B) ring B in nisin. (PDB: 1WCO) (52). 
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terminal nisin-like ring structure suggesting their capability of binding to lipid II as well (Figure 
1.2). For instance, recent NMR characterization and mode of action studies confirmed that 
microbisporicin exerts its antimicrobial activity via biding to lipid II (56). However due to the 
shorter C-terminus of microbisporicin, stable nisin-like pores were not observed. Similar 
observations have been made for the lanthipeptides gallidermin, and mutacin 1140. These two 
lantibiotics are able to bind to lipid II however they do not induce pore formation presumably 
due to their C-terminus not being long enough to span target membranes (57-59) (Figure 1.2). 
The lanthipeptides haloduracin α, mersacidin, and actagardine are also capable of 
inhibiting cell wall biosynthesis by interacting with lipid II (60-65). However these peptides are 
not capable of mediating pore formation and lack the characteristic nisin-like lipid II binding 
motif (Figure 1.2). Biding studies using mersacidin as a model system revealed this peptide 
lacked affinity for lipid I (lipid II precursor without GlcNac) suggesting recognition to be 
different from nisin and mediated by the GlcNac sugar (65). Furthermore, mutational studies on 
this lantibiotic revealed a conserved Glu residue within a C-terminal MeLan ring (Figure 1.2, C 
ring in mersacidin) to be important for mediating Ca+-dependent binding interactions to lipid II 
(66). The conservation of this ring among other lanthipeptide members highlights its importance 
for lanthipeptide bioactivity constituting an additional lipid II binding motif (Figure 1.2). 
Noteworthy several lanthipeptides like epilancin 15X are able to mediate pore formation as well 
(67). However these lanthipeptides do not contain the characteristic lipid II-binding motif present 
in nisin or mersacidin suggesting they may target a different bacterial cellular component yet to 
be identified (67, 68).  
Despite the promising antimicrobial activities exhibited by members of this RiPP 
subfamily several obstacles hinder their development as therapeutics. For instance, even though 
nisin was capable of eliciting a positive response during in vivo infection mice models, its poor 
pharmacokinetics led to its rapid blood clearance (69). Two possible alternatives could be 
employ to overcome such hurdles. Genome mining offers an opportunity to identify 
lanthipeptides with different structural variations that could lead to more stable compounds for a 
wide variety of applications as it was recently reported for the lanthipeptide geobacillin I (70). 
Another alternative is to logically modify the structure of these peptides in order to increase their 
stability and pharmacokinetic properties. To fully exploit the latter option a thorough 
understanding of lanthipeptide biosynthesis is needed. 
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1.3. Biosynthesis of lanthipeptides 
Thought to be biosynthesized only by Gram-positive bacteria, lanthipeptides can also be 
produced by Gram-negative bacteria as revealed by recent genome mining approaches (16, 71). 
In all cases, lanthipeptide biosynthesis initiates in the bacterial cytoplasm with the ribosomal 
translation of a precursor peptide termed LanA (Figure 1.4a). Similar to most RiPPs, this 
precursor peptide consists of an N-terminal leader peptide and a C-terminal core region, which 
becomes the final mature lanthipeptide (21). The characteristic Lan and MeLan crosslinks in 
lanthipeptides are installed post-translationally in a two-step process (Figure 1.4b). First, 
selected Ser and Thr residues within the LanA core region are dehydrated to Dha and Dhb 
residues, respectively. Cys thiols are then conjugated via a Michael-type addition onto the α,β-
unsaturated amino acids to yield Lan or MeLan rings. Most of the lanthipeptides characterized to 
date contain a D configuration at the Cα of the former dehydroamino acid generated from the si 
face attack of the Cys thiol. However, more recently the L configuration was found on 
lanthipeptide ring’s containing the amino acid motif Dhx-Dhx-Xxx-Xxx-Cys (Dhx-
dehydroamino acid, Xxx-any amino acid except Cys) (22). The presence of two consecutive 
Figure 1.4 Overview of lanthipeptide biosynthesis. (a) Schematic representation of lanthipeptide biosynthesis. 
Each circle represents an amino acid. A line connecting circles represents a thioether crosslinkage. (b) Chemical 
scheme of (methyl)lanthionine formation during lanthipeptide biosynthesis. Selected Ser/Thr in the core region of a 
precursor peptide are dehydrated followed by the conjugation of Cys thiols onto the unsaturated amino acids. Two 
Lan/MeLan isomers could be generated based on the directionality by which the Cys thiol attacks the double bond. 
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dehydroamino acids impose a conformational constraint within the precursor peptide responsible 
for inverting the face selectivity of the Michael type cyclization but still retaining overall anti 
addition (72). Consequently, the inversion of the Cys attack results in the formation of the 
unusual LL-(Me)Lan isomer (Figure 1.4b). Examples exhibiting this uncommon thioether ring 
isomer are the lanthipeptides haloduracin β and geobacillin II (72). Following the post-
translational modifications a dedicated transporter, normally encoded within the biosynthetic 
gene cluster, is responsible for secreting the modified peptide outside the cell (Figure 1.4a) (73). 
A membrane bound lanthipeptide protease then removes the leader peptide releasing the mature 
active compound (74). While many lanthipeptides follow this biosynthetic logic, notably, some 
members deviate from this scheme at latter stages of their biosynthesis. For instance, within the 
microbisporicin biosynthetic gene cluster, no open reading frame coding for a peptidase is 
present (75). This observation has led to the speculation, of an endogenous protease not involved 
in lanthipeptide biosynthesis as being responsible for removing the leader peptide from this RiPP. 
In addition, the peptidase that removes the leader during epilancin 15X biosynthesis is a 
cytoplasmic protease and not a membrane bound enzyme (68). 
 
1.3.1. Lan and MeLan formation in lanthipeptides  
Four different strategies are employed by nature to afford the installation of Lan/MeLan 
containing rings in lanthipeptides and serves to further classify this RiPP subfamily into four 
different classes (I, II, III, IV) (Figure 1.5a) (71). Class I lanthipeptides, exemplified by nisin, 
epilancin 15X, microbisporicin, geobacillin I, and Pep5 (Figure 1.2), need two enzymes to 
catalyze Lan/MeLan formation. A lanthipeptide dehydratase (also known as lantibiotic 
dehydratases) termed LanB is responsible for dehydrating Ser/Thr residues within a precursor 
peptide core region (LanA). A separate enzyme, a lanthipeptide cyclase commonly termed LanC, 
then catalyzes the Michael-type addition of Cys thiols onto the newly formed dehydroamino acid.  
Class I lanthipeptide dehydratases are ~100 kDa proteins that share very little homology 
to members within the same enzyme family (< 30% seq. id.) and no homology at all with 
proteins in the non-redundant protein database. LanB enzymes are predicted to have three 
distinct conserved domains including an N-terminal lantibiotic dehydratase N-terminus, a central 
lantibiotic dehydratase C terminus, and a C-terminal SpaB_C domain named based on the shared 
sequence similarity to the C-terminus of SpaB, a lantibiotic dehydratase involved in subtilin 
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biosynthesis (Figure 1.5a) (76). Functional characterization of LanB enzymes as being 
responsible for the dehydration step in lanthipeptide biosynthesis came from genetic studies 
using the Pep5 biosynthetic machinery as a model system. Gene deletion studies of the 
lanthipeptide dehydratase PepB resulted in the accumulation of non-dehydrated PepA (Pep5 
precursor peptide) suggesting PepB to be involved in dehydration of Ser/Thr residues (77). 
However, a direct biochemical link between class I lanthipeptide dehydratases and their putative 
function only came 18 years later with the in vitro reconstitution of the lanthipeptide dehydratase 
NisB involved in nisin biosynthesis (78). NisB dehydration activity was recently shown to 
proceed via glutamylation of Ser/Thr residues in the precursor peptide NisA followed by 
glutamate elimination (Figure 1.5b) (78). Reconstitution of NisB activity required the presence 
of an unidentified cofactor present in Escherichia coli cells. This observation provides an 
explanation for previous failed attempts at reconstituting the activity of these enzymes in vitro 
(79). The identity of the cofactor required for NisB activity is still unknown and as such the 
characterization of the molecular mechanism for glutamate utilization employed by NisB 
remains elusive (78). 
Following dehydrations a lanthipeptide cyclase catalyzes the formation of MeLan/Lan 
rings on the precursor peptide LanA. Structural and biochemical characterization of the 
lanthipeptide cyclase NisC, involved in nisin biosynthesis, have revealed the mechanism 
Figure 1.5 Overview of the four different lanthipeptide biosynthetic machinery. (a) Domain organization of the 
enzymes responsible for Lan/MeLan formation. The generic name associated with each enzyme is shown. Lant_N, 
lantibiotic dehydratase N-terminus, Lant_C, lantibiotic dehydratase C-terminus. (b) Proposed mechanism of 
dehydroamino acid formation for each class of lanthipeptide biosynthetic machinery. 
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employed by these enzymes (80, 81). Class I lanthipeptide cyclases are metalloproteins that 
utilize a bound Zn2+ ion to activate Cys thiols in the precursor peptide for nucleophilic attack 
onto Dha/Dhb residues (Figure 1.5a). The Zn2+ ion is coordinated by the side chains of a 
conserved Cys-Cys-His triad essential for catalytic activity as determined by NisC mutagenesis 
studies (81). While the activity of class I lanthipeptide dehydratases and cyclases have been 
reconstituted individually in vitro, it is believe both enzymes form a membrane-associated 
multioligomeric complex in vivo where dehydrations and cyclizations within the precursor 
peptide occurs in a cooperative and alternating mechanism (82-84).  
The thioether rings in class II lanthipeptides, exemplified by cinnamycin, lacticin 481, 
nukacin, actagardine, and mersacidin (Figure 1.2), are installed by a bifunctional lanthionine 
synthetase, termed LanM. LanM proteins contain an N-terminal dehydratase domain and a C-
terminal cyclase domain homologous to class I lanthipeptide cyclases (Figure 1.5a). Despite the 
absence of sequence homology to known protein kinases, dehydrations in class II lanthipeptides 
proceed through the ATP-dependent phosphorylation of Ser/Thr followed by phosphate 
elimination to yield Dha/Dhb (Figure 1.5b) (85). Recent structural characterization of the class 
II lanthionine synthetase CylM, involved in cytolysin biosynthesis, revealed the N-terminal 
dehydratase domain adopts an unexpected catalytic fold characteristic of eukaryotic lipid kinases, 
though lacking sequence homology (86). Co-crystallization studies with AMP and mutagenesis 
data revealed that the kinase active site and the phosphate elimination active site are spatially 
overlapping. This structural arrangement suggests that phosphorylation and phosphate 
elimination in class II lanthionine synthetases occurs in a processive manner. The observed ADP 
dependency of the phosphate elimination reaction and the absence of detectable phosphorylated 
precursor peptide intermediates provide additional evidence supporting this claim (86, 87). The 
C-terminal domain of CylM has a similar fold as the lanthipeptide cyclase NisC suggesting 
LanMs catalyzes Michael-type additions in an analogous way as class I lanthipeptide cyclases 
(80, 86).  
Members from the lanthipeptide classes III and IV are modified by trifunctional 
lanthionine synthetases termed LanKC and LanL, respectively (88, 89). These synthetases are 
characterized for containing an N-terminal phospho-Ser/phospho-Thr lyase domain, a central 
Ser/Thr kinase domain and a C-terminal cyclase domain (Figure 1.5a). While the C-terminal 
domain of LanLs share sequence similarity to class I lanthipeptide cyclases, the corresponding 
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domain in class III synthetases shares little homology to LanCs (24). In addition, the LanKC 
putative cyclase domain lacks the residues involved in Zn2+ binding characteristic of class I 
cyclases suggesting these enzymes utilize an alternative mechanism to catalyze thioether ring 
formation (89). Interestingly, besides the characteristic Lan/MeLan rings present in 
lanthipeptides, selected class III members contain an additional carbacyclic moiety termed 
labionin. The labionin moiety is believed to originate from a nucleophilic attack of the enolate, 
generated upon Lan formation, onto a second Dha moiety (90). Biochemical characterization of 
class III and IV synthetases has shown that dehydrations of their respective substrates occur via 
phosphorylation of Ser/Thr residues followed by phosphate elimination (89, 91). However, 
different to LanM enzymes, LanKC mediated dehydrations are believed to be catalyzed via a 
step-wise phosphorylation/elimination as observed from the accumulation of phosphorylated 
intermediates during the processing of the class III lanthipeptide curvopeptin (92). Interestingly 
while LanM and LanL synthetases have been shown to only utilize ATP as the phosphate donor, 
AciKC involved in the maturation of the class III lanthipeptide catenulipeptin, was capable of 
utilizing ATP, GTP, CTP, and TTP (93). Similarly, CurKC the synthetase involved in the 
biosynthesis of curvopeptin also displayed relaxed substrate specificity towards NTPs (94). The 
relaxed NTPs specificity observed for AciKC and CurKC is not shared among other class III 
LanKCs. For instance, LabKC, a class III synthetase involved in the biosynthesis of 
labyrinthopeptin A2, was only active in the presence of GTP/dGTP (89). The molecular 
interactions responsible for the NTP specificity observed for class III synthetases are still 
unknown. 
 
1.3.2. Leader peptide removal during lanthipeptide biosynthesis 
Irrespective of the lanthipeptide class, the final maturation step during lanthipeptide 
biosynthesis involves the removal of the N-terminal leader peptide. Removal of the leader 
peptide in class I lanthipeptides is performed by a subtilisin-like serine peptidase generally 
termed LanP. The involvement of LanP in the processing of class I leader peptides has been 
inferred from genetic and in vivo studies (74, 95). In addition only EpiP, the peptidase involved 
in epidermin biosynthesis, has been reconstituted in vitro (96). Consequently little is known 
about the substrate specificity governing the selectivity of this type of peptidases.  
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Class II leader peptides are removed by a bi-functional enzyme generally termed LanT. 
LanT enzymes are responsible for exporting the modified precursor peptide outside the cell with 
concomitant proteolysis of the leader peptide after a highly conserved Gly-(Gly/Ala/Ser) 
sequence motif (Figure 1.6) (97). Three conserved domains are present within these enzymes: an 
N-terminal papain-like Cys protease domain, a central ATP-binding cassette (ABC) 
transmembrane domain, and a C-terminal ABC transporter domain. Reconstitution of the N-
terminal protease domain of LctT, involved in lacticin 481 biosynthesis, revealed this domain 
was sufficient for leader peptide removal from the precursor peptide LctA (98). Other LanT 
enzymes for example NukT, required the presence of the C-terminal ABC transporter domain for 
efficient substrate processing suggesting a cooperative function between leader peptide removal 
and translocation of the modified precursor peptide (99). Besides recognition of the Gly-
(Gly/Ala/Ser) sequence motif, LanT enzymes recognize secondary structural elements within 
their respective substrates as observed from the lower efficiency LctT had at removing the leader 
peptide from LctA mutants lacking a predicted helical structure within the leader peptide. (98). 
In addition to LanT enzymes, some class II lanthipeptide members employ the use of a second 
protease responsible for removing a short N-terminal oligopeptide. In these cases LanTs first 
remove most of the leader peptide and in a second proteolytic event a subtilisin-like serine 
peptidase homologous to class I LanPs remove a remaining short six amino acid sequence (100).  
The leader peptide of class III lanthipeptide members is removed by prolyl-
oligopeptidases (POP) (101). Similar to LanPs, these peptidases use a nucleophilic serine for 
amide bond hydrolysis on their respective substrates but belong to a different enzyme family 
(102). POP enzymes are characterized for cleaving amide bonds C-terminal to Pro residues. As 
of today, no peptidase has been characterized associated with class IV lanthipeptide biosynthetic 
gene clusters. 
 
1.3.3. Role of the leader peptide during lanthipeptide biosynthesis 
A unifying feature among all lanthipeptide classes is the use of a leader peptide during 
biosynthesis. This leader peptide varies in length and composition among the different classes. 
However, conserved amino acid motifs within the leader peptide can be identified for each class 
(e.g. the amino acid sequence F-N-L-D for class I, E-L-X-X-I-L for class II, I-L-E-L-Q for class 
III, and L-P-E-T for class IV) (Figure 1.6). Several functional roles have been proposed for the
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Figure 1.6 Sequence conservation in lanthipeptide leader peptides. Multiple sequence alignment of selected 
lanthipeptide leader peptides from (a) class I, (b) class II, (c) class III, and (d) class IV. Conserved regions are 
highlighted in different colors based on class. The following precursor peptides were used for the analysis NisA 
(nisin), GeoA1 (geobacillin I), SpaS (subtilin), ElxA (epilancin 15X), MibA (microbisporicin), EpiA (epidermin), 
LctA (lacticin 481), NukA (nukacin), VarA (variacin), MutAII (mutacin II), RumA (ruminococcin A), Bvi79A 
(butyrivibiocin), LabA1 (labyrinthopeptin A1), LabA2 (labyrinthopeptin A2), NAI-112, RamS (SapB), AmfS, AciA 
(catenulipeptin), CurA (curvopeptin), VenA (venezuelin), GCF_147 (precursor peptides identified bioinformatically 
in ref. (103). Name in parenthesis refers to the name of the mature lanthipeptide. 
 
leader peptide. These include acting as a recognition sequence for translocation of the modified 
precursor peptide to the extracellular environment, as a protective mechanism by keeping the 
lanthipeptide inactive, as an allosteric effector trapping an active conformation of the 
lanthipeptide biosynthetic machinery, and as a guide for lanthipeptide biosynthetic enzymes to 
install the different post-translational modifications within the precursor peptide’s core region 
(104). Recent reports using the lanthipeptide biosynthetic machinery from classes I, II, and III, 
have provided additional evidence supporting the last two roles. 
Many lanthipeptides contain the same type of modification across different parts of the 
core peptide region (Figure 1.2). More surprisingly, in some cases a single enzyme installs the 
same post-translational modification in a regio- and stereo- specific manner in multiple different 
substrates (105, 106). As such, it is difficult to envision a single enzyme being sufficiently 
tolerant to accommodate a variety of sequences within an active site and at the same time 
specific enough to only modify its cognate substrate. Nature solves this paradox in a very elegant 
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way by partially deconvoluting substrate recognition from catalysis within the lanthipeptide 
biosynthetic machinery. In this model most of the binding interactions are provided by an 
invariable amino acid sequence within the precursor peptide that is not directly engaged by the 
enzyme’s active site, namely the leader peptide.  
Studies using the nisin biosynthetic machinery suggested that the lanthipeptide 
dehydratase NisB and cyclase NisC were capable of partially modifying a leaderless NisA 
precursor peptide. When the NisA leader peptide was provided in trans the extent of 
modifications in the NisA core region increased. Similar results have been observed for other 
lanthipeptides, including lacticin 481 (class II) and catenulipeptin (class III), where enzymatic 
efficiency was increased by providing the leader peptide either in trans, fused to the enzyme, or 
covalently attached to the core peptide (wild-type substrate) (93, 107-109). These results suggest 
the leader peptide potentiates enzymatic activity through binding interactions with the 
lanthipeptide biosynthetic machinery. However, the observed enzymatic activity in the absence 
of a leader peptide suggests that the lanthipeptide biosynthetic machinery also recognizes to 
some extent the core peptide.  
Fluorescence polarization assays revealed synergistic binding of the HalA2 leader 
sequence and core peptide by its cognate class II lanthionine synthetase HalM2 (110). HalM2 is 
responsible for installing three dehydrations and four thioether rings in the precursor peptide 
HalA2 (111). HalM2 affinity (Kd) for the HalA2 leader peptide and its unmodified precursor 
peptide was measured to be within the micromolar range. Very weak affinity was measured for 
just the HalA2 core region (> 500 µM). However, by providing the leader peptide fused to the 
lanthionine synthetase HalM2, the binding affinity for the HalA2 core region increased by 6 fold 
(110). This result is consistent with a model where leader peptide binding presumably induces a 
conformational change on the enzyme increasing its affinity for the core peptide sequence. 
Consequently, by recognizing the invariable leader peptide the lanthipeptide biosynthetic 
machinery could then have relaxed substrate specificity towards different portions of a core 
region.  
 Several mutational studies on lanthipeptide leader peptides from class I, II, and III have 
been performed to dissect functional domains within this region important for recognition by the 
biosynthetic machinery. Using an in vivo copurification strategy it was shown that NisB and 
NisC copurified from pull down assays using NisA variants lacking Ser, Thr, or Cys residues 
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within the core region (112). This result suggests that the sites of modification within NisA are 
not crucial for binding to the nisin biosynthetic machinery. On the other hand, reduced amounts 
of NisB and NisC were copurified when the FNLD motif within the NisA leader peptide (23 
residues long) (Figure 1.6a, red) was mutated using alanine-scanning mutagenesis, suggesting 
this region to be crucial for binding (113). Surface plasmon resonance and isothermal titration 
calorimetry measurements have been employed to determine the binding constants (Kd) between 
the NisA leader peptide and either NisB or NisC respectively (114, 115). In agreement with the 
in vivo studies, these in vitro experiments have shown that mutating the FNLD box in the NisA 
leader peptide abolishes NisC and NisB binding completely. Together these studies suggest a 
binding mechanism where both the lanthipeptide dehydratase and cyclase compete for the same 
binding site in the precursor peptide (FNLD motif).  
 Conserved regions in the leader peptide of class II and III have been identified to be 
important for efficient recognition and processing by their respective lanthipeptide synthetases. 
Many class II lanthipeptides have a conserved E-L-X-X-I-L motif towards the C- terminus of 
their leader peptides (Figure 1.6b, blue). Mutational studies on the leader peptide of LctA 
suggested that the identity of each amino acid within this motif was not essential for 
dehydrations and cyclizations since a similar modification extent was observed for various LctA 
mutant peptides when compared to wild-type substrate (116). However, upon disruption of the 
predicted helical character of the E-X-X-I-L motif in LctA, LctM activity was diminished 
suggesting lanthionine synthetases recognize secondary structural elements within the class II 
leader peptides (116).  
Similar results have been reported for the interaction between class III lanthipeptide 
synthetases and their respective substrates. Class III lanthipeptides are characterized for 
containing a conserved I-L-E-L-Q towards the N-terminus of their leader peptide region (Figure 
1.6c, green). Double point mutations on this conserved region decreased the LabKC catalyzed 
modification extent of the class III lanthipeptide LabA2 (117). This result suggests that 
interactions between class III lanthipeptide synthetases and their substrates are not mediated by 
single amino acids and instead the full conserved region contributes to efficient recognition by 
these enzymes. Similar plasticity has been observed for class I and II lanthipeptides. Moreover, 
disruption of the predicted helical character found in the N-terminal region of the precursor 
peptide substrate LabA2 also decreased LabKC activity (117). Studies aimed at characterizing 
	 18 
conserved regions of class IV lanthipeptide leader peptides (Figure 1.6d, yellow) important for 
efficient processing by their respective synthetases have not been performed yet. While 
mutational studies have provided an window for identifying important interactions between 
leader peptides and the lanthipeptide biosynthetic machinery, the absence of structural models of 
these enzymes in complex with their respective substrates prevents further molecular 
characterization of the leader peptide recognition mechanism employed by the lanthipeptide 
biosynthetic machinery. 	
1.3.4. Additional post-translational modifications present in lanthipeptides and their 
potential for combinatorial biosynthesis 
The intrinsic relaxed substrate specificity and modularity reported for the lanthipeptide 
biosynthetic machinery (80, 118) as well as the brevity of their biosynthetic pathways makes 
lanthipeptides an excellent combinatorial biosynthetic platform for the generation of post-
translationally modified peptide variants. Using the different post-translational modifications as a 
“chemical toolbox,” this technology in principle could engineer different peptides with improved 
chemical stability or novel biological activities through the introduction of various lanthipeptide 
structural scaffolds. For instance, novel lanthipeptides carrying non-cognate post-translational 
modifications have been generated from the combination of enzymes from different 
lanthipeptide biosynthetic pathways (119). In addition, the lanthipeptide dehydratase NisB and 
cyclase NisC have been used to increase the stability of therapeutic peptides via introduction of 
thioether crosslinks (118, 120). Altogether the accumulated knowledge on lanthipeptide 
biosynthesis has provided researchers with the necessary and fundamental biochemical 
knowledge needed to exploit the potential of not only NisB and NisC but also of many other 
class II lanthionine synthetases such as LctM (121), to be used as tools to incorporate Dha, Dhb, 
MeLan and Lan residues into lantibiotics and non-lantibiotic therapeutic peptides. 
Interestingly, besides the common post-translational modifications (PTMs) characteristic 
of lanthipeptides (Dha, Dhb, Lan, MeLan) some members contain additional modifications 
including hydroxylations (cinnamycin), reductions (epilancin 15X), halogenations 
(microbisporicin), glycosylations (NAI-112), and decarboxylations (mersacidin) (Figure 1.7) (31, 
32, 68). These modifications are introduced by additional tailoring enzymes normally encoded 
within the lanthipeptide biosynthetic gene cluster. The presence of these PTMs allow for further 
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fine-tuning of the binding of lanthipeptides to their targets as well as releasing the structural 
constraints imposed on precursor peptides by the use of only proteinogenic amino acids. A 
further important improvement for lanthipeptide combinatorial biosynthesis would be to also 
utilize these additional posttranslational modifications (PTM) that have been identified in 
lanthipeptides (Figure 1.7) to generate additional peptide variants. This approach could serve to 
unveil an unexploited reservoir of compounds useful for different therapeutic purposes. At 
present, the use of these additional enzymes for lanthipeptide combinatorial biosynthesis has not 
been employed mainly because many of these enzymes have not been reconstituted in vitro and 
consequently their substrates specificities have not been characterized. 
Figure 1.7 Additional post-translational modifications present in lanthipeptides.  
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1.4. Summary and Outlook 
Lanthipeptides are ribosomally synthesized and post-translationally modified peptides 
(RiPPs) possessing a varied array of structural diversity. The antimicrobial activities associated 
with some of these compounds has sparked a growing interest in this class of peptides for their 
potential to be used for therapeutic purposes. Furthermore, the biochemistry employed by the 
lanthipeptide biosynthetic machinery exemplifies innovative strategies used by nature to append 
unique chemical scaffolds onto these peptides. Finally, the low genetic complexity, associated 
with the biosynthetic machinery responsible for installing the different post-translational 
modifications in lanthipeptides makes them excellent candidates for combinatorial biosynthesis 
approaches. Consequently, efforts aimed at understanding the biosynthetic pathways implicated 
in the generation of these post-translationally modified peptides are needed to fully exploit the 
lanthipeptide biosynthetic machinery for the generation of peptide scaffolds useful for a wide 
variety of applications.  
This dissertation reports on the biochemical characterization of several biosynthetic 
enzymes responsible for the post-translational modification during the biosynthesis of the class I 
lanthipeptides nisin, microbisporicin and epilancin 15X. The knowledge gathered from these 
studies was envisioned to be fundamental to advance bioengineering efforts towards the 
development of lanthipeptides for therapeutic applications. The studies presented in Chapter 2 
identified the lanthipeptide dehydratase NisB as a glutamyl-tRNAGlu-dependent enzyme. The 
identification of glutamyl-tRNAGlu as a co-substrate of NisB provided all the required 
constituents to reconstitute the activity of this enzyme in vitro. Additionally, structural 
characterization of NisB in complex with its substrate peptide NisA provided the first insights 
into the molecular mechanism used by the lanthipeptide biosynthetic machinery to recognize the 
leader peptide of their respective substrates. Taken together, the biochemical and structural 
characterization of NisB shed light on the enzymatic mechanism utilized by this enzyme to 
dehydrate its precursor peptide NisA. Building upon the studies in Chapter 2, in Chapter 3, the 
use of glutamyl-tRNAGlu as a general strategy employed by lanthipeptide dehydratases to 
catalyze the dehydration of Ser/Thr residues in class I lanthipeptides was determined. 
Furthermore, important identity elements within the tRNAGlu acceptor stem were identified to be 
crucial for efficient utilization of glutamyl-tRNAGlu by class I lantibiotic dehydratases. This 
knowledge led to the development of a heterologous expression system in Escherichia coli 
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suitable for the production of class I lanthipeptides. The methodology presented in Chapter 3 is 
projected to serve as a tool for the characterization of not only class I lanthipeptides but also of 
any other RiPPs biosynthesized in a tRNA-dependent manner thus increasing our potential of 
finding novel natural products. Chapter 4 aimed at characterizing the substrate specificity of the 
subtilisin-like serine peptidase ElxP responsible for removing the leader peptide from modified 
ElxA during epilancin 15X biosynthesis. ElxP substrate recognition involved the amino acid 
residues at position –5, –4, –1, and 1 from its substrate peptide ElxA (negative numbers indicate 
amino acids in the leader peptide region; positive number indicates amino acid in the core 
region). The substrate specificity observed in ElxP served to explore the potential of this 
peptidase as a tool to remove leader peptides from other non-cognate lanthipeptides. Finally, 
Chapter 5 describes the efforts undertaken towards the characterization of a flavin-dependent 
cysteine decarboxylase and a flavin-dependent tryptophan halogenase involved in the 
biosynthesis of microbisporicin. The substrate specificity of both enzymes was determined as 
well as their potential to be used for lanthipeptide combinatorial biosynthesis. Together, the 
studies presented in this dissertation provide fundamental knowledge that advances our 
understanding of lanthipeptide biosynthesis and will be beneficial in the characterization of 
additional RiPPs identified via genome mining approaches.   
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Chapter 2. Insights into the Dehydration Mechanism of Lantibiotic Dehydratases* 	
2.1. Introduction 
Twenty-six years since the characterization of the first lantibiotic gene cluster (1), the 
mechanism by which lantibiotic dehydratases (LanB) introduce dehydroamino acids in class I 
lantibiotics like nisin has remained enigmatic. Functional assignment of lantibiotic dehydratases 
as the enzymes responsible for dehydration of lantibiotics came from early in vivo and genetic 
studies on NisB, the lantibiotic dehydratase involved in nisin biosynthesis (2, 3) (Figure 2.1a) 
(please refer to Chapter 1 for more details). However biochemical reconstitution of lantibiotic 
dehydratases remained elusive for the subsequent thirteen years. Recently, a previous group 
member, Dr. Neha Garg, was able to reconstitute NisB activity in vitro. NisB was shown to 
dehydrate the precursor peptide NisA by activating serine and threonine residues via an 
unprecedented and cryptic glutamylation mechanism (Figure 2.1b) (4). However, NisB was only 
active in the presence of an unknown macromolecular component within Escherichia coli cell 
extract (4). In this chapter, I identified glutamyl-tRNAGlu as the key component needed to 
catalyze the formation of dehydroamino acids in class I lantibiotics. In addition, Prof. Satish K. 
Nair and his graduate student Yue Hao solved the co-crystal structure of NisB bound to its 
substrate peptide NisA, providing key information on the unprecedented glutamyl-tRNAGlu 
dependent esterification of Ser/Thr residues in NisA and offering the first insights into leader 
peptide binding and substrate recognition by lantibiotic dehydratases. 
 
2.2. Results 
2.2.1. Identification of glutamyl-tRNAGlu as an essential co-substrate for NisB activity 
In the previously proposed dehydration mechanism (4), glutamate needs to be activated 
prior to the formation of an ester linkage with the side chain of Ser/Thr residues in NisA. To 
identify the required component for activation, anion exchange chromatographic fractions of E. 
coli cell extracts were analyzed for supporting NisB-catalyzed dehydration activity on NisA by 																																																								*	Parts of this chapter are reprinted with permission from Ortega, M.A., Hao, Y., Zhang, Q., Walker, M.C., van der 
Donk, W.A., and Nair, S.K. (2015) Structure and Mechanism of the tRNA-dependent lantibiotic dehydratase NisB, 
Nature 517: 509–512. Copyright (2015) Nature Publishing Group. 
All structural studies presented in this Chapter were performed by Prof. Satish K. Nair and Yue Hao. 
Bioinformatic studies were directed by Dr. Qi Zhang and Dr. Mark Walker. 
 
	 33 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). 
The E. coli cell extract fractionated into two major fractions (Figure 2.2a). Surprisingly, the 
A260/A280 ratio for the fraction supporting in vitro NisB activity (Figure 2.2b-c) was 1.7, 
suggesting the presence of nucleic acids. To determine which type of nucleic acid was important 
for NisB activity, E. coli cell extract was treated with either DNase or RNase prior to 
dehydration assays. Treatment of E. coli cell extract with DNase did not prevent NisB-catalyzed 
dehydration of NisA but treatment with RNase abolished activity (Figure 2.2d-f). 
The requirements for glutamate and RNA suggested the possibility of a glutamyl-
tRNAGlu dependent dehydration process. I therefore cloned, expressed, and purified glutamyl-
tRNA synthetase (GluRS) as well as tRNAGlu from E. coli. MALDI-TOF MS analysis of NisA 
Figure 2.1 Biosynthesis of the lantibiotic nisin. (a) Post-translational modifications involved in nisin biosynthesis. 
NisB dehydrates Ser/Thr residues in the precursor peptide NisA via (b) glutamylation followed by Glu elimination 
to yield dehydroalanine (Dha, green) and dehydrobutyrine (Dhb, purple), respectively. NisC catalyzes the formation 
of lanthionines (red) and methyllanthionines (blue). NisP removes the leader peptide. Negative numbers represent 
the position of an amino acid in the leader peptide with respect to the core region. 
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after incubation with NisB, Glu, ATP, GluRS and tRNAGlu revealed up to eight dehydrations in 
NisA (Figure 2.3a-b). No activity was observed when GluRS, tRNAGlu, or NisB were omitted 
from the reaction assay (Figure 2.3c-e). The inability of NisB to dehydrate NisA in the absence 
of GluRS (Figure 2.3c) demonstrates that NisB does not aminoacylate tRNAGlu but instead 
utilizes the glutamyl-tRNAGlu synthesized in situ by GluRS. To probe this hypothesis I 
determined the aminoacylation extent of in vitro transcribed E. coli tRNAGlu by its cognate 
GluRS (Figure 2.4a) and performed dehydration assays with purified glutamyl-tRNAGlu. 
MALDI-TOF MS analysis confirmed glutamyl-tRNAGlu as the sole co-substrate needed for NisB 
activity (Figure 2.4b-d).  
Figure 2.2 RNA-dependent dehydration of His6-NisA. (a) Anion exchange chromatogram of E. coli BL21 (DE3) 
cell extract. Fractionation was monitored at 280 nm (blue trace) and sample was eluted using a NaCl gradient (red 
trace). Two major peaks were observed with a retention volume of 7.3 mL and 10.3 mL respectively. MALDI-TOF 
MS of His6-NisA after in vitro reaction with His6-NisB in the presence of (b) the 10.3 mL fraction, (c) the 7.3 mL 
fraction, (d) E. coli cell extract, and E. coli cell extract treated with (e) DNase or (f) RNase. Numbers above the 
mass spectra correspond to the number of dehydrations of His6-NisA after incubation with His6-NisB and the 
corresponding fraction. (M) His6-NisA (average mass calc. [M+H]+ 7996, obs. 7992), (3) three-fold dehydrated 
His6-NisA (average mass calc. [M+H]+ 7942, obs. 7941), (5) five-fold dehydrated His6-NisA (average mass calc. 
[M+H]+ 7906, obs. 7905), and (7) seven-fold dehydrated His6-NisA (average mass calc. [M+H]+ 7870, obs. 7870). 
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The observed NisB requirement for E. coli glutamyl-tRNAGlu raised the question whether 
the nisin producer strain, Lactococcus lactis, employs the same tRNA-dependent biosynthetic 
strategy. I therefore cloned, expressed, and purified L. lactis HP GluRS; isolated total RNA from 
L. lactis HP and performed in vitro NisA dehydration assays. MALDI-TOF MS analysis of NisA 
treated with NisB, Glu, ATP, and both purified components revealed up to eight dehydrations in 
NisA (Figure 2.5a). Omission of either L. lactis GluRS, L. lactis RNA, Glu, or NisB precluded 
dehydration activity (Figure 2.5b-e) Together, these results establish the use of glutamyl-
tRNAGlu by NisB to catalyze the formation of dehydroamino acids in nisin. 
Figure 2.3 Reconstitution of NisB activity in vitro. MALDI-TOF MS analysis of His6-NisA incubated with Glu, 
ATP and His6-NisB in the presence of (a) E. coli cell extract, (b) E. coli His6-GluRS and E. coli tRNAGlu (c) E coli 
tRNAGlu, (d) E. coli His6-GluRS, or (e) E. coli GluRS and E. coli tRNAGlu in the absence of His6-NisB. Numbers 
above the mass spectra represent the number of dehydrations of His6-NisA. (M) His6-NisA (average mass calc. 
[M+H]+ 7996, obs. 7993), (6) six-fold dehydrated His6-NisA (average mass calc. [M+H]+ 7888, obs. 7888), (7) 
seven-fold dehydrated His6-NisA (average mass calc. [M+H]+ 7870, obs. 7870), and (8) eight-fold dehydrated His6-
NisA (average mass calc. [M+H]+ 7852, obs. 7853). The small shoulder peaks seen at lower m/z to the left of the 
starting peptide (M) are the result of laser-induced deamination. These shoulder peaks are only observed for high 
molecular weight peptides (>6 kDa) and are not observed after proteolytic removal of the leader peptide ref. (35). 
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Figure 2.4 Glutamyl-tRNA dependent dehydration of His6-NisA. (a) Glutamylation of in vitro transcribed E. coli 
tRNAGlu by purified E. coli GluRS using L-[14C(U)]-glutamic acid (0.1 µCi µL–1, 260 mCi mmol–1). Acid gel 
electrophoresis of aminoacylation reaction resolved in a 7% urea-sodium acetate polyacrylamide gel. Gel was 
stained with methylene blue (top), dried, exposed to a phosphorimager screen, and scanned (bottom). Recombinant 
purified GluRS is capable of aminoacylating E. coli tRNAGlu lacking post-transcriptional modifications. Gel was 
cropped for visualization purposes. (b-d) MALDI-TOF mass spectra of the precursor peptide His6-NisA after 
incubation with (b) His6-NisB, glutamyl-tRNAGlu and ATP, (c) His6-NisB and glutamyl-tRNAGlu or (d) glutamyl-
tRNAGlu. Numbers above the mass spectra correspond to the number of dehydrations of His6-NisA after incubation 
with His6-NisB. (M) His6-NisA (average mass calc. [M+H]+ 7996, obs. 7995), (2) two-fold dehydrated His6-NisA 
(average mass calc. [M+H]+ 7960, obs. 7959), (4) four-fold dehydrated His6-NisA (average mass calc. [M+H]+ 
7924, obs. 7924).  
Figure 2.5 His6-NisB-catalyzed dehydration of His6-NisA in the presence of Lactococcus lactis HP RNA and 
GluRS. (a-e) MALDI-TOF MS analysis of His6-NisA after incubation with (a) His6-NisB, L. lactis His6-GluRS, L. 
lactis RNA, Glutamate (Glu), and ATP, (b) His6-NisB, L. lactis His6-GluRS, L. lactis RNA, and ATP, (c) His6-
NisB, L. lactis His6-GluRS, Glu, and ATP, (d) His6-NisB, L. lactis RNA, Glu, and ATP, or (e) L. lactis His6-GluRS, 
L. lactis RNA, Glu, and ATP. Numbers above the mass spectra correspond to the number of dehydrations of His6-
NisA after incubation with His6-NisB. (M) His6-NisA (average mass calc. [M+H]+ 7996, obs. 7997), (5) five-fold 
dehydrated His6-NisA (average mass calc. [M+H]+ 7906, obs. 7906), (7) seven-fold dehydrated His6-NisA (average 
mass calc. [M+H]+ 7870, obs. 7870), and (8) eight-fold dehydrated His6-NisA (average mass calc. [M+H]+ 7852, 
obs. 7853). 
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2.2.2. Structural characterization of the lantibiotic dehydratase NisB in complex with its 
substrate peptide NisA 
The unexpected requirement of tRNAGlu by the lantibiotic dehydratase NisB merited 
structural characterization of this enzyme. Prof. Satish K. Nair and his graduate student Yue Hao 
solved the 2.9 Å resolution structure of NisB in complex with its substrate peptide NisA (PDB 
ID 4WD9). Two domains are apparent within the 117-kDa dehydratase separated by a bifurcated 
cleft-like structure in the center (Figures 2.6a and 2.7a). The N-terminal multi-domain is 
composed of amino acids Ser5 through Ile706 while residues Arg716 through Glu990 form a 
single C-terminal domain (Figure 2.6a). The lack of electron density corresponding to residues 
Ile706–Arg716 and Val893–Gly919 prevented their assignment within the final structural model.  
Previous mutational analysis performed by Dr. Neha Garg identified residues important 
for the glutamylation and glutamate elimination activity of NisB (4). These residues map to two 
different clusters within the amino- and carboxy-terminal regions in the NisB structure (Figure 
2.7b). NisB residues previously shown to be important for the glutamylation of NisA are located 
within a 10 Å radius in the amino-terminal region (Figure 2.6b). This N-terminal region is 
composed of 700 residues and can be delineated as the glutamylation domain. Analogously, 
NisB residues Arg786, Arg826, and His961, which were shown by Dr. Neha Garg to be 
important for glutamate elimination but not for glutamylation activity (4), are located within the 
C-terminal domain of NisB (Figure 2.6c). Consequently, the C-terminal 300-residue domain of 
NisB is responsible for catalyzing the glutamate elimination step.  
RNA binding proteins are characterized for having dense basic patches which mediate 
binding to their cognate RNAs via electrostatic interactions (5). The NisB requirement for 
glutamyl-tRNAGlu prompted the search for the presence of basic patches on the NisB surface. 
Indeed, mapping the electrostatic potential onto the surface of NisB reveals the presence of a 
densely basic cavity within the inner face of the cleft-like structure (Figure 2.7c). This cavity has 
suitable dimensions to accommodate the acceptor stem of polyanionic tRNA. As such this region 
likely engages the glutamyl-tRNAGlu co-substrate. To further elaborate on this observation, Prof. 
Satish K. Nair built a tRNAGlu-NisB binding model based on limited structural homology of this 
NisB region to the X. laevis dsRNA binding protein A (PDB ID 1DI2) and using a structure of 
bacterial tRNA from T. thermophilus (PDB ID 1N78) (Figure 2.7d). This model places the 3’ 
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end of the tRNA in close proximity to the pocket defined by the NisB residues that are critical 
for glutamylation activity, providing additional support for the model.  
The unique structural fold present in NisB was corroborated when structure-based 
similarity searches against the Protein Data Bank failed to identify obvious homologous protein 
folds. Only searches using smaller domains of NisB resulted in hits with low structural 
homology to previously characterized protein sub-domains (Figure 2.7e). NisB residues 
Phe136–Tyr820 showed homology to the amino-terminal domain of TruD, a heterocyclase 
involved in cyanobactin biosynthesis, another class of RiPPs (6, 7). In addition, a second region 
within the carboxy-terminus of NisB (Phe734 through Tyr820) showed structural similarity to 
the LsrG proteins that carry out the epimerization of activated quorum sensing molecules (8). 
However, despite the structural homology and similar chemistry (abstraction of a relatively 
Figure 2.6 Crystal structure of the lantibiotic dehydratase NisB. (a) Overall structure of the NisB homodimer in 
complex with its substrate peptide NisA showing the disposition of the glutamylation (purple) and glutamate 
elimination (green) domains. Residues important for glutamylation and glutamate elimination are shown as spheres 
and the NisA peptide is shown in red. (b, c) Residues in NisB essential for either the glutamylation (b) or glutamate 
elimination activities (c) are clustered in the crystal structure. (d) Simulated annealing omit difference Fourier map 
(Fo-Fc) contoured to 2.5σ of residues Lys–20 through Lys–9 within the leader peptide of NisA. NisB residues 
involved in binding of the NisA leader peptide (green) are shown in yellow. Figure provided by Prof. Satish K. Nair. 	
	 39 
acidic proton next to a carbonyl) residues important for LsrG catalysis are not conserved in NisB. 
Instead residues important for glutamate elimination in NisB are located between the LsrG-like 
region and a second subdomain of the glutamate elimination site (Figure 2.8a-b). Yet, the 
crystal structure of NisB allowed the identification of an additional conserved positively charged 
residue important for glutamate elimination, Arg784 (Figure 2.8c). Indeed the NisB-R784A 
mutant resulted in the accumulation of NisA glutamylated intermediates, providing additional 
Figure 2.7 Surface representation, structural homology, and model for tRNA engagement by NisB. (a) The 
NisB homodimer is shown with one monomer colored in gold (glutamylation domain) and blue (glutamate 
elimination domain) and the other monomer colored pink (glutamylation domain) and green (glutamate elimination 
domain). The NisA peptide is shown as spheres. (b) Transparent cartoon representation of the dimer showing the 
clustering of the residues important for glutamylation (in the pink domain) and glutamate elimination (in the green 
domain) represented as yellow sticks. (c) Calculated electrostatic potential mapped onto the NisB surface showing 
the basic patch (blue) that likely engages the glutamyl-tRNAGlu. The NisA peptide is shown in yellow. (d) tRNAGlu-
NisB binding model with the NisB glutamylation domain (pink) and elimination domain (green). The leader peptide 
is shown in a yellow ball-and-stick representation. The dsRNA binding protein A complexed with its cognate RNA 
(PDB ID: 1DI2) was used to derive a NisB docking pose for binding to bacterial tRNAGlu (T. thermophilus tRNA 
taken from 1N78). The model results in the placement of the aminoacylated CCA terminus in the vicinity of residues 
that have been shown to be important for glutamylation activity. (e) Domains within the overall structure of NisB 
that share notable homology are shown for the leader peptide binding site (gold), and the site for glutamate 
elimination (cyan). Structures that are related by homology are shown adjacent to the respective domains. Figure 
made by Prof. Satish K Nair. 
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support for our assignment of this region as the glutamate elimination active site (Figure 2.8d).  
Electron density from the substrate peptide NisA was observed for the leader sequence 
spanning residues Lys–9 through Lys–20 (Figure 2.6d). Beyond Lys–9, moving towards the C-
terminal core region, no electron density was detected possibly reflecting on NisA 
Figure 2.8 Structure analysis of the glutamate elimination domain in NisB. (a) Cartoon representation of the 
LsrG (PDB ID 3QMQ) protein. Residues involved in LsrG catalysis are shown as sticks. The putative LsrG active 
site, located between the α-helices and β-sheet, was proposed based on the presence of an unidentified ligand ref. 
(8). Mutations of residues in the proposed active site of LsrG demonstrated their importance in activity but no 
functions were assigned to individual residues ref. (8). (b) Cartoon representation of the NisB glutamate elimination 
domain. Segment with structural homology to LsrG is colored light blue; the rest of the elimination domain is 
colored yellow. Residues important for glutamate elimination or dehydration ref. (4) are shown as sticks. (c) 
Residues important for glutamate elimination and net dehydration delineate a putative glutamate elimination active 
site. Residues Arg786, Arg826, and His961 are important for glutamate elimination ref. (4) and Glu823 has been 
previously shown to be partially important for dehydration ref. (4). The importance of Arg784 in the glutamate 
elimination step was determined in this study. (d) MALDI-TOF MS analysis of His6-NisA purified after 
coexpression with His6-NisB-R784A. The presence of multiple glutamylated intermediates demonstrates Arg784 to 
be important for glutamate elimination and not for glutamylation. The designation of 1Glu and 2Glu above the peaks 
indicate the number of glutamate adducts on the family of peaks, with the number shown below indicating the 
additional number of dehydrations for each peak. (M) His6-NisA (average mass calc. [M+H]+ 7444, obs. 7444), (5) 
five-fold dehydrated His6-NisA (average mass calc. [M+H]+ 7354, obs. 7354), (1Glu-4) monoglutamylated and four-
fold dehydrated His6-NisA (average mass calc. [M+H]+ 7501, obs. 7501), (1Glu-2) monoglutamylated and two-fold 
dehydrated His6-NisA (average mass calc. [M+H]+ 7535, obs. 7535), (2Glu-4) bisglutamylated and four-fold 
dehydrated His6-NisA (average mass calc. [M+H]+ 7629, obs. 7630), (2Glu-2) bisglutamylated and two-fold 
dehydrated His6-NisA (average mass calc. [M+H]+ 7664, obs. 7666). 
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conformational flexibility. Residues Lys–9 through Lys–20 within NisA adopted an extended β 
strand conformation adding to the other three β strands within NisB formed by residues Leu166 
–Asn175 (Figure 2.6a). NisA, like most class I lantibiotic precursor peptides, contains a F-D/N-
L-N/D conserved motif within the leader peptide, which has been implicated in substrate 
recognition by NisB (9-11). The amino acid Phe–18 of NisA in this motif binds to NisB within a 
hydrophobic pocket composed of residues Val176, Val198, Tyr202, Leu209, and Tyr213. 
Likewise, Leu–16 of NisA is clustered inside a second hydrophobic cavity within NisB 
consisting of residues Ile171, Tyr213, and Leu217. Finally, D–15 of NisA is within hydrogen 
bonding distance of Arg154 possibly interacting via electrostatic interactions (Figure 2.6d). 
These interactions observed in the crystal structure provide a rationale for why previous 
mutations within the FNLD sequence in NisA greatly reduce NisB binding (10, 11).  
The presence of the leader peptide-binding site on the N-terminal domain raised the 
question whether the glutamate elimination activity requires the leader peptide as well. To gain 
further insight, I tested the NisB-catalyzed glutamate elimination activity on purified 
glutamylated NisA core peptide in the absence of leader peptide. MALDI-TOF MS analysis after 
incubation with NisB revealed the presence of dehydrated NisA core (Figure 2.9).  
 
 
Figure 2.9 NisB-catalyzed glutamate elimination of glutamylated NisA core peptide. MALDI-TOF MS analysis 
of glutamylated NisA core peptide (a) before, and (b) after incubation with His6-NisB. The data show that the leader 
peptide is not required for NisB-catalyzed glutamate elimination. Numbers above the mass spectra correspond to the 
number of glutamate adducts or dehydrations of NisA core. (M) NisA core (average mass calc. [M+H]+ 3498, obs. 
3499),  (1) one-fold dehydrated (average mass calc. [M+H]+ 3480, obs. 3481), and (4) four-fold dehydrated NisA 
core (average mass calc. [M+H]+ 3426, obs. 3427). (1Glu-1) monoglutamylated and one-fold dehydrated NisA core 
peptide (average mass calc. [M+H]+ 3609, obs. 3611), (1Glu-2) monoglutamylated and two-fold dehydrated NisA 
core (average mass calc. [M+H]+ 3591, obs. 3593), (2Glu-1) bisglutamylated and one-fold dehydrated NisA 
(average mass calc. [M+H]+ 3738, obs. 3740), and (2Glu-2) bisglutamylated and two-fold dehydrated NisA core 
(average mass calc. [M+H]+ 3720, obs. 3722). 
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2.2.3. Bioinformatic analysis of lantibiotic dehydratases  
Lantibiotic dehydratases (LanB) are widely distributed among gram-positive bacteria 
(12). A protein similarity map of LanB proteins in the databases constructed by previous group 
member Dr. Qi Zhang identified several sub-families (Figure 2.10). One large group is formed 
predominantly by sequences that contain both the glutamylation and elimination domains in one 
polypeptide (full length LanB, green). Another less well-defined group is formed by 
dehydratases involved in the biosynthesis of another class of RiPPs including thiopeptides (cyan) 
and goadsporin (pink). In these LanBs the glutamylation and elimination domains are in separate 
polypeptides. Whether these enzymes use glutamate or perhaps another amino acid for activation 
of Ser/Thr remains to be determined. Perhaps the most intriguing group is formed by shorter 
uncharacterized sequences (small LanBs, red) that lack the elimination domain and for which no 
open reading frame encoding a stand-alone elimination protein is found within neighboring 
genes (Figure 2.10). These small LanBs are often part of non-ribosomal peptide synthesis 
(NRPS) clusters (Figure 2.10, yellow), and the observation that they lack the elimination domain 
suggests they may add amino acids to a growing peptide in a tRNA-dependent manner.  
	
Figure 2.10 Protein similarity map of the glutamylation domain (Lant_dehyd_C, PF04738) present in various 
lantibiotic dehydratases and homologs. Each node in the network represents a protein sequence and each edge 
represents sequences with BLASTP e-values below the indicated cutoff. NRPS, non-ribosomal peptide synthesis; 
TOMM, thiazole/oxazole-modified microcin. 
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 Further phylogenetic analysis performed by group member Dr. Mark Walker on the 
polypeptides containing the elimination domain reveals the presence of distinct clades, which 
grouped together based on their respective biosynthetic function (Figure 2.11a). Interestingly, 
putative Diels-Alderases involved in the [4+2] cycloaddition during the biosynthesis of 
thiopeptides (13, 14) contain an elimination domain and clustered together as a separate clade 
(Figure 2.11a, purple). A sequence alignment comparison performed with the help of Dr. Mark 
Walker of the elimination domain among full length LanBs, thiopeptide dehydratases and the 
putative thiopeptide Diels-Alderases reveals that residues important for glutamate elimination in 
lantibiotic dehydratases are only conserved in thiopeptide dehydratases but not in Diels-
Alderases (Figure 2.11b). Hence despite their limited sequence similarity to the LanB 
elimination domain, these putative Diels-Alderases will likely contain a similar fold as the one 
presented herein (Figure 2.8b) serving for a different purpose yet to be determined. 
Figure 2.11 Bioinformatic analysis of the glutamate elimination domain (a) Phylogenetic tree analysis of the 
glutamate elimination domain present in various lantibiotic dehydratases and homologs. Several clades can be 
identified based on the proposed function and natural product class. Only splits with a posterior probability higher 
than 50% are shown. (b) Sequence alignment of selected elimination domains present in full LanBs (NisB, SpaB), 
thiopeptide dehydratases (NocD, SioK, CltF), and putative thiopeptide Diels-Alderases (NocO, SioL, and CltG). 
Residues involved in glutamate elimination (red) are conserved in full LanBs and thiopeptide dehydratases but not 
in the putative Diels-Alderases. 
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2.3. Discussion 
This chapter presents biochemical and structural data that identifies glutamyl-tRNAGlu as 
a co-substrate of the lantibiotic dehydratase NisB. This finding provides a long-awaited answer 
as to why the in vitro activity of these enzymes could not be reconstituted in the past. Moreover 
the observation that dehydration occurs in the presence of just glutamyl-tRNAGlu suggests that 
dehydration of Ser/Thr residues located at different positions within NisA occurs stochastically 
and is not driven by the consumption of energy. This result argues against the possibility of NisB 
coupling ATP hydrolysis to pull its substrate peptide from one end analogous to a threading 
mechanism. This hypothesis was put forward as one of the explanations as to how NisB 
catalyzed dehydrations at different locations within the NisA peptide (15, 16). 
Structural characterization of NisB revealed the presence of two individual domains 
involved in the glutamylation and glutamate elimination during the NisB-catalyzed dehydration 
of NisA. The boundaries for the two domains correspond with the two proteins of roughly 800 
residues and 300 residues encoded in the biosynthetic clusters of thiopeptides, another class of 
RiPPs, suggesting they carry out aminoacylation and elimination, respectively, to achieve the 
dehydration of their substrate peptides. The characterization of NisB as a tRNA-dependent 
enzyme sets the stage to reconstitute the activity of these dehydratases involved in thiopeptide 
biosynthesis.  
For many years mutational studies were the only tool available to reveal mechanistic 
aspects of leader peptide recognition by the RiPP biosynthetic machinery due to the structural 
intractability of these enzymes bound to their substrates. The structure of NisB in complex with 
NisA provides the first insights into the molecular mechanism employed by these biosynthetic 
enzymes for substrate recognition. NisA binds to the region in NisB that is homologous to the 
amino terminal domain of TruD, suggesting that different classes of RiPP biosynthetic enzymes, 
likely use similar structural elements for engaging their substrate peptides. Upon completing this 
dissertation chapter additional structural and bioinformatic studies of other RiPP biosynthetic 
enzymes have revealed that indeed this structural motif is widely used for leader peptide 
recognition (17-19). The structural studies presented herein provide a clear canvas where 
previous mutational analysis reporting on leader peptide recognition by the RiPP biosynthetic 
machinery could be mapped, rationalized, and analyzed in a structural context.  
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The structural and biochemical data gathered here provide explanations for several long-
standing observations within the lanthipeptide research field. First, NisB substrate recognition is 
mediated by hydrophobic interactions between NisB and the FNLD motif in NisA. The presence 
of this motif in many class I lantibiotic precursor peptides suggests a similar recognition 
mechanism employed by their respective class I lantibiotic dehydratases. In addition, the NisB-
catalyzed dehydration of NisA has been shown to proceed with N-to-C terminal directionality 
(15, 20). This observation combined with the demonstration that NisB dehydrates NisA in a 
distributive manner (Figure 2.2) and with the leader peptide binding site identified in the co-
crystal structure, suggests that directionality is achieved by the distance between the leader 
peptide binding site and the glutamylation active site. Residues closer to the leader peptide (N-
terminus) have a higher likelihood to access the glutamylation active site than residues that are 
further away (C-terminus). This also puts in context the observed extended conformation of the 
leader peptide, which presumably ensures the core region to reach the glutamylation active site. 
The presence of a distinct leader peptide binding site also explains why Ser and Thr residues 
within the leader peptide are never dehydrated and why there is a minimal distance requirement 
from the F-D/N-L-N/D motif to the first dehydrated amino acid in class I lantibiotics (10, 21) (i.e. 
distance required to reach the glutamylation site). After glutamylation, the flexible core region 
from the precursor peptide reaches the glutamate elimination active site where the glutamate 
adduct is then eliminated. Such flexibility can be accounted by the diminished electron density 
observed for the C-terminal portion of NisA. Furthermore, the leader peptide does not appear to 
be critical for glutamate elimination, suggesting that the local structure of glutamylated Ser/Thr 
determines substrate recognition by the elimination domain. In addition, since glutamylated 
intermediates are not accumulated during the dehydration process, glutamate elimination must be 
faster than glutamylation under the current assay conditions. 
Taken together, the observations presented in this Chapter predict that aminoacylated 
tRNA may find much broader participation in natural product biosynthesis than currently 
appreciated (22-25). The demonstrated use of glutamylated tRNA by NisB to transiently affect 
glutamylation of Ser/Thr side chains in NisA is a new addition to a growing number of uses of 
aminoacylated tRNA for functions other than ribosomal protein synthesis (26, 27). 
	 46 
2.4. Methods 
General Methods 
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, 
IA) (Table 2.1). Reagents used for molecular biology were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Chemicals were purchased from Sigma-Aldrich (St. Louis, MO). L-[14C(U)]-
glutamic acid (0.1 µCi mL–1, 260 µCi mmol–1) was purchased from PerkinElmer (Waltham, MA). 
Escherichia coli DH5α and BL21 (DE3) strains were used for plasmid maintenance and protein 
overexpression respectively. Cloning inserts were sequenced at ACGT Inc. (Wheeling, IL). 
MALDI-TOF MS analysis was performed using a Bruker UltrafleXtreme MALDI TOF-TOF 
mass spectrometer (Billerica, MA) in reflective mode at The University of Illinois Mass 
Spectrometry Laboratory. Reflective mode was used to resolve mass peaks differing by 18 Da 
within the 7–8 kDa size range. The small shoulder peaks appearing to the left of unmodified 
NisA (M) corresponds to the laser-induced deamination of the parent peak. Deamination occurs 
as a consequence of analyzing large peptides using reflective mode (35). All biochemical assays 
were performed with hexa-histidine (His6) tagged substrates and enzymes. 
 
Table 2.1 Oligonucleotides used in this study. 
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Expression and Purification of His6-NisA, glutamylated His6-NisA, and His6-NisB 
The nisA gene was cloned previously into pET15b with an N-terminal hexahistidine tag 
(28). E. coli BL21 (DE3) cells (50 µL) were electroporated with the plasmid his6-nisA-pET15b 
(50 ng), cells were plated on Luria-Bertani (LB) agar plates supplemented with ampicillin (amp, 
100 µg mL–1) and grown at 37 °C for 12-15 h. A single colony was used to inoculate 50 mL of 
LB broth supplemented with amp, grown for 12-15 h at 37 °C, and the culture was used to 
inoculate 4 L of terrific broth (TB) media, supplemented with amp, to an OD600 of 0.025. 
Cultures were grown at 37 °C to a final OD600 of 1.0. Peptide expression was induced by the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and 
cultures were grown at 18 °C for 18 h. Peptide purification was performed following a 
previously described method (28). The cloning, expression, and purification of His6-NisB and 
glutamylated His6-NisA is described elsewhere (4). 
 
Preparation of Escherichia coli BL21 (DE3) cell extract 
The cell extract of E. coli BL21 (DE3) was prepared following a previously described 
method (29) with minor modifications. E. coli BL21 (DE3) cells were inoculated in 2 L of TB 
media and grown at 37 °C to a final OD600 of 1.0. Cells were harvested (4,650 × g, 10 min, 4 °C) 
and the pellet was washed three times by resuspending it in S30 buffer (10 mM Tris-acetate 
buffer pH 8.2, 14 mM Mg(OAc)2, 60 mM KOAc, 1 mM DTT, 0.3 mM EDTA, 0.3 mM MgCl2) 
followed by centrifugation (4,650 × g, 10 min, 4 °C). Cells were then resuspended in 1 mL S30 
buffer per 1 g of wet cells and lysed using a MultiFlex C3 Homogenizer (Avestin). The cell 
lysate was centrifuged twice (22,789 × g, 30 min, 4 °C) and the supernatant was dialyzed 4 times 
against 50 volumes of S30 buffer (without DTT) using a dialysis cassette with a molecular 
weight cutoff (MWCO) of 10 kDa. The cell extract was then centrifuged (4,000 × g, 10 min, 4 
°C) and the supernatant was frozen and stored in 1 mL aliquots at –80 °C for future use. 
 
Anion Exchange Fractionation of E. coli cell extract 
An aliquot of 1 mL of cell extract was loaded onto a 1 mL Hi Trap DEAE FF (GE 
Healthcare) column equilibrated with 5 column volumes (CV) of Start Buffer (10 mM Tris-HCl 
pH 8.0) using an ÄKTA FPLC system (Amersham Pharmacia Biosystems). The column was 
washed with 10 CV of Start Buffer and the sample was eluted using a gradient of 0–100 % (v/v) 
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of Elution Buffer (10 mM Tris-HCl, 1 M NaCl pH 8.0) in Start Buffer over 20 CV. Eluent was 
detected by absorbance at 280 nm (Figure 2.2). Collected fractions were desalted by washing 
five times with 500 µL of S30 buffer (without DTT) using a 10 kDa MWCO Amicon centrifugal 
filter (Millipore) (14,000 × g, 10 min, 4 °C). Fractions were stored at –80 °C. 
 
Cloning, Expression, and Purification of Escherichia coli BL21 (DE3) GluRS  
The gene gltX was cloned into pET28a with an N-terminal hexahistidine tag. gDNA from 
E. coli BL21 (DE3) cells was extracted using an UltraClean Microbial DNA isolation kit 
(MoBio) following the manufacturer’s protocol. The gltX gene was PCR amplified using the 
following conditions: Phusion HF buffer (1×), dNTP (0.2 mM), primers (1 µM each, Table 2.1), 
gDNA template (10 ng), DMSO (3% v/v), and Phusion polymerase (0.04 U µL–1) in a total 
volume of 50 µL. The amplification was performed in 20 cycles: denaturation (98 °C for 60 s), 
annealing (67 °C for 60 s), and amplification (72 °C for 42 s). The PCR product was purified by 
gel extraction on a 1% (w/v) agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). The 
vector pET28a and gltX PCR fragment were digested using NdeI and XhoI (NEB) restriction 
endonucleases, purified by gel extraction as described above, and the resulting fragments were 
ligated in 20 µL using T4 DNA ligase (NEB) at 16 °C for 18 h. An aliquot of 10 µL from the 
ligation reaction was used to transform E. coli DH5α cells using the heat shock method. The 
cells were plated on LB agar plates supplemented with kanamycin (kan, 50 µg mL–1), and the 
plates were incubated at 37 °C for 12-15 h. Single colonies were picked and grown in LB 
supplemented with kan at 37 °C for 12-15 h, and the plasmid his6-gltX-pET28a was isolated 
using a QIA prep Spin Miniprep Kit (QIAGEN). Insert integrity was verified by sequencing the 
plasmid with the appropriate primers. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with his6-gltX-pET28a (50 ng), 
plated on LB agar plates supplemented with kan, and grown at 37 °C for 12-15 h. A single 
colony was used to inoculate 50 mL of LB broth supplemented with kan, grown for 12-15 h at 37 
°C, and the culture was used to inoculate 3 L of TB media supplemented with kan to an OD600 of 
0.025. Cultures were grown at 37 °C to an OD600 of 0.5. Protein expression was induced by the 
addition of IPTG to a final concentration of 0.2 mM, and cultures were grown at 18 °C for 20 h. 
Protein purification was performed as described for His6-NisB (4). After elution from a HisTrap 
HP 5 mL column (GE Healthcare), the protein was desalted using a PD-10 desalting column (GE 
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Healthcare), concentrated using a 30 kDa MWCO Amicon centrifugal filter (Millipore) (4,000 × 
g, 20 min, 4 °C) and stored in Storage Buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% 
glycerol) at –80 °C. 
 
Cloning, expression and purification of Lactococcus lactis HP GluRS 
The gene gltX from L. lactis HP was cloned into pET28a with an N-terminal 
hexahistidine tag. The gDNA from L. lactis HP cells was extracted using an UltraClean 
Microbial DNA isolation kit (MoBio) following the manufacturer’s protocol. The gltX gene was 
amplified by PCR using similar conditions as described above with appropriate primers (Table 
2.1). The amplification was performed in 20 cycles: denaturation (98 °C for 60 s), annealing (65 
°C for 60 s), and amplification (72 °C for 60 s). The PCR purification, ligation, expression of L. 
lactis GluRS and purification were performed as described above for E. coli GluRS. 
 
Purification of Escherichia coli tRNAGlu and glutamyl-tRNAGlu 
Primers for E. coli tRNAGlu were designed according to a previously described method 
(30) (Table 2.1). The tRNAGlu dsDNA template for in vitro transcription was prepared by filling 
5’ overhangs using the following conditions: NEB Buffer 2 (1×), primers (4 µM each, Table 
2.1), dNTP (33 µM), NEB DNA pol I (large Klenow fragment) (1 U µg–1 DNA) in a final 
volume of 50 µL. The reaction was incubated at 25 °C for 15 min, quenched with EDTA (10 
mM), incubated at 75 °C for 25 min, and dsDNA tRNAGlu template was precipitated with EtOH. 
In vitro transcription was performed using a previously described method (31).  
Glutamylation of tRNAGlu was performed using the following conditions: tRNAGlu (50 µM), L-
glutamate (10 mM), ATP (10 mM), E. coli GluRS (5 µM), thermostable inorganic 
pyrophosphatase (TIPP) (New England BioLabs) (0.04 U µL–1), HEPES pH 7.5 (100 mM), KCl 
(10 mM), MgCl2 (20 mM) and DTT (1 mM) in a final volume of 500 µL. The reaction was 
incubated at 37 °C for 1 h and desalted by washing ten times with 500 µL HEPES pH 7.5 (100 
mM) using a 10 kDa MWCO Amicon centrifugal filter (Millipore) (14,000 × g, 10 min, 4 °C). 
Glutamyl-tRNAGlu was then purified by acidic phenol extraction using a previously described 
method (32). 
To assess the extent of aminoacylation on in vitro transcribed E. coli tRNAGlu, glutamyl-
tRNAGlu was analyzed by denaturing acidic polyacrylamide gel electrophoresis using a 
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previously described procedure (32, 33). The tRNA aminoacylation assays were performed using 
L-[14C(U)]-glutamic acid (0.1 µCi mL–1, 260 µCi mmol–1) under the following conditions: in 
vitro transcribed E. coli tRNAGlu (3 µM), L-[14C(U)]-glutamic acid (50 µM), HEPES pH 7.5 (100 
mM), ATP (5 mM), TCEP (1 mM), KCl (10 mM), MgCl2 (20 mM), TIPP (0.02 U µL–1) and 
purified E. coli GluRS (1 µM) in a final volume of 50 µL. The reaction was incubated at 37 °C 
for 1 h and quenched with NaOAc pH 5.6 (300 mM). Glutamyl-tRNAGlu was precipitated by 
standard EtOH precipitation. The resulting pellet was dissolved in 10 µL of acidic loading buffer 
(100 mM NaOAc pH 5.6, 7M Urea, 0.05% bromophenol blue) and the sample was loaded onto a 
7% acidic polyacrylamide gel (100 mM NaOAc, 8 M Urea). Electrophoresis was performed at 
100 V (constant voltage) in an ice bath for 120 min using 100 mM NaOAc pH 5.6 as running 
buffer. To visualize tRNA, the gel was stained with staining solution (500 mM NaOAc pH 5.6, 
0.06% methylene blue) for 30 min and destain in water. After drying the gel overnight using a 
gel drying kit (Promega) following the manufacturer’s procedure, glutamyl-tRNAGlu was 
visualized by exposing the dried gel onto a phosphorimager cassette for 4 days. The film was 
then visualized using a STORM 840 Phosphorimager Scanner (Amersham Biosciences) (Figure 
2.5). 
 
RNA extraction from Lactococcus lactis HP 
Lactococcus lactis HP cells were grown in 2 L of M17 media supplemented with 0.5% 
(w/v) glucose for 16 h at 30 °C. Cells were washed three times with S30 Buffer and cell extract 
was prepared as described above for E. coli cells. RNA was extracted from the cell extract by 
acidic phenol extraction. Briefly, an aliquot of 500 µL of cell extract was mixed with 500 µL of 
acidic phenol (pH ~4.5) and the resulting emulsion was vortexed for 1 min. The sample was 
centrifuged (14,000 × g, 5 min, 4 °C) and the aqueous phase was collected for a second acidic 
phenol extraction. After centrifugation, the aqueous layer was extracted twice with 500 µL of 
chloroform:isoamyl alcohol (24:1). The sample was vortexed for 1 min and centrifuged (14,000 
× g, 5 min, 4 °C). Total RNA was precipitated by standard EtOH precipitation and dissolved in 
RNase-free distilled water. To remove any aminoacylated tRNA, total RNA (0.66 µg µL–1) was 
incubated for 1 h at 37 °C in EDTA (0.6 mM) and Tris-HCl pH 9.0 (66 mM). The sample was 
acidified with NaOAc (300 mM) and RNA was extracted by standard EtOH precipitation (33). 
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In vitro dehydration assays 
The following reaction conditions were used for dehydration assays: E. coli cell 
extract/fraction (10 µL), HEPES pH 7.5 (100 mM), DTT (1 mM), L-glutamate (10 mM), NisA 
(200 µM), MgCl2 (10 mM), KCl (10 mM), NisB (5 µM), TIPP (0.02 U µL–1) and ATP (5 mM) in 
a final volume of 30 µL. The assay was incubated at 30 °C for 5 h, centrifuged to remove 
insoluble material (14,000 × g, 5 min, 25 °C) and desalted using a C-18 ZipTip concentrator 
(Millipore). The sample was mixed in a 1:1 ratio with sinapinic acid matrix and spotted on a 
Bruker MALDI-TOF plate. When noted, the cell extract (10 µL) was substituted with E. coli 
GluRS (5 µM) and E. coli tRNAGlu (50 µM). In addition when noted, the cell extract (10 µL) was 
treated with either RNase (10 U) or RNase-free DNase (10 U) in the presence of CaCl2 (100 µM) 
and incubated at 25 °C for 1 h prior to dehydration assays.  
For dehydration assays using glutamyl-tRNAGlu the following conditions were used: 
HEPES pH 7.5 (100 mM), DTT (500 µM), MgCl2 (10 mM), KCl (10 mM), His6-NisA (10 µM), 
Glu-tRNAGlu (~100 µM), and His6-NisB (5 µM) in a final volume of 30 µL. The assay was 
incubated at 30 °C for 12 h and prepared as described above for analysis by MALDI-TOF MS. 
In a separate experiment, ATP (1 mM) was added to the reaction mixture. 
For dehydration assays using L. lactis HP total RNA the following conditions were used: 
L. lactis RNA (1 µg µL–1), glutamate (10 mM), MgCl2 (10 mM), KCl (10 mM), HEPES pH 7.5 
(50 mM), L. lactis GluRS (10 µM), NisB (5 µM), NisA (100 µM), ATP (5 mM), TIPP (0.02 U 
µL–1), and TCEP (1 mM). The assay was incubated at 30 °C for 3 h and prepared as described 
above for analysis by MALDI-TOF MS.  
 
Glutamate elimination assays 
The glutamylated precursor peptide NisA was incubated with the endoprotease ArgC 
under the following conditions: glutamylated NisA (500 µM), Tris-HCl (20 mM), CaCl2 (10 
mM), EDTA (0.5 mM), DTT (5 mM), and ArgC (0.005 µg µL–1). The reaction was incubated for 
4 h at 37 °C. Glutamylated core and leader peptide were purified by analytical high performance 
liquid chromatography (HPLC) on a Phenomenex C18 column (Luna, 10u, 250 mm × 4.60 mm, 
10 µ, 100 Å) connected to an Agilent 1260 infinity liquid chromatography system. Peptides were 
separated using a linear gradient of 2% (v/v) Solvent B (80% (v/v) Acetonitrile (MeCN), 20% 
(v/v) H2O, 0.086% (v/v) trifluoroacetic acid (TFA)) in Solvent A (0.1% (v/v) TFA in H2O) to 
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100% (v/v) Solvent B over 60 min at a flow rate of 1 mL min–1. Peptide was monitored using a 
220 nm wavelength. Desired fractions were lyophilized and stored at –20 °C. 
The following reaction conditions were used for the glutamate elimination assays: 
HEPES pH 7.5 (100 mM), glutamylated His6-NisA core (~ 100 µM), NisB (5 µM) MgCl2 (10 
mM), KCl (10 mM) and TCEP (1 mM). The reaction was performed in a 15 µL volume, 
incubated for 60 min at 30 °C and analyzed by MALDI-TOF MS as described above. 
 
Coexpression of NisB mutant R784A with NisA 
Site directed mutagenesis was performed on his6-nisA/nisB pRSF Duet-1 (4) to replace 
the conserved Arg784 in NisB to Ala using a previously described method (34) with appropriate 
primers (Table 2.1). The resultant plasmid was used for coexpression of His6-NisA with NisB 
R784A and modified His6-NisA was purified following a previously described method (4). 
 
Construction of LanB protein sequence similarity map 
The LanB sequences were obtained by iterative Psi-Blast search, and the hits were 
grouped into full-length LanB and short LanB based on whether they had the SpaB-C terminal 
domain. Thiopeptide dehydratase sequences were obtained from the ThioBase database (35). 
Network analysis was performed by BLASTP searches comparing each sequence against each 
other. A Matlab script was written to remove all duplicate comparisons, and the result was 
imported into the Cytoscape software package. Each node in the network represents a protein 
sequence, and each edge represents the pairwise connection between two sequences with 
BLASTP e-value lower than the cutoff value. The nodes were arranged using the yFiles organic 
layout provided with Cytoscape version 2.8.3. Accession numbers are listed in the publication 
associated with this Chapter (36). Construction of the protein similarity network was performed 
by previous group member Dr. Qi Zhang. 
 
Phylogenetic tree construction 
Sequences for the SpaB C-terminal domain containing proteins were obtained by 
searching the NCBI assembled bacterial genomes database with the SpaB_C PFAM (37) hidden 
markov model using HMMER3 (38). Putative Diels-Alderase sequences were identified 
constructing a hidden Markov model from an alignment of NosO orthologs obtained from the 
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Thiobase (35) database. This hidden markov model was used in the same manner as the Spab_C 
hidden markov model. The portions of protein sequences that aligned to the SpaB_C PFAM or 
the putative Diels-Alderase hidden markov model were combined and clustered using CD-HIT 
(39), identifying representative sequences that shared no more than 50% identity. The genomic 
contexts of these representative sequences were examined to determine the type of protein and 
biosynthetic cluster in which these domains resided. Then, the sequences were aligned using 
PRALINE (40). The alignment was then manually adjusted to remove poorly aligning regions 
and subsequently used to construct a phylogenetic tree using Mr. Bayes (41). A portion of 
invariable and gamma-distributed (4 categories) rates, the WAG amino acid substitution model, 
and random starting trees were utilized to calculate the likelihood over 7,500,000 generations of 
2 runs with 4 chains each. The final tree was generated using a 25% relative burnin. Phylogenetic 
tree construction was performed by group member Dr. Mark C. Walker. 
 
Representative sequence alignment 
Representative sequences for thiopeptide dehydratases and putative Diels-Alderases were 
selected from ThioBase (35). The SpaB C-terminal domains of these proteins were identified by 
HMMER as described above and aligned with the SpaB C-terminal domains of characterized full 
length LanB proteins using MUSCLE (42). Sequence alignment was performed with the help of 
Dr. Mark C. Walker. 
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Chapter 3. Class I Lantibiotic Dehydratases as General tRNA-Dependent Enzymes* 	
3.1. Introduction 
Lantibiotics are lanthipeptides (lanthionine-containing peptides) that possess 
antimicrobial activity (1). As described in Chapter 1, this group of RiPPs can be further 
subdivided into four different classes (I-IV) (2). Only lanthipeptides from class I and II have 
been shown to possess antimicrobial activities to date. Class II lantibiotics are synthesized by a 
bifunctional lanthionine synthetase (LanM) (2). This bifunctional enzyme catalyzes the ATP-
dependent dehydration of Ser/Thr residues as well as the conjugate addition of Cys thiols onto 
dehydroamino acids (3, 4) (reviewed in Chapter 1). While both class I and class II lantibiotics 
share structural commonalities, the thioether crosslinkages in class I lantibiotics are installed by 
the action of two enzymes, a lantibiotic dehydratase (LanB) and a lantibiotic cyclase (LanC) 
(Figure 3.1a) (2). Whereas the mechanism of Ser/Thr activation employed by LanM synthetases 
has been known for over 10 years, only recent studies have started to shed light onto the Ser/Thr 
activation catalyzed by LanB dehydratases (5). 
The biochemical studies presented in Chapter 2 on the lantibiotic dehydratase NisB, 
involved in the biosynthesis of the food preservative nisin, revealed an unexpected requirement 
for glutamyl-tRNAGlu during catalysis (6). Biochemical and structural data demonstrated that 
glutamate is transferred from glutamyl-tRNAGlu to selected Ser/Thr side chains within the 
precursor peptide of nisin giving rise to a series of glutamylated intermediates (5, 6). Upon 
glutamate elimination, Ser/Thr residues are converted to their unsaturated counterparts (5). 
While these key insights provided the first information regarding the enzymatic mechanism of 
class I lantibiotic dehydratases, it raised the question as to whether the use of glutamyl-tRNAGlu 
was a common feature shared among lantibiotic dehydratases.  
Class I lantibiotic dehydratases are widely distributed among different bacterial species 
(7). A comprehensive phylogenetic analysis of these enzymes revealed that they grouped into 
clades according to their microbial phyla (8). Thus, the general use of glutamyl-tRNAGlu by 
lantibiotic dehydratases could be assessed by characterizing representative enzymes from 
																																																								
* Prof. Satish K. Nair and his graduate student Yue Hao performed all of the structural experiments presented in this 
chapter. 
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different phyla. Having already characterized the activity of a lantibiotic dehydratase (NisB) 
from a Firmicute (Lactococcus lactis) (6), herein I characterized and reconstituted the enzymatic 
activity of MibB, a lantibiotic dehydratase from an Actinobacterium. MibB is involved in the 
biosynthesis of NAI-107 (also called microbisporicin), produced by the actinomycete 
Microbispora sp. 107891 (Figure 3.1b) (9, 10). NAI-107 functions by interrupting cell wall 
biosynthesis and demonstrates activity against a wide panel of antibiotic resistant bacterial 
strains. Currently, NAI-107 is in late pre-clinical trials for the treatment of multidrug resistant 
Gram-positive bacterial infections (11).  
Biosynthesis of NAI-107 is predicted to initiate with the oxidative decarboxylation of 
Cys24 within the NA1-107 precursor peptide MibA. This reaction is catalyzed by the flavin-
containing cysteine decarboxylase MibD (for characterization of MibD refer to Chapter 5). 
Figure 3.1 Overview of lantibiotic biosynthesis. (a) Two-step biosynthetic formation of (methyl)lanthionine rings 
in lantibiotics catalyzed by a lantibiotic dehydratase and a lantibiotic cyclase. (b) Biosynthesis of the lantibiotic 
NAI-107. The lantibiotic dehydratase MibB dehydrates seven Ser/Thr residues (green and blue) in MibA followed 
by cyclization events catalyzed by MibC. Additional enzymes involved in NAI-107 biosynthesis include a flavin-
dependent decarboxylase (MibD), flavin-dependent Trp halogenase (MibH), flavin reductase (MibS) and a Pro 
monooxygenase (MibO) responsible for additional post-translational modifications found in NAI-107 (10). 
Lanthionine rings are shown in red. Methyl-lanthionine rings are shown in blue. Negative numbers indicate the 
position of an amino acid in the leader peptide (underlined) with respect to the core region. The shorthand notation 
for the chemical structures of chlorinated Trp and bishydroxylated Pro are shown. 
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Following decarboxylation, MibB is predicted to dehydrate seven Ser/Thr residues within the 
precursor peptide MibA while the lantibiotic cyclase MibC catalyzes the nucleophilic addition of 
Cys thiols onto five unsaturated amino acid residues (Figure 3.1b) (10). In addition to these 
post-translational modifications, the microbisporicin biosynthetic gene cluster encodes a flavin-
dependent Trp halogenase (MibH) and a P450 monooxygenase (MibO) predicted to be 
responsible for the formation of 5-chlorotryptophan and 3,4–dihydroxyproline residues present 
in NA1-107 (10) (for characterization of MibH refer to Chapter 5). At present, the peptidase 
responsible for removal of the leader peptide during NA1-107 biosynthesis has not been 
characterized.  
To determine the generality of glutamyl-tRNAGlu usage among lantibiotic dehydratases I 
reconstituted the enzymatic activity and characterized the tRNA specificity of MibB. In addition, 
Prof. Satish K. Nair and his student Yue Hao solved the 2.7 Å resolution X-ray crystal structure 
of MibB. Biochemical and structural data demonstrates that the enzyme indeed uses glutamyl-
tRNAGlu as the source of activated glutamate needed to catalyze the glutamylation of Ser/Thr 
residues in MibA. This observation provides evidence for a general use of glutamyl-tRNAGlu by 
class I lantibiotic dehydratases. In addition, the data presented in this Chapter suggest that 
nucleotides A73–U72 within the Microbispora tRNAGlu acceptor stem are important elements 
for recognition by MibB. Furthermore, the acquired knowledge on the tRNA specificity of MibB 
allowed the development of an expression system in Escherichia coli suitable for the production 
of NAI-107 analogs despite the inability of MibB to utilize E. coli tRNAGlu. This methodology 
provides an alternative route for the study and characterization of lantibiotics produced by 
Actinobacteria, a phylum that has recently emerged with a vast potential for producing 
previously uncharacterized lantibiotics (12-14). 
 
3.2. Results 
3.2.1. Reconstitution of the enzymatic activity of MibB 
The lantibiotic dehydratase MibB and its substrate peptide MibA were each 
heterologously expressed in Escherichia coli and purified as N-terminal hexahistidine tagged 
constructs. Building on the recent characterization of the lantibiotic dehydratase NisB presented 
in Chapter 2 (6), I sought to reconstitute the in vitro activity of MibB using E. coli tRNAGlu and 
E. coli glutamyl tRNA synthetase (GluRS). Despite several attempts MibB was only able to 
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Figure 3.2 Reconstitution of MibB activity in vitro. MALDI-TOF MS analysis of His6-MibA following 
dehydration reactions performed with glutamate, ATP, His6-MibB and in the presence of (a) Microbispora total 
RNA and Microbispora His6-GluRS, (b) Microbispora tRNAGluCUC and Microbispora His6-GluRS, (c) Microbispora 
tRNAGluCUC, (d) Microbispora His6-GluRS, or (e) Microbispora tRNAGluCUC and Microbispora His6-GluRS in the 
absence of MibB. M, unmodified MibA (average mass calc. [M+H]+ 8013, obs. 8014); 2, two-fold dehydrated MibA 
(average mass calc. [M+H]+ 7977, obs. 7981); 3, three-fold dehydrated MibA (average mass calc. [M+H]+ 7959, 
obs. 7963); 4, four-fold dehydrated MibA (average mass calc. [M+H]+ 7943 m/z, calc. 7941 m/z); 5, five-fold 
dehydrated MibA (average mass calc. [M+H]+ 7923, obs. 7925); 6, six-fold dehydrated MibA (average mass calc. 
[M+H]+ 7905, obs. 7907); 7, seven-fold dehydrated MibA (average mass calc. [M+H]+ 7887, obs. 7889); +1glu, 
monoglutamylated MibA intermediates with various numbers of dehydrations (five-fold dehydrated, average mass 
calc. [M+H]+ 8052, obs. 8054), (four-fold dehydrated, average mass calc. [M+H]+ 8070, obs. 8072), (three-fold 
dehydrated, average mass calc. [M+H]+ 8088, calc. 8089). 
Figure 3.3 Glutamylation analysis of Microbispora tRNAGluCUC. Glutamylation assays were performed in vitro 
using heterologously expressed and purified Microbispora GluRS, in vitro transcribed Microbispora tRNAGluCUC 
and L-(14C)- glutamic acid. Reaction was analyzed by gel electrophoresis. The gel was stained with methylene blue 
(top), dried, exposed to a phosphorimager screen and scanned (bottom). The gel was cropped for visualization 
purposes. 
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catalyze one or two dehydrations in MibA as observed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), instead of the 
required seven dehydrations (vide infra).  
Reasoning that the partial activity observed might be a consequence of differences 
between the tRNAGlu of the NAI-107 producer strain and that of E. coli, total RNA from the 
NAI-107 producer strain Microbispora sp. 107891 was purified. This strain was obtained from 
Dr. Stefano Donadio and Dr. Margherita Sosio at Ktedogen. In addition, the recently sequenced 
genome of Microbispora sp. 107891 (15) facilitated cloning, heterologous expression, and 
purification of Microbispora GluRS. Upon incubation of MibB, MibA, glutamate, ATP, 
Microbispora GluRS, and Microbispora total RNA, MibB dehydrated MibA up to four times as 
observed by MALDI-TOF MS (Figure 3.2a). To further confirm tRNAGlu was required for 
MibB activity, I purified in vitro transcribed Microbispora tRNAGluCUC, determined the extent of 
in vitro aminoacylation by Microbispora GluRS (Figure 3.3), and performed in vitro 
dehydration assays. MALDI-TOF MS analysis revealed the generation of up to seven-fold 
dehydrated MibA (Figure 3.2b). Omission of either Microbispora tRNAGluCUC, Microbispora 
GluRS or MibB resulted in the abolishment of dehydration activity suggesting MibB catalyzes 
MibA dehydration in a glutamyl-tRNAGlu dependent manner (Figure 3.2c-e).  
In addition to dehydrated MibA intermediates, peaks whose masses corresponded to 
monoglutamylated and partially dehydrated MibA were observed by MALDI-TOF MS (Figure 
3.2b). The appearance of these peaks suggests a dehydration mechanism similar to NisB, which 
proceeds through glutamylation of Ser/Thr residues followed by glutamate elimination (5). 
Previous alanine scanning mutagenesis of conserved residues in NisB, performed by previous 
group member Dr. Neha Garg, identified Arg786 to be important for glutamate elimination (5). 
To confirm that MibB-catalyzed dehydrations proceed through a similar mechanism, the 
corresponding residue in MibB, Arg870, was mutated to Ala. In vitro dehydration assays with 
MibB-R870A revealed the accumulation of glutamylated MibA peptides (Figure 3.4). This 
result suggests that, similar to NisB, MibB catalyzes the dehydration of MibA through 
glutamylation of Ser/Thr residues followed by glutamate elimination.  
Intriguingly, the observed monoglutamylated and partially dehydrated MibA 
intermediates only start to appear once five-fold, six-fold, or seven-fold dehydrated MibA 
accumulates during the dehydration assay (compare Figures 3.2a and 3.2b). This observation 
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Figure 3.4 Identification of residues in MibB important for glutamate elimination. Dehydration assays were 
performed using His6-MibB-R870A mutant. This residue is conserved in the lantibiotic dehydratase NisB and its 
importance for the glutamate elimination step has been assigned (5). The importance of this corresponding residue in 
MibB was investigated in this study. (a-b) MALDI-TOF MS analysis of His6-MibA after dehydration assays 
performed in the absence (a) or presence of His6-MibB-R870A (b). The appearance of MibA glutamylated adducts 
after MALDI-TOF MS analysis suggests R870 is involved in the glutamate elimination step catalyzed by MibB. M, 
unmodified His6-MibA (average mass calc. [M+H]+ 8013, obs. 8013); 1glu, monoglutamylated His6-MibA (average 
mass calc. [M+H]+ 8142, obs. 8142); 2glu, bisglutamylated His6-MibA (average mass calc. [M+H]+ 8271, obs. 
8271); 3glu, triglutamylated His6-MibA (average mass calc. [M+H]+ 8400, obs. 8400); 4glu, tetraglutamylated His6-
MibA (average mass calc. [M+H]+ 8529, obs. 8530). 
Figure 3.5 Improvement of glutamate elimination upon MibA thioether ring formation. (a–d) MALDI-TOF 
MS analysis of His6-MibA after dehydration assays in the presence of glutamate, ATP, Microbispora His6-GluRS, 
Microbispora tRNAGluCUC and (a) no His6-MibB, (b) with His6-MibB, (c) with His6-MibB and His6-MibC or (d)  
His6-MibB and His6-MibC-H364A. M, unmodified MibA (average mass calc. [M+H]+  8013, obs. 8013); 5, five-fold 
dehydrated MibA (average mass calc. [M+H]+ 7923, obs. 7924); 7, seven-fold dehydrated MibA (average mass calc. 
[M+H]+  7887, obs. 7887); +1glu-3, monoglutamylated and three-fold dehydrated MibA (average mass calc. [M+H]+  
8088, obs. 8088). Gray area highlights the mass range of monoglutamylated and partially dehydrated MibA 
intermediates.  
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suggests that glutamate is eliminated faster from early glutamylated intermediates than from 
those formed at a later stage of dehydration. Recent kinetic characterization of HalM2, a class II 
lanthionine synthetase involved in the dehydration and cyclization of HalA2, revealed that 
formation of thioether rings in HalA2 appeared to increase the rate of subsequent dehydrations 
(16). The observed difference in the efficiency of glutamate elimination might therefore be a 
consequence of MibA having to be partially cyclized in order for MibB to efficiently eliminate 
glutamate as the reaction proceeds. To test this hypothesis MibB dehydration assays were 
performed in the presence of the cyclase MibC.  
MibC was heterologously expressed and purified as an N-terminal hexahistidine tagged 
protein. Dehydration assays were then performed in the presence and absence of MibC (Figure 
3.5a-d). Upon incubation of MibB together with MibC, the monoglutamylated intermediates 
were no longer observed by MALDI-TOF MS (compare Figures 3.5b and 3.5c). To demonstrate 
that MibA indeed needs to be partially cyclized for MibB to eliminate glutamate more efficiently, 
rather than MibC causing a conformational change in MibB that increases the efficiency of Glu 
elimination, dehydration reactions were performed with MibC-H364A, a mutant that disrupts the 
catalytically critical zinc binding site (17). Dehydration assays performed in the presence of 
MibC-H364A again resulted in the appearance of monoglutamylated partially dehydrated MibA 
intermediates as observed by MALDI-TOF MS analysis (Figure 3.5d). Collectively, these 
results are consistent with a model that requires some thioether rings in MibA to be installed for 
MibB to efficiently eliminate glutamate from later glutamylated MibA intermediates. Based on 
this observation subsequent dehydration assays were performed in the presence of MibC unless 
otherwise noted. 
  
3.2.2. Structural characterization of the lantibiotic dehydratase MibB 
To obtain further insights into the dehydration process the 2.7 Å resolution X-ray crystal 
structure of MibB was solved by Prof. Satish K. Nair and Yue Hao (Figure 3.6a). The structure 
of the 120-kDa MibB dehydratase shares similar topology and domain organization when 
compared to the structure of the lantibiotic dehydratase NisB discussed in Chapter 2 (PDB ID 
4WD9) despite the low sequence identity shared among them (20%) (Figure 3.7a) (6). Two 
monomers appear to be forming a functional dimer with a cleft-like structure in the center 
(Figure 3.7b). Amino acids spanning Asp4 through Ser809 form a multi-domain N-terminal 
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Figure 3.6 Crystal structure of the lantibiotic dehydratase MibB. (a) Cartoon representation of the overall 
structure of the MibB homodimer. The glutamylation domain in one monomer is colored purple, the elimination 
domain within the same monomer is colored green and the second monomer is colored gray. Residues important for 
glutamylation and glutamate elimination are shown as spheres. (b-c) Conserved residues among lantibiotic 
dehydratases shown to be important for either (b) glutamylation or (c) glutamate elimination cluster together at the 
N-terminus and C-terminus of the structure respectively. (d) Sequence alignment of selected lanthipeptide 
dehydratases mapped onto the structure of MibB (left). For visualization purposes the elimination domain was 
rotated. The glutamylation domain is not shown for clarity (right). Figures in panel (a-c) were made by Prof. Satish 
K. Nair. 
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Figure 3.7 Structural comparison between the structures of MibB and NisB. (a) Homodimer superpositions of 
the NisB (PDB ID 4WD9) (teal) and MibB (magenta) structural cartoon representations respectively. Overall the 
similar structural topology of both enzymes is apparent. Monomers only differ in the orientation in space of the 
glutamate elimination domain. Possibly this difference is due to a structural rearrangement in NisB upon binding to 
its substrate peptide NisA. (b) Overall surface representation of the MibB homodimer. The N-terminal multidomain 
region of monomer A and B is colored in wheat and purple respectively. The C-terminal domain of each respective 
monomer is colored teal and green. A bifurcated cleft, possibly involved in tRNA binding is observed in the center 
of the structure. (c) Calculated electrostatic potential mapped onto the surface of the MibB monomer. Negative 
(red), neutral (white), and positive (blue). A basic patch within a cavity is observed. The basic patch found in this 
area may suggest a putative tRNA binding site, as described for NisB in Chapter 2. (d) Structural comparison of the 
leader peptide binding domain of the lantibiotic dehydratases MibB (magenta) and NisB (PDB ID 4WD9) (cyan) 
and the cyanobactin heterocyclases TruD (PDB ID 4BS9) (green) and LynD (PDB ID 4VIT) (orange). All leader 
peptide-binding domains share structural homology where the last β sheet engages their respective substrate 
peptides. Compare NisB (substrate NisA) and LynD (substrate PatE’) structures. 
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region while residues spanning Pro813 through His1114 form an individual C-terminal domain     
(Figure 3.6a). No electron-density was observed for residues Glu20 through Asp78 and as a 
result they were not modeled in the final structure. Despite the similar topology when compared 
to NisB, the Cα r.m.s. deviation between both structures was 3.8 Å over 892 residues. The 
relative high r.m.s. deviation observed can be attributed to a slightly different spatial 
arrangement of the C-terminal domain in MibB when compared to NisB. Possibly, this observed 
difference between both structures could result from a conformational change in NisB upon 
substrate binding. 
Analogous to NisB, a region within the N-terminus of MibB is similar in structure to 
RNA recognition motif binding domains that engage ribonucleic acid substrates (18). Mapping 
the electrostatic potential onto the surface of MibB reveals a basic patch within this region 
(Figure 3.7c). The dimensions of the basic patch are similar to the one present in NisB (6), and 
as such this region is likely responsible for binding glutamyl-tRNAGlu. A second small region 
within the N-terminal domain composed of residues Gln201 through Leu286 has structural 
homology to the leader peptide-binding domain found in the NisB co-crystal structure (Figure 
3.7d) (6). This structural element is also present in additional RiPP biosynthetic enzymes and it 
was recently shown to be a prevalent motif important for leader peptide recognition across 
several classes of RiPPs (19-21). Consequently, this domain likely constitutes the binding site 
that engages the LDLD motif present in the MibA leader peptide (Figure 3.1b). 
Residues identified to be important for glutamylation and glutamate elimination in NisB 
(5) are all conserved in MibB (Figure 3.8) and map to distinct clusters in the amino- and 
carboxy-terminal regions in the MibB structure (Figure 3.7b-c). Most of the corresponding 
residues in MibB that were shown to be important for glutamylation in NisB by previous group 
member Dr. Neha Garg map to within a 10 Å radius in the N-terminal region (Figure 3.6b). As a 
result, this 800-residues amino terminal region of MibB is demarcated as the glutamylation 
domain. Likewise, the corresponding residues in MibB that were shown to be important for 
glutamate elimination in NisB by Dr. Neha Garg, including MibB-Arg870, are grouped together 
in a small site in the C-terminal domain (Figure 3.6c). Therefore, the carboxy-terminal 300-
residue domain of MibB can be considered the glutamate elimination domain. Furthermore, a 
sequence alignment of selected lanthipeptide dehydratases from different phyla mapped to the 
MibB structure revealed substantial amino acid conservation within the glutamylation and 
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glutamate elimination active sites (Figure 3.7d). Together the current biochemical and structural 
data points towards a similar glutamyl-tRNAGlu dependent mechanism employed by lantibiotic 
dehydratases in general. 
 
3.2.3. Characterization of MibB tRNA specificity 
A tRNA scanning analysis, performed with the help of Dr. Mark Walker, on the recently 
published Microbispora sp. 107891 genome (15) revealed the presence of two additional 
tRNAGlu gene copies in addition to the one used for the in vitro assays described above. One of 
the copies encodes a tRNAGluCUC isoacceptor similar to the one already described (Figure 3.9a). 
The other copy encodes a tRNAGluUUC isoacceptor (Figure 3.9a). The presence of these three 
different tRNAGlu sequences prompted determination if MibB displayed any isoacceptor 
preference. I purified all three isoacceptors from in vitro transcribed reactions and analyzed the 
extent of MibB-catalyzed MibA dehydration using each tRNAGlu. To ensure differences 
observed in MibA dehydration were not the result of reduced amounts of aminoacylated tRNA, 
functional tRNAGlu concentrations were calculated from radioactive aminoacylation assays for 
each isoacceptor (Figure 3.10). Despite the small sequence differences between each tRNAGlu 
isoacceptor (Figure 3.10a), MALDI-TOF MS analysis of dehydration assays performed under 
Figure 3.8 Sequence alignment of NisB and MibB. Residues shown to be important for glutamylation and 
glutamate elimination in NisB ref. (5) are highlighted in blue and red, respectively. All residues are conserved in the 
class I lantibiotic dehydratase MibB. Number in top of sequence is the amino acid location within the MibB primary 
sequence. 
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continuous aminoacylation conditions revealed a greater extent of MibA dehydration when either 
one of the CUC isoacceptors was used compared to the use of the UUC isoacceptor (Figure 
3.9b-e). These results indicate that MibB is not only able to discriminate between tRNAGlu from 
different organisms (as observed from the low levels of dehydration when using E. coli tRNAGlu), 
but it also discriminates between tRNAGlu isoacceptors encoded in the genome of Microbispora 
sp. 107891. 
Based on the previously proposed tRNA-NisB binding model presented in Chapter 2 (6), 
nucleotides within the tRNAGlu acceptor stem were proposed to be major elements involved in 
binding to NisB. The observed variation in the extent of MibA dehydration when using different 
tRNAGlu isoacceptors could therefore arise from nucleotide differences within this region. 
Figure 3.9 MibB tRNAGlu isoacceptor specificity. (a) Predicted cloverleaf structure of the different tRNAGlu 
isoacceptors present in the Microbispora sp. 107981 genome. (b-e) MALDI-TOF MS analysis of His6-MibA after 
dehydration reactions performed in the presence of glutamate, ATP, His6-MibB, His6-MibC, Microbispora His6-
GluRS and (b) no tRNAGlu, (c) with Microbispora tRNAGluCUC-1, (d) with Microbispora tRNAGluCUC-2, or (e) with 
Microbispora tRNAGluUUC. M, unmodified MibA (average mass calc. [M+H]+ 8013, obs. 8013); 3, three-fold 
dehydrated MibA (average mass calc. [M+H]+ 7959, obs. 7960); 7, seven-fold dehydrated MibA (average mass calc. 
[M+H]+ 7887, obs. 7888). 
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Comparing the nucleotide sequence of the acceptor stem of both tRNAGluCUC isoacceptors 
revealed a conserved A at position 73 and a conserved U72 forming a G1:U72 base pair, whereas 
they contain different base pairs at positions 3–70 and 4–69. Because the use of both 
isoacceptors resulted in a similar extent of MibA dehydration the base pairs at these latter 
positions appear not to be important for efficient MibB dehydration activity (Figures 3.9a and 
3.10a). The tRNAGluUUC isoacceptor also contains the conserved A at position 73 but differs at 
position 72 resulting in a G1:C72 base pair (Figure 3.10a). Finally, E. coli tRNAGlu contains a G 
at position 73 and a C at position 72 forming a G1:C72 base pair similar to the tRNAGluUUC 
found in Microbispora sp. 107981 (Figure 3.11a). These differences in nucleotide sequence at 
positions 72 and 73 could explain why the E. coli tRNAGlu is not used efficiently by the 
lantibiotic dehydratase MibB. If indeed these two nucleotides are elements important for 
Figure 3.10 Glutamylation extent of Microbispora tRNAGlu isoacceptors. (a) Sequence alignment of all three 
Microbispora tRNAGlu isoacceptor sequences. Conserved nucleotides in all three sequences or in two sequences are 
highlighted dark purple or light purple respectively. (b) Glutamylation analysis of Microbispora tRNAGlu 
isoacceptors by liquid scintillation counting (LSC). Glutamylation reactions were performed in triplicate with 5 µM 
tRNAGlu as determined by UV spectroscopy of each isoacceptor (dashed line), 10 µM Microbispora GluRS, and 25 
µM L-(14C)-glutamic acid. Functional concentrations of tRNA were calculated based on the amount of radioactivity 
left on tRNA after extensive washes. Data shown is plotted as the average ± standard error of three independent 
experiments. Based on these assays the functional amount of tRNAGluUUC was five fold lower when compared to 
either tRNAGluCUC isoacceptor. To compensate for this discrepancy, dehydration reactions described in Figure 3.8 
were performed with five fold molar excess of tRNAGluUUC over tRNAGluCUC. The observed difference in 
aminoacylation extent is possibly due to improperly folded tRNA. 
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Figure 3.11 Engineering of E. coli tRNAGlu. (a) Acceptor stem nucleotide sequence of E. coli tRNAGlu, tRNAGlu 
G73A, and tRNAGlu G73A C72U. Mutated nucleotides are shown in red. (b-e) MALDI-TOF MS analysis of His6 -
MibA after dehydration assays performed in the presence of glutamate, ATP, His6-MibB, His6-MibC, E. coli His6 -
GluRS and (b) no tRNAGlu, (c) with E. coli tRNAGlu, (d) with E. coli tRNAGlu G73A, or (e) with E. coli tRNAGlu 
G73A C72U. M, unmodified MibA (average mass calc. [M+H]+ 8013, obs. 8013); 1, one-fold dehydrated MibA 
(average mass calc. [M+H]+ 7995, obs. 7995); 5, five-fold dehydrated MibA (average mass calc. [M+H]+ 7923, obs. 
7924); 7, seven-fold dehydrated MibA (average mass calc. [M+H]+ 7888, obs. 7888). 
Figure 3.12 Glutamylation extent of Escherichia coli tRNAGlu variants. (a) Glutamylation assays were performed 
in vitro using heterologously expressed and purified E. coli GluRS, in vitro transcribed E. coli tRNAGlu and variants 
and L-(14C)-glutamic acid. Reactions were analyzed by gel electrophoresis. The gel was stained with methylene blue 
(top), dried, exposed to a phosphorimager screen and scanned (bottom). The gel was cropped for visualization 
purposes. (b) Quantification of the extent of aminoacylation compared to E. coli glutamyl-tRNAGlu wild-type (WT). 
Quantification was performed using ImageJ64 software. 
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recognition by MibB, the E. coli tRNAGlu sequence may be engineered to be a better substrate for 
MibB.  
 Step-by-step mutations were performed on the E. coli tRNAGlu acceptor stem region. I 
first introduced a G73A mutation in the E. coli tRNAGlu followed by a second mutation, C72U, 
in order to mimic the M. corallina sp. 107891 tRNAGlu isoacceptors. Dehydration assays were 
then performed with each in vitro transcribed and purified E. coli tRNAGlu variant and the extent 
of MibA dehydration was assessed by MALDI-TOF MS analysis. Interestingly, the more the E. 
coli tRNAGlu resembled the Microbispora sp. 107981 tRNAGluCUC acceptor stem region, the more 
efficient MibA dehydration was observed (Figure 3.11b-e). These results are not a consequence 
of differences in the amounts of glutamyl-tRNAGlu present for each mutant, since all E. coli 
tRNAGlu variants were aminoacylated by E. coli GluRS to a similar degree (Figure 3.12). Based 
on the observed MibB preference for Microbispora sp. 107891 tRNAGluCUC and on the 
mutational analysis on the E. coli tRNAGlu, nucleotides A73 and U72 within the acceptor stem 
region of the tRNAGluCUC are important elements for recognition by MibB. 		
3.2.4. Heterologous expression of NAI-107 analogs in Escherichia coli 
Recently, several lantibiotic production systems have been developed in E. coli by 
coexpressing precursor peptides together with the corresponding lantibiotic biosynthetic 
machinery affording the fully modified lantibiotics (22-25). This methodology provides a tool 
for the characterization and engineering of previously uncharacterized lantibiotics circumventing 
several problems associated with such studies when using native producer strains (26, 27). 
However, for several class I lantibiotics, the E. coli lantibiotic expression system is only capable 
of delivering precursor peptides carrying an incomplete number of dehydrations (e.g. ref. (28)). 
The selectivity exhibited by MibB towards the tRNA acceptor stem prompted attempts to 
improve the E. coli coexpression system.  
A plasmid compatible with the T7 expression system in E. coli was designed using the 
pACYC-Duet-1 vector backbone. Four copies of the Microbispora sp. 107891 tRNAGluCUC-1 
isoacceptor were cloned into the multiple cloning site 1 (MCS 1) of pACYC-Duet-1. Each tRNA 
copy was flanked with a T7 promoter sequence at the 5’ end and an rrnC terminator sequence at 
the 3’ end (Figure 3.13a). To ensure that sufficient levels of Microbispora glutamyl-tRNAGlu 
were available during coexpression experiments, the Microbispora sp. GluRS was cloned into 
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the MCS 2 of pACYC-Duet-1. Heterologous production experiments were then performed by 
expressing MibB, MibC, Microbispora tRNAGlu and GluRS with hexahistidine tagged MibA in 
E. coli. Using this expression system we were able to generate NAI-107 analogs containing up to 
seven dehydrations as observed by MALDI-TOF MS analysis after immobilized metal affinity 
chromatography (Figure 3.13b). This expression platform resulted in a significant improvement 
over the levels of MibA dehydration observed without the expression of Microbispora tRNAGlu 
and Microbispora GluRS (compare Figure 3.13b (top and bottom)). 
 
 
 
Figure 3.13 Heterologous expression of NAI-107 analogs in Escherichia coli. (a) Representation of the plasmids 
used for co-expression experiments in E. coli. (b) MALDI-TOF MS analysis of purified His6-MibA after E. coli co-
expression of MibB and MibC (top) or MibB, MibC, Microbispora tRNAGlu and Microbispora GluRS (bottom). 1, 
one-fold dehydrated MibA (average mass calc. [M+H]+ 7231, obs. 7229); 7, seven-fold dehydrated MibA (average 
mass calc. [M+H]+ 7123, obs. 7125). Plasmid map not drawn to scale. 
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3.3. Discussion 
Recent biochemical and structural studies on the lantibiotic dehydratase NisB 
demonstrated that the enzyme uses glutamyl-tRNAGlu as a co-substrate to catalyze Ser/Thr 
dehydration (6). In this Chapter I provide evidence that this is a general mechanism by 
characterizing the enzymatic activity of a representative class I lantibiotic dehydratase from 
Actinobacteria, MibB. Reconstitution of the enzymatic activity of MibB confirmed the use of 
glutamyl-tRNAGlu by this enzyme. MibB, which is a lantibiotic dehydratase from a different 
phylum than NisB (8), still required glutamyl-tRNAGlu for activity suggesting a common use of 
glutamyl-tRNAGlu by class I lantibiotic dehydratases. This hypothesis is also supported by the 
observed conservation of residues among selected class I lanthipeptide dehydratases from 
Actinobacteria, Firmicutes, and Bacteriodetes that mapped to the glutamylation and glutamate 
elimination active sites of MibB (Figure 3.6d). 
The current biochemical data indicates glutamyl-tRNAGlu is serving as a source of 
activated glutamate. Upon MibA leader peptide binding, the core region reaches the 
glutamylation domain in MibB where glutamate is transferred from glutamyl-tRNAGlu to 
selected Ser/Thr side chains on the precursor peptide. After each glutamylation the core region 
moves to the elimination domain where glutamylated Ser/Thr residues are converted to 
dehydroamino acids. Based on the orientation of the glutamylation and glutamate elimination 
domains in NisB and MibB, dimerization of lanthipeptide dehydratases might be a requirement 
for catalysis. Distance constraints also suggest glutamylation of the core region occurs within the 
glutamylation domain of one monomer while glutamate elimination occurs within the glutamate 
elimination domain of the other monomer.  
Including this study, two class I lantibiotic dehydratases have been reconstituted in vitro. 
However, it is noteworthy to mention that in 2007 Saris and coworkers reported the biosynthesis 
of the lantibiotic nisin in vitro by expressing the genes nisA (precursor peptide), nisB 
(dehydratase) and nisC (cyclase) using a cell–free translation system (29). At that time in vitro 
reconstitution of lantibiotic dehydratases was still elusive, however using this translation system 
the authors were able to make nisin as observed from bioactivity assays. This result could only 
be achieved if NisB was active in vitro. Now that lantibiotic dehydratases are known to be 
tRNA-dependent enzymes, the presence of glutamyl-tRNAGlu within the cell–free translation 
system explains why NisB activity could be reconstituted initially.  
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Previous yeast two hybrid assays have shown that NisB forms a multioligomeric complex 
with additional lantibiotic biosynthetic enzymes including the lantibiotic cyclase NisC (30). This 
observation supports the notion that thioether ring formation during lantibiotic biosynthesis is a 
process that alternates between dehydration and cyclization (31, 32). The observed dependency 
of the glutamate elimination catalyzed by MibB on thioether ring formation (Figure 3.5) 
provides additional evidence supporting such alternating activities. Together the results 
presented here suggest that cyclized MibA might adopt a critical structural conformation needed 
for faster glutamate eliminations catalyzed by the glutamate elimination active site.  
 Common to all RiPPs is the presence of a leader peptide that is important in guiding the 
biosynthetic machinery during biosynthesis. The sequence of this leader peptide varies 
depending on the RiPP subclass (e.g. lantibiotics, cyanobactins, thiopeptides). As such it was 
predicted that RiPP biosynthetic enzymes within different RiPP subclasses would have different 
binding scaffolds suitable for binding to their respective leader peptides. However, while the 
predicted leader peptide-binding domain in MibB is similar to the leader peptide-binding domain 
in NisB, this region also shares similarity to the N-terminus	 of	 TruD (4BS9), a heterocyclase 
involved in cyanobactin biosynthesis (33). Recent structural studies on the cyanobactin 
heterocyclase LynD (TruD homolog) demonstrated that this N-terminal region in cyanobactin 
heterocyclases is indeed involved in cyanobactin leader peptide binding (20). Despite the 
sequence differences between lantibiotic and cyanobactin leader peptides, both leader peptides 
bind to their respective enzymes as an extended antiparallel β sheet on similar domains (6, 20) 
(Figure 3.7d). Furthermore, the recent identification of this structural motif in different 
subclasses of RiPP biosynthetic enzymes suggests this leader peptide-binding motif serves as a 
general scaffold important for leader peptide recognition during RiPP biosynthesis (19). 
Despite MibB and NisB catalyzing the same tRNAGlu-dependent dehydration reaction 
and having similar structural topology, MibB exhibited a distinct preference for Microbispora 
tRNAGlu. This observation suggests that lantibiotic dehydratases may have co-evolved with their 
cognate aminoacylated tRNAs. Overall, MibB activity was enhanced when tRNAGlu sequences 
containing nucleotides A73 and U72 in their acceptor stem region were used as co-substrates. 
Previous work on the tRNA specificity of tRNA-dependent enzymes, including aminoacyl-tRNA 
synthetases and cyclodipeptide synthetases, has shown nucleotides within the tRNA acceptor 
stem to be important elements for efficient recognition by their respective enzymes (34-36). The 
	 76 	
presence of specific nucleotides within this region is believed to facilitate the 3’ CCA end of the 
tRNA to adopt a conformation suitable for catalysis (37, 38). Based on this precedent, 
presumably the nucleotides A73 and U72 within the Microbispora sp. 107891 tRNAGlu are 
responsible for helping the acceptor stem achieve a suitable conformation for either binding to 
MibB or for catalysis. Furthermore, specific amino acid residues may be important for nucleotide 
recognition within the tRNAGlu binding pocket of lantibiotic dehydratases. Differences within 
these residues between NisB and MibB could account for the different tRNAGlu specificity 
observed.  
Interestingly, codon frequency analysis of all putative open reading frames in 
Microbispora sp. 107891 genome shows GAG as the most frequent Glu codon (frequency per 
thousand: GAG-50.9, GAA-4.2). The observed tRNA specificity seen in MibB for tRNAGluCUC 
(decodes GAG) over tRNAGluUUC(decodes GAA) could serve as a strategy to avoid the depletion 
of a limited pool of aminoacylated tRNAGluUUC by tRNA-dependent processes other than protein 
biosynthesis. As such, nucleotides in the acceptor stem region could be used as a tRNA identity 
element by MibB to discriminate between the different tRNAGlu isoacceptors. A similar tRNA 
specificity was recently reported for E. coli L/F transferase. These enzymes are responsible for 
mediating protein turnover following the N-rule degradation by attaching either Leu or Phe in a 
tRNA-dependent manner at the N-terminus of selected proteins (39). Similar to MibB, E. coli 
L/F transferase showed substrate selectivity towards the E. coli tRNA that decodes the most 
abundant Leu codon (GUG) (35). 
Recent genome mining efforts have identified Actinobacteria as a vast reservoir of 
previously uncharacterized lantibiotics (14). The recent characterization of a new family of class 
I lantibiotics from Actinobacteria exemplify the opportunities for discovery of novel compounds 
in this phylum (12). However, only a limited number of lantibiotics from Actinobacteria have 
been identified, possibly because they are not expressed under typical growth conditions. Co-
expression strategies in E. coli that produce fully modified lantibiotics in principle can overcome 
lack of production in the native producer (22-24). Yet for class I lantibiotics, the heterologous 
expression system often fails to generate fully modified lantibiotics. In here, I developed an 
improved coexpression system in E. coli by coexpressing a lantibiotic dehydratase with its 
cognate tRNAGlu and GluRS. This methodology for the first time allowed production in E. coli of 
a class I lantibiotic analog from Actinobacteria carrying a complete number of dehydrations. The 
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methodology described herein offers an opportunity to characterize unexplored chemistry 
associated with the biosynthesis of these compounds in addition to increasing the repertoire of 
possible antibiotic candidates. I envision this methodology to be useful for the future 
characterization of not only previously uncharacterized class I lantibiotics produced by 
Actinobacteria but also of other RiPPs predicted to be biosynthesized in a tRNA-dependent 
manner (6) overcoming challenges that may be associated with the native producer strains.  
In conclusion, through the biochemical characterization of the lantibiotic dehydratase 
MibB I was able to provide additional evidence of a common use of glutamyl-tRNAGlu by these 
unusual catalysts as well as a new methodology for the production of lantibiotics useful for 
future genome mining efforts.  
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3.4. Methods 
General Methods 
Oligonucleotides and gBlocks gene fragments used in this Chapter were purchased from 
Integrated DNA Technologies Inc. (Coralville, IA). Reagents used for molecular biology were 
purchased from New England BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, 
MA), or Gold Biotechnology Inc. (St. Louis, MO). Chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). L-[14C(U)]-glutamic acid (0.1 µCi µL–1, 260 mCi mmol–1) was 
purchased from PerkinElmer (Waltham, MA). Escherichia coli DH5α and BL21 (DE3) strains 
were used for plasmid maintenance and protein overexpression respectively. Polymerase chain 
reactions (PCRs) were performed on a C1000TM thermal cycler (Bio-Rad). Primer sequences are 
listed in Table 3.1. Inserts were sequenced at ACGT Inc. using the following primer pairs: 
T7/T7 terminator for sequencing inserts cloned in pET28a, ACYCDuetUP1/DuetDOWN1 for 
sequencing inserts cloned in MCS 1 of Duet-1 vectors and DuetUP2/T7 terminator for 
sequencing inserts cloned in MCS 2 of Duet-1 vectors  (Wheeling, IL). MALDI-TOF MS 
analysis was performed using a Bruker UltrafleXtreme MALDI TOF-TOF mass spectrometer 
(Bruker Daltonics) in reflective mode at The University of Illinois Mass Spectrometry 
Laboratory. MS data was analyzed using the flexAnalysis software package from Bruker. 
Spectra were exported, normalized and plotted using Microsoft Excel. All biochemical assays 
were performed with hexahistidine tagged substrates and enzymes. 
 
Cloning, expression, and purification of His6-MibA  
The gene coding the precursor peptide mibA was codon optimized previously by Dr. 
Neha Garg (GeneArt) (Table 3.1) for expression in E. coli. In addition, Dr. Neha Garg inserted a 
Lys between the leader and core region of MibA to aid in solubility and ionization efficiency. 
The mibA gene was cloned into pET28a with an N-terminal His6 tag following standard cloning 
procedures. Briefly the codon optimized mibA gene was amplified by PCR using the following 
conditions: Phusion HF buffer (1×), dNTP (0.2 mM), primers (1 µM each; Table 3.1; MibA 
NdeI F;	MibA XhoI R), mibA template (10 ng, provided by Dr. Neha Garg), DMSO (3% v/v), 
and Phusion polymerase (0.04 U µL–1) in a total volume of 50 µL. The amplification was 
performed in 20 cycles: denaturation (98 °C for 60 s), annealing (62 °C for 60 s), and 
amplification (72 °C for 6 s). The PCR product was purified by gel extraction on a 1% (w/v) 
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agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). The vector pET28a and the mibA 
PCR fragment were digested using NdeI and XhoI (NEB) restriction endonucleases, purified by 
gel extraction as described above, and the resulting fragments were ligated in a 20 µL volume 
using T4 DNA ligase (NEB) at 16 °C for 18 h. An aliquot of 10 µL from the ligation reaction 
was used to transform E. coli DH5α cells using the heat shock method. The cells were plated on 
Luria Bertani agar (LBA) plates supplemented with kanamycin (kan, 50 µg mL–1) and single 
colonies were grown at 37 °C for 12-15 h. The plasmid his6-mibA-pET28a was isolated using a 
QIA Spin Miniprep Kit (QIAGEN). Insert integrity was verified by sequencing the plasmid with 
the appropriate primers. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with his6-mibA-pET28a (50 ng), 
plated on LBA plates supplemented with kan, and grown at 37 °C for 12-15 h. A single colony 
was used to inoculate 50 mL of LB broth supplemented with kan, grown for 12-15 h at 37 °C, 
and the culture was used to inoculate 9 L of Terrific Broth (TB) media, supplemented with kan, 
to an OD600 of 0.025. Cultures were grown at 37 °C to a final OD600 of 1.0. Peptide expression 
was induced by the addition of IPTG to a final concentration of 0.2 mM and cultures were grown 
at 37 °C for 3 h. Peptide purification was performed following a previously described method 
(40). 
 
Cloning expression and purification of MibB and MibB-R870A 
The NAI-107 (microbisporicin) biosynthetic gene cluster was previously reported (15) 
(10). The cosmid containing the microbisporicin biosynthetic gene cluster (provided by 
Ktedogen) was previously isolated from E. coli cells by a previous group member Dr. Bo Li. The 
gene coding for the lantibiotic dehydratase mibB was cloned into pET28a with an N-terminal 
His6 tag. The mibB gene was amplified by PCR using the following conditions: Phusion HF 
buffer (1×), dNTP (0.2 mM), primers (1 µM each; Table 3.1; MibB NdeI F; MibB XhoI R), 
mibB-pRSF Duet-1 (10 ng, template provided by Dr. Neha Garg), DMSO (3% v/v), and Phusion 
polymerase (0.04 U µL–1) in a total volume of 50 µL. The amplification was performed in 35 
cycles: denaturation (98 °C for 10 s), annealing (63 °C for 30 s), and amplification (72 °C for 
101 s). The PCR product was purified by gel extraction on a 1% (w/v) agarose gel using the 
QIAquick Gel Extraction Kit (QIAGEN). Cloning of mibB into pET28a was performed as 
described above for MibA. The resulting plasmid was then used as a template for site-directed 
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mutagenesis using a previously described method (41) and appropriate primers (Table 3.1; MibB 
R870A F; MibB R870A R) to construct his6-mibBR870A-pET28a. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with either his6-mibB-pET28a or 
his6-mibB-R870A-pET28a (50 ng), and cells were plated on LBA plates supplemented with kan 
and grown at 37 °C for 12-15 h. A single colony was used to inoculate 50 mL of LB broth 
supplemented with kan, grown for 12-15 h at 37 °C, and the culture was used to inoculate 2 L of 
TB media, supplemented with kan, to an OD600 of 0.025. Cultures were grown at 37 °C to a final 
OD600 of 0.6. Protein overexpression was induced by the addition of IPTG to a final 
concentration of 0.1 mM, and cultures were grown at 18 °C for 20 h. Protein purification was 
performed following a similar protocol as described previously (5). 
 
Cloning, expression, and purification of MibC and MibC-H364A 
The gene coding for the lantibiotic cyclase mibC was cloned into pET28a with an N-
terminal His6 tag. The mibC gene was amplified by PCR using the following conditions: Phusion 
HF buffer (1×), dNTP (0.2 mM), primers (1 µM each; Table 3.1; MibC NdeI F; MibC XhoI R), 
mibC-pACYC Duet-1 (10 ng, template provided by Dr. Neha Garg), DMSO (3% v/v), and 
Phusion polymerase (0.04 U µL–1) in a total volume of 50 µL. The amplification was performed 
in 35 cycles: denaturation (98 °C for 10 s), annealing (68 °C for 30 s), and amplification (72 °C 
for 45 s). The PCR product was purified by gel extraction on a 1% (w/v) agarose gel using the 
QIAquick Gel Extraction Kit (QIAGEN) and cloned in the vector pET28a as described above 
using NdeI and XhoI. The resulting plasmid was then used as a template for site-directed 
mutagenesis using a previously described method (41) and appropriate primers (Table 3.1; MibC 
H364A F; MibC H364A R) to construct his6-mibC-H364A-pET28a. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with either his6-mibC-pET28a or 
his6-mibC-H364A-pET28a (50 ng), and cells were plated on LBA plates supplemented with kan 
and grown at 37 °C for 12-15 h. A single colony was used to inoculate 50 mL of LB broth 
supplemented with kan, grown for 12-15 h at 37 °C, and the culture was used to inoculate 1 L of 
TB media, supplemented with kan, to an OD600 of 0.025. Cultures were grown at 37 °C to a final 
OD600 of 0.6. Protein overexpression and purification was performed using a method described 
previously (40). 
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Cloning, expression, and purification of Microbispora sp. 107891 GluRS and Escherichia 
coli GluRS  
The gltX gene from Microbispora sp. 107891 (mgltx) was cloned into pET28a with an N-
terminal hexahistidine tag. Genomic DNA (gDNA) from Microbispora sp. 107891 cells was 
extracted using an UltraClean Microbial DNA isolation kit (MoBio) following the 
manufacturer’s protocol. The mgltX gene was PCR amplified using the following conditions: 
Phusion HF buffer (1×), dNTP (0.2 mM), primers (1 µM each; Table 3.1;	Microbispora gltX 
NdeI F; Microbispora gltX HindIII R), gDNA template (10 ng), DMSO (3% v/v), and Phusion 
polymerase (0.04 U µL–1) in a total volume of 50 µL. The amplification was performed in 30 
cycles: denaturation (98 °C for 180 s), annealing (65 –	72 °C for 6 s), and amplification (72 °C 
for 42 s). The PCR product was purified by gel extraction on a 1% (w/v) agarose gel using the 
QIAquick Gel Extraction Kit (QIAGEN). The vector pET28a and mgltX PCR fragment were 
digested using NdeI and HindIII (NEB) restriction endonucleases, purified by gel extraction as 
described above, and the resulting fragments were ligated in 20 µL using T4 DNA ligase (NEB) 
at 16 °C for 18 h. An aliquot of 10 µL from the ligation reaction was used to transform E. coli 
DH5α cells using the heat shock method. The cells were plated on LB plates supplemented with 
kan, and the plates were incubated at 37 °C for 12-15 h. Single colonies were picked and grown 
in LB supplemented with kan at 37 °C for 12-15 h, and the plasmid his6-mgltX-pET28a was 
isolated using a QIA prep Spin Miniprep Kit (QIAGEN). Insert integrity was verified by 
sequencing the plasmid with the appropriate primers. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with his6-mgltX-pET28a (50 ng), 
plated on LBA plates supplemented with kan, and grown at 37 °C for 12-15 h. A single colony 
was used to inoculate 50 mL of LB broth supplemented with kan, grown for 12-15 h at 37 °C, 
and the culture was used to inoculate 3 L of TB media supplemented with kan to an OD600 of 
0.025. Cultures were grown at 37 °C to an OD600 of 1.0. Protein expression was induced by the 
addition of IPTG to a final concentration of 0.2 mM, and cultures were grown at 18 °C for 20 h. 
Protein purification was performed using a method previously described in Chapter 2 (6). After 
elution from a HisTrap HP 5 mL column (GE Healthcare), the protein was dialyzed overnight 
(20 mM HEPES pH 7.5, 300 mM NaCl, and 10 % (v/v) glycerol) using a 10 kDa MWCO 
membrane, concentrated using a 10 kDa MWCO Amicon centrifugal filter (Millipore) (4,000 ×	
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g, 20 min, 4 °C) and stored in aliquots at –80 °C. The cloning, expression, and purification of 
Escherichia coli GluRS was already described previously in Chapter 2. 
 
RNA extraction from Microbispora sp. 107891  
Microbispora sp. 107891 cells were grown in 2 L of Seed M media (tripticase 30 g L–1, 
dextrose 17.5 g L–1), yeast extract 2 g L–1, NaCl 5 g L–1, and CaCO3 1 g L–1) for six days at 30 
°C. Cells were washed three times with S30 Buffer (10 mM Tris-acetate buffer pH 8.2, 14 mM 
magnesium acetate, 60 mM potassium acetate, 1 mM dithiothreitol (DTT), 0.3 mM EDTA, 0.3 
mM MgCl2) and cell extract was prepared as described previously	(5). RNA was extracted from 
the cell extract by acidic phenol extraction using a previously described method in Chapter 2. 
 
In vitro transcription and purification of tRNAGlu 
The tRNAGlu sequences within the Microbispora sp. 107891 genome were identified 
using the algorithm tRNAscan-SE (42). Escherichia coli tRNAGlu sequence was obtained from 
the genomic tRNA database (43). Primers for E. coli tRNAGlu, Microbispora sp. 107891 tRNAGlu 
and the different variants and isoacceptors used in this study were designed according to a 
previously described method (44). The tRNAGlu dsDNA template for in vitro transcription was 
prepared by filling 5’	 overhangs using the following conditions: Tris HCl pH 7.5 (10 mM), 
primers (4 µM each, See Table 3.1 for sequences), dNTP (400 µM), NEB DNA pol I (large 
Klenow fragment) (0.05 U µL–1) in a final volume of 500 µL. The following primer pairs (listed 
in Table 3.1) were used: for E. coli tRNAGlu (E. coli tRNAGlu F and E. coli tRNAGlu R), for E. 
coli tRNAGlu G73A (E. coli tRNAGlu F and E. coli tRNAGlu G73A R) for E. coli tRNAGlu G73A 
C72U (E. coli tRNAGlu F and E. coli tRNAGlu G73A C72U R) for Microbispora tRNAGluCUC-1 
(Microbispora tRNAGlu (CUC-1) F and Microbispora tRNAGlu (CUC-1) R) for Microbispora 
tRNAGlu CUC-2 (Microbispora tRNAGlu (CUC-2) F and Microbispora tRNAGlu (CUC-2) R) for 
Microbispora tRNAGluUUC (Microbispora tRNAGlu (UUC) F and Microbispora tRNAGlu (UUC) 
R). The reaction was incubated at 10 °C for 30 s followed by an incubation at 37 °C for 30 s (a 
total of 8 cycles), quenched with EDTA (10 mM) at 75 °C for 25 min, and dsDNA tRNAGlu 
template was purified by standard phenol extraction. In vitro transcription was performed using a 
previously described method (45). tRNAGlu was then purified by acidic phenol extraction using a 
previously described method with minor modifications (46). After precipitation, tRNA was 
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dissolved in 300 µL of RNase free water and was desalted using a 10 kDa MWCO Amicon 
centrifugal filter (Millipore) (14,000 ×	g, 10 min, 4 °C, 5 cycles).  
 
tRNAGlu aminoacylation assays 
To assess the extent of aminoacylation on in vitro transcribed tRNAGlu, glutamyl-tRNAGlu 
was analyzed by either denaturing acidic polyacrylamide gel electrophoresis using a procedure 
previously described in Chapter 2 or by liquid scintillation counting (LSC). For LSC each 
Microbispora tRNAGlu isoacceptor was further purified by preparative denaturing 
polyacrylamide gel electrophoresis. Each band was gel extracted using a previously described 
method (47). Purified tRNA was then quantified by UV spectroscopy using a NanoDrop 2000 
(Thermo Fischer). 
Aminoacylation assays were then performed in triplicates using the following conditions: 
HEPES pH 7.5 (100 mM), MgCl2 (10 mM), KCl (10 mM), ATP (5 mM), TCEP (1 mM), 
Microbispora sp. 107891 GluRS (10 µM), each Microbispora sp. 107891 tRNAGlu isoacceptor 
(5µM), L-[14C(U)]-glutamic acid (25 µM), thermostable inorganic pyrophosphatase (0.02 U µL–
1) and water up to 35 µL. Reactions were incubated at 30 °C for 1 h. Afterwards 10 µL from each 
reaction was spotted on a 3MM Whatman filter paper disks pre-soaked with 5% trichloroacetic 
acid (TCA). Each disk was washed three times with 5% TCA for 5 min, one time with 75% cold 
EtOH, and one time in ether. Disks were air dried for 30 min and analyzed by LSC using Ultima 
Gold (PerkinElmer) as LSC cocktail on a Tri-Carb 2910TR (PerkinElmer).  
 
In vitro dehydration assays 
The following reaction conditions were used for dehydration assays: HEPES pH 7.5 (100 
mM), TCEP (1 mM), L-glutamate (10 mM), MibA (1-200 µM), MgCl2 (10 mM), KCl (10 mM), 
MibB (0.1-5 µM), thermo stable inorganic pyrophosphatase (TIPP) (0.02 U µL–1), Microbispora 
sp. 107891 total RNA (1 µg µL–1), Microbispora GluRS (4-10 µM), and ATP (5 mM) in a final 
volume of 30 µL. When noted total RNA was substituted for Microbispora tRNAGlu (2–20 µM). 
In addition, when specified MibC (1-5 µM) and ZnCl2 (1-5 µM) were also added to the reaction.  
The assay was incubated at 30 °C for 3–5 h, centrifuged to remove insoluble material (14,000 ×	
g, 5 min, 25 °C) and desalted using a C-18 ZipTip concentrator (Millipore). The sample was 
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mixed in a 1:1 ratio with 2,5-dihidroxybenzoic acid matrix and spotted on a Bruker MALDI-
TOF plate.  
For dehydration assays using the Escherichia coli tRNAGlu variants the same conditions 
described above were used except the Microbispora GluRS and tRNAGlu were substituted for E. 
coli GluRS (10 µM) and the corresponding E. coli tRNAGlu (20 µM). All Biochemical assays 
were performed with hexahistidine tagged substrates and enzymes. 
 
Heterologous production of NAI-107 in Escherichia coli 
The genes encoding MibA and MibB were cloned in MCS 1 containing an N-terminal 
hexahistidine tag and MCS 2 of pET-Duet-1 respectively using a similar procedure described 
elsewhere (22). The mibA and mibB genes were cloned using Gibson assembly with appropriate 
primers (Table 3.1; MibA_pET_Duet_Gibson_F and MibA_pET_Duet_Gibson_R for mibA 
cloning; MibB_pET_Duet_Gibson_F and MibB_pET_Duet_Gibson_R for mibB cloning) (48). 
The pET-Duet-1 vector was linearized using restriction nucleases BamHI/HindIII for cloning 
mibA and NdeI/XhoI for cloning mibB. Similarly mibC was cloned in MCS 1 of pCDF-Duet-1 
using Gibson assembly with appropriate primers (Table 3.1; MibC pCDF F; MibC pCDF R) 
(48). The plasmid pCDF-Duet-1 was linearized by PCR using primers pCDF linear F and pCDF 
liner R (Table 3.1). Four copies of Microbispora sp. 107891 were cloned into pACYC-Duet-1 
MCS 1 using Gibson assembly as follows. The Microbispora sp. tRNAGluCUC-1 was assembled 
from oligonucleotide sequences. A 5’	 oligonucleotide sequence (Table 3.1; Microbispora 
tRNAGlu (CUC-1) coex F) and a 3’	 oligonucleotide sequence containing a downstream rrnC 
terminator (Table 3.1; Microbispora tRNAGlu (CUC-1) coex R) were used to prepare the tRNA 
DNA template by filling 5’	overhangs as described above. After standard phenol extraction this 
template was used for PCR reactions in order to insert an upstream T7 promoter sequence and 40 
base pairs of homology to the vector backbone for Gibson assembly. The following PCR 
conditions were used: Phusion HF buffer (1×), dNTP (0.2 mM), primers (1 µM each Table 3.1; 
Gibson Microbispora tRNAGlu (CUC-1) F; Gibson Microbispora tRNAGlu (CUC-1) R), template 
(10 ng), DMSO (3% v/v), and Phusion polymerase (0.04 U µL–1) in a total volume of 50 µL. The 
amplification was performed in 20 cycles: denaturation (98 °C for 10 s), annealing (63 °C for 30 
s), and amplification (72 °C for 4 s). The pACYC-Duet backbone was linearized by PCR using 
similar conditions as described above with appropriate primers (Table 3.1; 
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pACYC_tRNA_linear_F;  pACYC_tRNA_linear_R). The amplification was performed in 20 
cycles: denaturation (98 °C for 10 s), annealing (70 °C for 30 s), and amplification (72 °C for 
120 s). Both PCR products were purified by gel extraction on a 1% (w/v) agarose gel using the 
QIAquick Gel Extraction Kit (QIAGEN). Gibson assembly was performed using the following 
conditions: linearized pACYC-Duet-1 (50 ng in 5µL), Microbispora tRNAGlu (1.25 ng, in 1 µL) 
and Gibson Master Mix  (1.33 ×, 15 µL). The reaction was incubated at 50 °C for 1 h and 20 µL 
were used to transform E. coli DH5α	using the heat shock method. The cells were plated on LBA 
plates supplemented with chloramphenicol (cm, 25 µg mL–1), and the plates were incubated at 37 
°C for 12-15 h. Single colonies were picked and grown in LB supplemented with cm at 37 °C for 
12-15 h and the plasmid tRNAGlu-pACYC-Duet-1 was isolated using a QIA prep Spin Miniprep 
Kit (QIAGEN). Insert integrity was verified by sequencing the plasmid with the appropriate 
primers. Microbispora sp. gltX was cloned in MCS 2 of tRNAGlu-pACYC-Duet-1 using standard 
cloning procedures as described above with the appropriate primers (Table 3.1; Microbispora 
gltX NdeI F; Microbispora gltX XhoI R) using NdeI and XhoI restriction sites. 
Additional three Microbispora sp. 107891 tRNAGlu (CUC-1) copies were introduced in 
the MCS 1 of tRNAGlu-mgltX-pACYC-Duet-1 by Gibson assembly. Three gBlocks gene 
fragments (I, II, III) were synthesized (for oligonucleotide sequences see Table 3.1). Each 
fragment contained a single copy of the Microbispora tRNAGluCUC-1 flanked by an upstream T7 
promoter sequence and a downstream rrnC terminator sequence. To avoid non-specific 
amplification during PCR, each gBlock was designed to contain a different Escherichia coli 
DNA linker upstream the T7 promoter region and downstream the rrnC terminator sequence. 
Each gBlock was assembled using restriction nucleases into a tRNA cassette as follows. The 
gBlock I was amplified with a reverse primer containing an NdeI restriction site (Table 3.1; 
Microbispora tRNAGlu I F; Microbispora tRNAGlu I NdeI R). The gBlock II was amplified with 
forward and reverse primers containing an NdeI and XhoI restriction sites respectively (Table 
3.1; Microbispora tRNAGlu II NdeI F; Microbispora tRNAGlu II XhoI R). The gBlock III was 
amplified using a reverse primer containing an XhoI restriction site (Table 3.1; Microbispora 
tRNAGlu III XhoI F; Microbispora tRNAGlu III R). The following conditions were used for PCR: 
Phusion HF buffer (1×), dNTP (0.2 mM), primers (1 µM each), gBlock template (10 ng), DMSO 
(3% v/v), and Phusion polymerase (0.04 U µL–1) in a total volume of 50 µL. The amplification 
was performed in 30 cycles: denaturation (98 °C for 45 s), annealing (66 °C for 30 s), and 
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amplification (72 °C for 11 s). The PCR products were purified by gel extraction on a 1% (w/v) 
agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). Each PCR was then digested 
with the appropriate restriction endonucleases for 2.5 h at 37 °C. The digestions were further 
purified by gel extraction as described above and the resulting fragments were ligated in a 1:1:1 
ratio in 20 µL using T4 DNA ligase (NEB) at 16 °C for 18 h. 
The ligation was used as a template to amplify the resulting tRNA cassette by PCR using 
similar conditions as described above with appropriate primers (Table 3.1; Microbispora 
tRNAGlu cassette F; Microbispora tRNAGlu cassette R). The amplification consisted of 30 cycles: 
denaturing denaturation (98 °C for 45 s), annealing (66 °C for 30 s), and amplification (72 °C for 
24 s). The plasmid tRNAGlu-mgltX-pACYC-Duet-1 was linearized by PCR using similar 
conditions as described above with appropriate primers (Table 3.1; pACYC_casette linear F; 
pACYC_cassette linear R). The amplification was performed in 30 cycles: denaturation (98 °C 
for 45 s), annealing and extension (72 °C for 180 s), and amplification (72 °C for 24 s). Both 
resulting PCRs were purified by gel extraction. Gibson assembly and E. coli DH5α	
transformation were performed as previously described above. Insert integrity was verified by 
sequencing plasmid with appropriate primers. 
E. coli BL21 (DE3) cells (50 µL) were electroporated with his6-mibA_mibB-pET-Duet-1 
(50 ng), mibC-pCDF-Duet-1 (50 ng), and tRNAGlu(4)_mgltX-pACYC-Duet-1 (50 ng) when noted. 
Cells were plated on LBA plates supplemented with ampicillin (amp, 25 µg mL–1), 
spectinomycin (sp, 50 µg mL–1), and cm (12 µg mL–1, if cells harbored tRNAGlu(4)_mgltX-
pACYC-Duet-1) and grown at 37 °C for 12-15 h. A single colony was used to inoculate 50 mL of 
LB broth supplemented with appropriate antibiotics, grown for 12-15 h at 37 °C, and the culture 
was used to inoculate 4 L of TB media, supplemented with appropriate antibiotics to an OD600 of 
0.025. Cultures were grown at 37 °C to a final OD600 of 0.6. Co-expression and purification was 
performed similarly as described elsewhere (22). Expression of proteins was induced with 50–
300 µM IPTG at 25 ºC.  
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Table 3.1 Oligonucleotides used in this study 
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Chapter 4. Characterization of the Substrate Specificity of Lanthipeptide 
Peptidases*. 	
4.1. Introduction 
As with most other RiPPs, lanthipeptides are synthesized as precursor peptides (LanA) 
composed of an N-terminal leader peptide and a C-terminal core region harboring the different 
post-translational modification sites (1). Several functional roles have been proposed for the 
leader peptide (reviewed in Chapter 1). Irrespective of its function, the final maturation step in 
lanthipeptide biosynthesis involves the removal of the leader peptide by a lanthipeptide peptidase. 
Failure to remove the leader peptide usually results in a final product devoid of biological 
activity (2-4). In the case of epilancin 15X (Figure 4.1a), a lanthipeptide produced by 
Staphylococcus epidermidis 15X154 that is remarkably potent against antibiotic-resistant strains 
of S. aureus and Enterococcus faecalis (5, 6), the peptidase ElxP is responsible for leader peptide 
removal. This step exposes an N-terminal Dha on the post-translationally modified core peptide, 
which hydrolyzes to the corresponding pyruvyl (Pyr), and the short chain dehydrogenase ElxO 
then reduces the ketone of the Pyr group to generate an N-terminal lactate moiety (Lac) in the 
final step of maturation (Figure 4.1b) (6) . 
Lanthipeptides are grouped into four classes (class I–IV) on the basis of differences in the 
biosynthetic machinery responsible for installing the (methyl)lanthionine rings, as discussed in 
Chapter 1 (7, 8). At present, four types of peptidases involved in the removal of the N-terminal 
leader peptide have been identified from classes I, II, and III (Figure 4.2). The removal of the 
leader peptide in class I lanthipeptides is performed by a peptidase homologous to subtilisin-like 
serine peptidases (Peptidase S8) termed LanP.  For class II lanthipeptides a bifunctional enzyme 
termed LanT removes the N-terminal leader peptide. LanTs share a conserved N-terminal 
papain-like cysteine peptidase domain (Peptidase C39) and are members of the ATP-binding 
cassette transporter, maturation and secretion (AMS) membrane protein family (9-11) (Figure 
4.2). Their main function is to transport the modified precursor peptide outside the cell with 
concomitant proteolysis of the leader peptide after a highly conserved Gly–Gly motif (9, 12-15). 																																																								*	Parts of this chapter are reprinted with permission from Ortega, M.A., Velásquez, J.E., Garg, N., Zhang, Q., Joyce, 
R., Nair, S.K., and van der Donk, W.A. (2014) Substrate specificity of the lanthipeptide peptidase ElxP and the 
oxidoreductase ElxO, ACS Chem Biol 9(8):1718–1725. Copyright (2014) American Chemical Society.	
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In several cases, class II lanthipeptide biosynthetic clusters also encode a second peptidase 
homologous to class I LanPs. These LanPs are responsible for removing a short oligopeptide 
after the removal of most of the leader peptide by LanT peptidases (16, 17). Leader peptides in 
some class III lanthipeptides are removed by prolyl oligopeptidases (18). Prolyl oligopeptidases 
(Peptidase S9) are serine peptidases that commonly cleave C-terminal to prolyl-residues (19). 
The peptidase involved in the biosynthesis of the lanthipeptide flavipeptin, FlaP, only processed 
the modified precursor substrate, suggesting that prolyl oligopeptidases recognize the modified 
core peptide (18). Finally, no protease responsible for cleaving the leader peptide from class IV 
lanthipeptides has been identified so far.  
In contrast to LanTs, little is known about the interactions that govern the substrate 
specificity of LanPs. A structural homology model of NisP, the peptidase involved in nisin 
biosynthesis, has suggested that the substrate specificity of NisP relies on electrostatic and 
hydrophobic interactions between the NisP S1/S4 binding pockets and residues Arg–1 and Ala–4 
of nisin’s precursor peptide NisA (negative numbers are used for the residues in the leader 
peptide counting back from the protease cleavage site) (20). Kuipers and coworkers showed that 
Figure 4.1 Biosynthesis of epilancin 15X. (a) Biosynthesis involves dehydration of Ser and Thr residues by the 
class I lantibiotic dehydratase ElxB to yield dehydroalanine (Dha, green), and dehydrobutyrine (Dhb, purple), 
formation of lanthionine (red) and methyllanthionine (blue) rings catalyzed by ElxC, removal of the leader peptide 
(bold) by the peptidase ElxP, and (b) reduction of the N-terminal pyruvyl moiety catalyzed by ElxO. Abu (2-
aminobutyric acid), Pyr (pyruvyl), Lac (lactyl). 
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mutating these two positions in the leader peptide of nisin precluded the removal of the leader 
peptide as observed by the in vivo accumulation of modified precursor nisin with the leader 
peptide still attached (2). In addition, work from the same group illustrated that in vivo NisP only 
removes the N-terminal leader peptide from the modified precursor peptide NisA (21). Despite 
this knowledge, our understanding of LanP substrate specificity is still limited in part because of 
the lack of detailed in vitro mechanistic studies, which are hampered by the intrinsic low 
expression yields and poor solubility associated with these enzymes (22-24).  
This chapter presents the biochemical reconstitution of the peptidase ElxP, which 
constitutes the first detailed characterization of the substrate specificity of a LanP enzyme. ElxP 
is involved in the removal of the N-terminal leader peptide from the class I lanthipeptide 
epilancin 15X (Figure 4.1a) (6). Unlike most LanPs, which are either membrane embedded or 
associated, ElxP is predicted to be a cytoplasmic peptidase. In contrast to NisP, ElxP is capable 
of removing the leader peptide from its unmodified precursor peptide substrate, ElxA, making it 
a better candidate for kinetic characterization. Bioinformatic, kinetic and mass spectrometry 
analysis revealed that ElxP recognizes the stretch of amino acids DLNPQS located near the 
proteolytic cleavage site of ElxA. When the ElxP recognition motif was inserted into the non-
cognate lanthipeptide NisA, ElxP was able to cleave the leader peptide from NisA. Together the 
data presented in this chapter provide insights into the substrate specificity of LanP enzymes and 
their applicability as specific peptidases for peptide engineering applications. 
 
Figure 4.2 Domain architecture of lanthipeptide peptidases. Selected peptidases from each lanthipeptide class 
are presented. 
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4.2. Results 
4.2.1. Reconstitution of ElxP activity in vitro 	 Experimental and bioinformatic analysis conducted by Dr. Juan E. Velásquez, a former 
member of the van der Donk laboratory, initially identified ElxP as the peptidase responsible for 
removing the leader peptide from the epilancin 15X precursor peptide, ElxA (6). While some 
insights were obtained into what residues within the leader peptide might be important for 
recognition by ElxP, the lack of kinetic data prevented the elucidation of its substrate specificity.  
ElxP was heterologously expressed and purified with an N-terminal maltose binding 
protein fusion tag (MBP-ElxP) (Figure 4.3a). Various attempts to remove the MBP tag from 
ElxP resulted in precipitated protein. As a result all biochemical assays and kinetic 
characterization were performed with tagged enzyme. The peptide ElxA was also heterologously 
expressed and purified as a hexahistidine tagged construct (His6-ElxA). To assess MBP-ElxP 
activity, His6-ElxA was incubated in the presence of MBP-ElxP and the extent of cleavage was 
analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS). Consistent with Dr. Velásquez’s results, MBP-ElxP was capable of 
Figure 4.3 Reconstitution of ElxP activity in vitro. (a) SDS-PAGE analysis of purified recombinant MBP-ElxP. 
Calculated molecular weight 80.6 kDa. (b) MALDI-TOF MS analysis of His6-ElxA following incubation in the 
presence of MBP-ElxP (blue) or MBP-ElxP S240A (red). PP, precursor peptide, average mass calc. [M+H]+ 8162, 
obs. 8160; LP, leader peptide, average mass calc. [M+H]+ 4864, obs. 4864; CP, core peptide, average mass calc. 
[M+H]+ 3316, obs. 3314. 
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removing the leader peptide from unmodified His6-ElxA as observed by the appearance of two 
mass peaks corresponding to the His6-ElxA leader peptide and the unmodified core region 
(Figure 4.3b, blue trace). The observed masses are consistent with amide bond hydrolysis 
between positions Gln–1 and Ser1 within His6-ElxA. 
 Sequence alignment of ElxP to selected characterized subtilisin-like serine peptidases 
identified Ser240 as the putative catalytic serine in ElxP. The importance of Ser240 for ElxP 
activity was assessed by mutagenesis studies. MBP-ElxP S240A was heterologously expressed 
and purified. Upon incubation of His6-ElxA with MBP-ElxP S240A no mass peaks 
corresponding to either ElxA unmodified core or leader peptide were observed by MALDI-TOF 
MS analysis (Figure 4.3b, red trace). 
 
4.2.2. Determination of ElxP substrate specificity  
To analyze the substrate specificity of ElxP, the sequences of several LanAs from class I 
lanthipeptides were first aligned. The alignment clearly shows that the sequences near the 
proteolytic cleavage site group into two different types (Figure 4.4a). The first group, from here 
on named NisA-group, contains a conserved G/A-A/G-x-x-R motif at the C-terminus of the 
leader peptide and an Ile residue at the first position of the core peptide. The second group, from 
here on named ElxA-group, contains a conserved E/D-L/V-x-x-Q motif at the C-terminus of the 
leader peptide and a dehydratable residue (Ser/Thr) as the first amino acid of the core peptide. To 
interrogate whether LanP enzymes are correlated with this grouping of LanAs, a Markov chain 
Monte Carlo (MCMC) phylogenetic tree of LanPs (Figure 4.4b) was constructed with very high 
fidelity by Dr. Qi Zhang, a former post-doctoral associate in the van der Donk laboratory. The 
analysis shows that LanPs involved in class I lanthipeptide biosynthesis fall into two major 
clades that correspond well with the grouping of LanAs. This analysis suggests that the 
conserved motif of LanAs near the proteolytic cleavage site likely serves as the recognition 
element for LanP enzymes (Figure 4.4b). 
 To test the hypothesis that the conserved motif in ElxA is important for ElxP activity, 
alanine-scanning mutagenesis was performed on the C-terminal E/D-L/V-x-x-Q motif present in 
the ElxA leader peptide. Indeed, single alanine mutations at the Q–1, L–4, and D–5 positions in 
the leader peptide of ElxA significantly reduced the cleavage efficiency of MBP-ElxP as 
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Figure 4.4 Bioinformatic analysis of class I lanthipeptide precursor peptides and their respective 
lanthipeptide peptidases. (a) Sequence alignment of selected leader peptides for which the mature products have 
been structurally characterized. The conserved “FDLN” motif is highlighted in green. The putative LanP recognition 
motifs are shown in blue and red boxes for the NisA-group and the ElxA-group, respectively. LanP cleavage sites 
are indicated with an arrow. (b) MCMC phylogenetic tree of LanP enzymes corresponding to the LanA substrates 
shown in (a). Bayesian inferences of posterior probabilities are shown above or below the branches. Two LanPs 
involved in class II lanthipeptide biosynthesis (LicP for lichenicidin and CylA for cytolysin) served as the out group 
of the tree. Analysis and figure provided by Dr. Qi Zhang. 
Table 4.1 MBP-ElxP cleavage of wild type and mutant His6-ElxA peptides.* 
* Observed masses are shown with the calculated mass in parenthesis. MBP-ElxP (5 µM) was incubated with 
mutant or wild type His6-ElxA (50 µΜ) in reaction buffer (50 mM Tris HCl pH 8.0) at room temperature for 2 h. 
Reactions were analyzed by MALDI-TOF MS. Results are based on the amount of substrate left after cleavage 
reaction based on normalized ion intensities. Complete cleavage (+++), partial cleavage (++), marginal cleavage 
(+). 
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observed by MALDI-TOF MS (Table 4.1). To quantify and distinguish the contribution of each  
amino acid to the substrate specificity of ElxP, the kinetic parameters of MBP-ElxP were 
determined by using the wild type peptide and three ElxA mutants, Q–1A, P–2A and L–4A, as 
substrates. Reversed phase high performance liquid chromatography (RP-HPLC) was used to 
monitor N-terminal leader peptide formation at different substrate concentrations (Figures 4.5). 
MBP-ElxP cleaved wild type ElxA with an efficiency of ~240 M–1 s–1 (Figure 4.6a), whereas 
the mutants Q–1A or L–4A were processed by ElxP with ~14-fold lower efficiency (Figures 
4.6b and 4.6c). In contrast, single alanine substitutions at Pro–2 and Asn–3 positions in ElxA did 
not obviously decrease the efficiency of MBP-ElxP in removing the N-terminal leader peptide 
from ElxA (Table 4.1 and Figure 4.6d), demonstrating that only the conserved amino acids in 
the E/D-L/V-x-x-Q motif of ElxA are important for ElxP activity. Although it is possible that 
Figure 4.5 HPLC-based quantification of ElxA leader peptide. (a) ElxA leader peptide standard curve. The 
absorbance of different concentrations of purified His6 tagged ElxA leader peptide was determined by analytical 
HPLC using a 220 nm wavelength for detection. Linearity was observed up to 50 µM leader peptide. Data plotted 
represents the average of two independent runs and error bars represent the standard error associated with the 
measurements. (b-e) Time dependent formation of the N-terminal leader peptide upon treatment of His6-ElxA and 
its mutants with MBP-ElxP (0.25–1 µM). (b) His6-ElxA, (c) His6-ElxA Q-1A, (d) His6-ElxA P-2A, and (e) His6-
ElxA L-4A were incubated at different concentrations (50 µM, ¡100 µM, ®150 µM, 200 µM, £250 µM, ¯300 
µM, °350 µM) with MBP-ElxP, and leader peptide formation (LP) was monitored at different time points by 
HPLC. Data was fit to a linear regression to obtain initial rates. 
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proteolysis by wild type ElxP of the ElxA peptide possessing the thioether rings would be more 
efficient, the catalytic efficiency of MBP-ElxP observed with linear peptides shows promise for 
the application of this enzyme as a sequence specific protease.	
Many leader peptides of class I lanthipeptides share an F-D/N-L-N/D sequence motif 
(Figure 4.4a). Biochemical and structural studies have shown that this conserved motif is 
important for substrate recognition by the enzymes involved in (methyl)lanthionine formation 
during lanthipeptide biosynthesis (23, 25-28). To probe whether this region is also important for 
recognition and efficient cleavage by ElxP, alanine-scanning mutagenesis was performed by Dr. 
Velásquez on the F-D-L-N motif present in ElxA and the cleavage efficiency was analyzed by 
MALDI-TOF MS. The results obtained show that the conserved F-D-L-N sequence is not 
important for ElxP recognition (Table 4.1).  
Figure 4.6 Kinetic characterization of ElxP peptidase activity for His6-ElxA and mutant peptides. Purified (a) 
ElxA, (b) ElxA Q–1A, (c) ElxA L–4A, and (d) ElxA P–2A at different concentrations were digested with ElxP and 
leader peptide formation was monitored at different time points by HPLC as shown in Figure 4.5. The rate of MBP-
ElxP catalysis was plotted as a function of different substrate concentrations. Data was fit to the Michaelis-Menten 
equation to give the kinetic parameters shown, and is presented as the average ± standard error of two independent 
experiments. 
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4.2.3. ElxP as a peptidase tool to remove non-cognate leader peptides from other RiPPs 
Based on the collected data, the conserved E/D-L/V-x-x-Q-T1/S1 motif present in the 
ElxA-group of precursor peptides likely serves as the main recognition element for their LanPs. 
This sequence could possibly be used as a tool to selectively remove tags from fusion proteins or 
leader peptides from other RiPPs. To determine this potential, I analyzed the ElxP activity on the 
non-cognate lanthipeptide precursor peptide NisA. As expected, ElxP could not cleave wild type 
NisA; upon incubation of NisA with ElxP, no new peaks corresponding to the N-terminal leader 
or core peptide masses were observed by MALDI-TOF MS analysis (Figure 4.7a). However, 
when we replaced the G-A-S-P-R-I sequence of NisA with a sequence similar to the recognition 
element in ElxA (D-L-N-P-Q-A), in which an Ala residue functions to mimic the dehydrated 
Ser1 residue of ElxA), the resultant mutant peptide (NisA-G–5D/A–4L/S–3N/R–1Q/Q–
Figure 4.7 MALDI-TOF MS traces for cleavage of NisA and NisA mutants by ElxP. (a) NisA (average mass 
calc. [M+H]+ 7996, obs. 7992) treated with ElxP, (b) NisA G–5D/A–4L/S–3N/R–1Q/Q–1_I1insA treated with ElxP. 
His6 NisA-G–5D/A–4L/S–3N/R–1Q/Q–1_I1insA unmodified core peptide (average mass calc. [M+H]+ 3569, obs. 
3568) and leader peptide (average mass calc. [M+H]+ 4063, obs. 4064) (c) NisA R–1Q (average mass calc. [M+H]+ 
7416, obs. 7412) treated with ElxP, (d) NisA R–1Q/Q–1_I1insA (average mass calc. [M+H]+ 7487, obs. 7485) 
treated with ElxP, and (e) NisA G–5D/A–4L/S–3N/R–1Q (average mass calc. [M+H]+ 7543, obs. 7542) treated with 
ElxP. PP-precursor peptide, CP-core peptide, and LP-leader peptide. *Ion corresponding to peptide bearing 
gluconoylation of the His6-tag of NisA. 
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1_I1insA) was completely cleaved by ElxP (Figure 4.7b; for the sequences of the NisA mutants, 
see Figure 4.8). Other NisA mutants with partial permutations in the G-A-S-P-R-I  sequence, 
including NisA-R–1Q, NisA-G–5D/A–4L/S–3N/R–1Q, and NisA-R–1Q/Q–1_I1insA, were not 
cleaved by ElxP (Figures 4.7c–4.7e). These results support the hypothesis that the ElxP 
specificity relies on the complete E/D-L/V-x-x-Q-T1/S1 sequence motif. 
 
4.3. Discussion 
Sequence comparison and mutagenesis studies confirmed that ElxP belongs to the 
subtilisin-like serine peptidase superfamily. This enzyme family employs a nucleophilic serine 
responsible for initiating amide bond hydrolysis on its substrates (29). In ElxP, S240 likely 
performs this function based on sequence conservation with other peptidases and as witnessed by 
the absence of activity when this residue was mutated to Ala. The successful reconstitution of 
ElxP in vitro that made this mutational analysis possible also provided a suitable platform to 
dissect the substrate specificity of this enzyme and ultimately revealed the recognition sequence 
for ElxP (E/D-L/V-x-x-Q-T1/S1). Installation of this sequence in the non-cognate lanthipeptide 
precursor NisA enabled ElxP-catalyzed proteolysis of NisA, thus demonstrating the potential of 
ElxP as a general peptidase for removing RiPP leader peptides in vitro in a sequence specific 
manner. 
In addition to the already known F-D/N-L-N/D motif conserved in lanthipeptide leader 
peptides (23, 25-28), the sequence comparison of characterized lanthipeptide precursor peptides 
revealed a second region of conservation. Two distinct motifs were shown to be present at the C-
terminus of these leader peptides (Figure 4.4a). Surprisingly, phylogenetic analysis of their 
associated lanthipeptide peptidases revealed two distinct clades that grouped together based on 
Figure 4.8 Leader peptide sequences of NisA variants. The cleavage recognition sequence of NisA is shown in 
blue. Amino acid mutations in the NisA variants are shown in red. ElxA leader peptide sequence is shown for 
reference. LanP cleavage site is indicated with an arrow. 
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the C-terminal motif in their substrates (Figure 4.4b). Mutational studies indeed confirmed that 
the sequence motif E/D-L/V-x-x-Q-T1/S1 located at the C-terminus of the ElxA leader peptide is 
important for recognition by ElxP. Additionally, ElxP does not recognize the same amino acid 
motif (FNLD) needed by the enzymes responsible for installing the lanthionine rings (e.g. LanBs 
and LanCs for the biosynthesis of class I lanthipeptides) (23, 25-28). This finding is in line with 
other studies that have found that different parts of the leader peptide are recognized by different 
post-translational modification enzymes during RiPP biosynthesis (30, 31). Together, these 
results suggest that precursor peptides and LanP proteins likely co-evolved and that LanP 
sequence specificity is mainly determined by the amino acids near the proteolytic site. As such, 
phylogenetic analysis of uncharacterized lanthipeptide proteases could be used as a tool to 
predict their substrate specificity, allowing for accurate mass prediction of core peptides 
identified by genome mining platforms. 
Kinetic analysis of MBP-ElxP using several ElxA mutant peptides revealed that within 
the C-terminal ElxA leader peptide sequence (DLNPQ), positions Q–1, L–4, and D–5 contribute 
the most to ElxP recognition as observed by the decrease in catalytic efficiency when compared 
to wild-type substrate. This observation is consistent with how other members of the subtilisin-
like serine peptidases recognize their respective substrates (29). Similar results were also 
recently obtained for the subtilisin-like serine peptidase LicP involved in the maturation of the 
two-component class II lanthipeptide lichenicidin (16). LicP is responsible for cleaving the short 
oligopeptide NDVNPE from the modified precursor peptide LicA2 yielding mature Licβ (17). 
While the ElxP and LicP substrate specificities are different, mutational studies revealed that the 
positions of the recognition element most critical for efficient LicP catalyzed cleavage are the 
same: positions –1, –4, and –5 or specifically E–1,V–4, and D–5 of the NDVNPE motif in LicA2 
(17). This similarity suggests that lanthipeptide peptidases might employ a general substrate 
recognition mechanism relying on the amino acids located at positions –1, –4 and –5 of their 
respective substrates. The different substrate specificities observed for ElxP and LicP further 
validate the phylogenetic analysis employed to initially identify the ElxP recognition motif. This 
is further highlighted by the observation that LicP belongs to a different clade from ElxP. 
When the DLNPQ motif was inserted in NisA, no cleavage activity by ElxP was 
observed. Activity was only detected when an Ala residue was inserted between positions Gln–1 
and Ile1 in the precursor peptide NisA (Figure 4.8). This result suggests that ElxP also 
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recognizes the first amino acid of the core region of its substrates and perhaps can only 
accommodate small amino acids at this position. This is in stark contrast to the specificity 
observed for LicP where proteolysis still occurred on a number of substrate analogs containing 
different residues at the first position of the core peptide (17). While no crystal structure of ElxP 
is available that might explain the observed substrate specificity, the recent structural 
characterization of LicP (17), and NisP in complex with a substrate peptide fragment 
(ANNRNSRGAVSVR) (32), gives a structural framework that explain general factors governing 
the specificity of LanP peptidases. 
Structural characterization of NisP revealed the presence of electron density within an 
open cleft arising from an autocatalytic self-cleavage event at its C-terminus (32). The similarity 
of the C-terminus of this peptide with the C-terminus of the NisA leader peptide and the close 
proximity of the catalytic Ser512 suggested that this region is responsible for binding the 
precursor peptide NisA (32) (Figure 4.9a, although the bound peptide is a NisP fragment, 
standard lanthipeptide leader peptide numbering will be used to facilitate comparison). Within 
the open cleft two distinct pockets, S1NisP and S4NisP, are present and accommodate residues R–1 
and V–4 (Figure 4.9a), respectively. The residue R–1 is coordinated via electrostatic interactions 
Figure 4.9 Surface representation of the substrate binding clefts present in lanthipeptide peptidases. (a) NisP 
in complex with a NisP peptide fragment (shown as green sticks) (PDB ID 4MZD), (b) LicP (PDB ID 4ZOQ), and 
(c) ElxP (predicted). The leader peptide sequence each peptidase recognizes is shown on top of the figure except for 
NisP where the sequence shown is the one observed in the crystal structure. Peptidase binding pockets are labeled. 
The peptide sequence in the NisP structure is labeled in parenthesis. For clarity the S5 pocket is not labeled. While 
the peptide bound to NisP does not originate from a lanthipeptide precursor, the same numbering system where the 
leader peptide has negative numbers counting back from the core is used to facilitate comparison.  
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with the side chain of Asp436 within the S1NisP subsite (32). The corresponding residue in the 
LicP structure is His291 in the S1 site and is similarly predicted to form electrostatic interactions 
with position –1 of the LicA2 leader peptide (i.e. E–1) (17) (Figure 4.9b). A structural 
homology model of ElxP based on the NisP crystal structure suggests that in ElxP Ser162 might 
be involved in mediating hydrogen bond interactions with Q–1 of the DLNPQ ElxA motif and 
thus responsible for determining the S1ElxP residue specificity (Figure 4.9c). These observations 
suggest that peptidase specificity for position –1 is mainly mediated by a corresponding residue 
present in the S1 pocket of LanPs. In addition, the size of each peptidase S1 pocket is different 
implying that not only side chain interactions determine the specificity of these proteases but also 
side-chain sterics as well (Figure 4.9).  
V–2 in the NisP cocrystal structure is within a less well-defined S2NisP pocket while S–3 
is solvent exposed (Figure 4.9a). This observation provides a structural rationale for why ElxA 
mutations at the –2 and –3 positions have no effect on processing by ElxP. A commonality 
between all peptidases is the presence of a small hydrophobic cavity within the substrate-binding 
cleft. In the NisP structure this S4NisP pocket is occupied by V–4 (32) and the analogous LicP 
cavity was predicted to accommodate V–4 of the recognition motif NDVNPE (17). A similar but 
larger hydrophobic cavity is present in ElxP and predicted to comprise Leu102, Leu106, Ala109, 
Ile119, and Tyr121. This is not surprising given that ElxP accommodates the larger L–4 residue 
of the DLNPQ motif and might explain why mutations at this position within the ElxA 
recognition motif altered the ElxP catalytic parameters (Figure 4.6).  
The ability of LicP to cleave substrates carrying different amino acids at the first position 
of the core peptide could be due to the wider substrate-binding cleft to the left of the S1LicP and 
S2LicP cavities relative to the one predicted to be present in ElxP (compare Figures 4.9b and 
4.9c). A similar wider binding cleft is present in NisP (Figure 4.9a). Presumably these wider 
clefts could serve to accommodate the N-terminal thioether ring present in Licβ and nisin. The 
absence of such a cleft in ElxP could reflect on the fact that this enzyme needs to accommodate 
an N-terminal linear sequence of amino acid residues in epilancin 15X, not a thioether ring. This 
might explain the stringent recognition by ElxP of the N-terminal residue within the core region 
of its substrate peptide. Further structural studies of ElxP in complex with its substrate peptide 
ElxA are needed to validate these observations. Despite the need of having a non-cognate amino 
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acid present in the final product, as when using peptidases like thrombin or TEV (33), ElxP still 
has the potential to be a useful tool to remove artificial tags and leader peptides.  
In conclusion, the structural and biochemical experiments presented in this chapter 
resulted in a much better understanding of ElxP and provide a framework for the future 
characterization of additional lanthipeptide peptidases. These lanthipeptide peptidases may also 
have useful applications as general proteases, as was recently described for LicP (17). 
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4.4. Methods 
General Methods 
All oligonucleotides used in this study were purchased from Integrated DNA 
Technologies (Table 4.2). Reagents used for molecular biology were purchased from New 
England BioLabs, Thermo Fisher Scientific, or Gold Biotechnology. Plasmid sequencing was 
performed by ACGT Inc. Escherichia coli DH5α and BL21 (DE3) were used for plasmid 
maintenance and protein or peptide overexpression, respectively. MALDI-TOF measurements 
were performed using a Bruker UltrafleXtreme MALDI-TOF-TOF instrument using a positive 
reflective mode and sinapic acid as a matrix. Structural homology model of ElxP was performed 
using the I-TASSER suite with the NisP structure as an initial template (PDB 4MZD) (34).	
 
Table 4.2 Oligonucleotides used in this study. 
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Expression and purification of MBP-ElxP 
The cloning of the gene encoding ElxP is described elsewhere (6). An aliquot of 50 ng of 
pelB-mbp-elxP-pET28b was used to transform 50 µL of electrocompetent E. coli BL21 (DE3) 
Rosetta 2 cells following standard procedures. After the incubation period, cells were plated on 
LB agar (LBA) plates supplemented with kanamycin  (kn, 25 µg mL–1) and chloramphenicol (cm, 
12.5 µg mL–1) at 37 °C overnight (O/N). A single colony was used to inoculate 1 mL of fresh LB 
supplemented with kn and cm and 1 mL was plated for a second time on LBA plates 
supplemented with kn and cm. Plates were kept at 37 °C O/N. For overexpression, 1 mL of LB 
supplemented with kn and cm was used to resuspend cells scraped out of the O/N LBA plates to 
be used as initial inoculum. Overexpression was performed in 6 L of LB supplemented with kn 
and cm with a starter OD600 of 0.025. Cultures were incubated at 37 °C, with shaking at 250 rpm 
until the OD600 reached ~1.0. At this OD, cultures were chilled on ice for 15 min and protein 
expression was induced with 0.1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). Protein 
overexpression was carried out at 18 °C at 250 rpm for 16 h. The cells were harvested (6976 × g, 
20 min, 4 °C), resuspended in 50 mL of lysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 
10% (v/v) glycerol, 1 mM EDTA) and lysed using an EmulsiFlex-C3 homogenizer with a 
pressure of less than 500 bar. To remove cell debris, the lysed fraction was centrifuged (22,789 × 
g, 4 °C, 30 min) and the supernatant was cleared through a 0.45 µm syringe-tip filter (Millipore). 
The protein was purified by affinity chromatography using an ÄKTA purifier (GE healthcare) 
equipped with an MBPTrap HP 5 mL column pre-packed with Dextrin SepharoseTM (GE 
healthcare) according to the manufacturer’s protocol. After loading the supernatant into the 
column pre-equilibrated with lysis buffer, the column was washed with lysis buffer until a stable 
baseline at 280 nm for the absorbance was reached. Protein was eluted with a linear gradient 
from 0–100% (v/v) of elution buffer (20 mM TrisHCl pH 8.0, 500 mM NaCl, 1 mM EDTA, 10 
mM maltose) in lysis buffer over 30 min. Collected fractions were analyzed by SDS-PAGE 
using a 4–20% TGX mini-protean gel (BioRad) and visualized by Coomassie staining. Fractions 
containing the desired MBP-ElxP were collected and desalted using gel filtration 
chromatography on a HiLoad 16/60 column packed with Superdex 200 PG eluting at 1 mL min–1 
of gel filtration buffer (300 mM NaCl, 20 mM Tris-HCl pH 8.0, 10% (v/v) glycerol). Protein was 
concentrated using an Amicon Ultra centrifuge tube of 30-kDa molecular weight cut off 
(MWCO) (3,488 × g, 30 min, 4 °C) (Millipore). The concentration of the purified protein was 
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determined spectrophotometrically using a calculated molar extinction coefficient of 113,485 M–
1 cm–1 and a molecular weight of 80.504 kDa. Purity was assessed by SDS-PAGE analysis 
(Figure 4.3a). Aliquots were frozen in liquid nitrogen for future use and stored at –80 °C. 
 
Cloning, expression, and purification of His6-ElxA and mutant variants 
The cloning of the gene encoding ElxA into pET28b is described elsewhere (6). The 
ElxA leader peptide variants were constructed using QuikChange mutagenesis following a 
previously described method (35). The his6-elxA-pET28b was used as a template to introduce the 
different mutations by PCR using the corresponding primer pair listed in Table 4.2. A typical 
PCR reaction consisted of 1 × HF Buffer, 0.2 mM DNTP, 1 µM forward and reverse primers, 10 
ng template DNA, 3% (v/v) DMSO and 0.02 U µL–1 Phusion polymerase (NEB). After PCR, 
reactions were incubated at 37 °C for 2 h with DpnI (5 U). After treatment with DpnI, samples 
were purified using the QIAquick PCR purification kit (Qiagen). An aliquot of 10 µL was used 
to transform E. coli DH5α cells using the heat shock method and cells were plated on LBA plates 
supplemented with kn (50 µg mL–1). Plates were incubated at 37 °C O/N. A single colony was 
inoculated in LB supplemented with kan, grown at 37 °C O/N, and plasmid was extracted using 
the QIAprep spin mini prep kit (Qiagen). The desired mutations were verified by DNA 
sequencing. 
Overexpression and purification of wild type ElxA and mutant variants was carried out 
using a previously described method with minor modifications (6). An aliquot of 50 ng of 
recombinant DNA from wild type ElxA and each of the mutants described above was used to 
transform 50 µL of electrocompetent E. coli BL21 (DE3) cells and plated on LBA supplemented 
with kan (50 µg mL–1) at 37 °C O/N. A single colony was used to inoculate a starter culture of 
LB supplemented with kn and incubated at 37 °C for 12 h. After the incubation period, 6 L of 
Terrific Broth (TB) supplemented with kn, and glycerol (4 mL L–1), were inoculated with the 
starter culture to obtain an initial OD600 0.025. Flasks were incubated at 37 °C, with shaking at 
250 rpm, and peptide expression was allowed to proceed at 18 °C, 250 rpm for 18 h after 
induction with 1.0 mM IPTG when the OD600 reached 1.0. Cells were harvested by centrifugation 
(6976 × g, 20 min, 4 °C), resuspended in 30 mL of LanA Buffer 1 (6 M guanidine hydrochloride, 
20 mM NaH2PO4 pH 7.5, 500 mM NaCl and 0.5 mM imidazole) and lysed by sonication (35% 
amplitude, 4.0 s pulse, 9.9 s pause, 15 min). Cell debris was removed by centrifugation (22789 × 
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g, 30 min, 4 °C) and supernatant was filtered through a 0.45 µm syringe filter unit. Purification 
was carried out using immobilized metal affinity chromatography (IMAC) with a HisTrap 5 mL 
column pre-packed with Ni SepharoseTM. After loading supernatant into the column, the column 
was washed with 10 column volumes (CV) of LanA Buffer 1 followed by 10 CV of LanA Buffer 
2 (4 M guanidine hydrochloride, 20 mM NaH2PO4 pH 7.5, 300 mM NaCl and 30 mM imidazole) 
to remove any non-specifically bound proteins, followed by peptide elution in 3 CV of LanA 
Elution Buffer (4 M guanidine hydrochloride, 20 mM Tris HCl pH 7.5, 100 mM NaCl, 1 M 
imidazole). To remove excess salts, the peptide was purified by reversed phase high performance 
liquid chromatography (RP-HPLC) using a C4 Waters Delta Pak cartridge column with a linear 
gradient of 2% (v/v) of solvent A [80% (v/v) MeCN, 20% (v/v) H2O, 0.086% (v/v) 
trifluoroacetic acid (TFA)] in solvent B [0.1% (v/v) TFA in H2O] to 75% (v/v) solvent A over 30 
min. Fractions were analyzed for the desired peptide by MALDI-TOF MS. Fractions containing 
peptide were freeze dried using a lyophilizer (Labconco) and stored at −20 °C. The purity of 
each peptide was assessed by analytical HPLC.  
 
Cloning, expression, and purification of His6-NisA and mutant variants 
The cloning of the gene encoding NisA into pRSF Duet-1 is described elsewhere (36). 
The NisA leader peptide variants were constructed using QuikChange mutagenesis. The his6-
nisA-pRSF Duet-1 plasmid was used as a template to introduce the different mutations by PCR 
using the corresponding primer pair listed in Table 4.2. PCR conditions, overexpression, and 
purification of peptides were performed as described above. 
 
MBP-ElxP activity assays by MS 
A typical activity assay consisted of 50 mM Tris HCl pH 8.0, 50 µM peptide, 5 µM 
MBP-ElxP in a final volume of 100 µL. The sample was incubated for 2 h at room temperature. 
To monitor cleavage activity, samples were desalted using a zip tip concentrator (Millipore), 
mixed in a 1:1 ratio with sinapic acid, and spotted on a MALDI-TOF Bruker plate. Ion intensities 
for the resulting precursor peptide, leader peptide and core peptide were normalized and the 
proteolytic efficiency was measured based on the amount of substrate left after cleavage reaction 
(Table 4.1). Reactions were performed with tagged enzyme and substrates unless otherwise 
noted.   
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Determination of ElxP kinetic parameters 
The kinetic parameters of MBP-ElxP were determined using an HPLC based assay 
following a previously described method (13). The peptidase activity of tagged ElxP was assayed 
in a 100 µL reaction mixture containing 50 mM Tris pH 8.0, and various concentrations of wild 
type His6-ElxA or mutant variants. The reaction was started by adding ElxP to a final 
concentration to consume less than 10% of the initial substrate concentration in the time frame of 
the assay. The enzyme concentration ranged from 0.25 µM to 1 µM. The reaction was incubated 
at room temperature and quenched in 0.1% (v/v) TFA and 5 mM TCEP at different time points. 
The reactions were loaded on a Hypersil Gold C4 (250 × 4.6 mm, 5 µ) analytical column 
(Thermo Fisher Scientific) connected to an Agilent 1260 Liquid Chromatography (HPLC) 
system (Agilent Technologies). Product formation was detected by monitoring the increase in the 
peak area of the leader peptide at 220 nm (Figure 4.5). The leader peptide was separated from 
the unmodified core and precursor peptide using a linear gradient from 2% to 75% (v/v) of 
solvent A [80% (v/v) MeCN, 20% (v/v) H2O, 0.086 % (v/v) TFA] in solvent B [0.1% (v/v) TFA 
in H2O] over 30 min at a flow rate of 1 mL min–1 at room temperature. The concentration of the 
leader peptide was calculated by converting the area under the leader peptide peak to leader 
peptide concentration using a calibration curve made from purified leader peptide (Figure 4.5). 
Rates of leader peptide formation were then plotted against substrate concentration and the 
resulting graph was fit to the Michaelis-Menten equation. Values were plotted as the average and 
standard error of two independent experiments. Reactions were performed with tagged enzymes 
and substrates unless otherwise noted.  
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Chapter 5. Biochemical Characterization of Enzymes Involved in the 
Decarboxylation and Halogenation of the Lanthipeptide Microbisporicin 
 
5.1. Introduction 
The availability of biosynthetic enzymes with wide substrate scopes is beneficial for 
RiPP combinatorial biosynthesis. To date only a limited set of RiPP post-translational 
modifications have been employed for this approach (1-3). To expand the number and type of 
post-translational modifications compatible with RiPP combinatorial biosynthesis, I 
characterized the substrate specificity of the lanthipeptide Cys decarboxylase MibD and the 
flavin-dependent Trp halogenase MibH. These two lanthipeptide tailoring enzymes are 
responsible for the decarboxylation and halogenation of the microbisporicin precursor peptide 
MibA (for an introduction to microbisporicin biosynthesis see Chapter 3). Surprisingly, unlike 
other RiPP biosynthetic enzymes, both catalysts exhibited high degrees of substrate specificity, 
hampering their use in RiPP combinatorial biosynthesis. Despite this undesired outcome, the 
work presented in this Chapter sets the stage for future studies aiming to engineer these enzymes 
to accept non-cognate substrates. 
Lanthipeptides contain the characteristic bis-amino acids lanthionine and 3-
methyllanthionine (reviewed in Chapter 1). Besides the common post-translational modifications 
present in this RiPP subfamily, some lanthipeptides contain additional modified residues 
installed by tailoring enzymes. For instance, epilancin 15X contains an N-terminal lactate moiety 
that serves to protect this peptide against the action of aminopeptidases (2) (see chapter 4 for an 
introduction to epilancin 15X). The lanthipeptide microbisporicin contains a 5-chlorotryptophan 
residue (ClTrp) responsible for increasing the biological activity of this peptide by two-fold 
when compared to its deschloro counterpart (4, 5). In addition, microbisporicin contains a C-
terminal S-[(Z)-2-aminovinyl]-(3S)-D-cysteine (AviCys) ring arising from the oxidative 
decarboxylation of a C-terminal Cys residue (Figure 3.1b) (5). Presumably this modification 
serves to protect the peptide from carboxypeptidases. The benefits these additional modifications 
confer to the stability and bioactivity of lanthipeptides prompted me to explore the possibility of 
using microbisporicin-tailoring enzymes for RiPP combinatorial biosynthesis. To achieve this 
objective, the substrate specificity of these enzymes required characterization. 
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Figure 5.2 Proposed Trp halogenation mechanism. The first step involves the reduction of FAD by a flavin 
reductase. The halogenase uses reduced flavin to generate a peroxy-(4a)flavin intermediate, which is central to 
catalysis by these enzymes. A hypohalite intermediate is then formed which subsequently is used by the halogenase 
to halogenate its substrate ref. (16). R, diphosphoribitol adenosyl. The corresponding Lys in MibH is Lys102. 
Figure 5.1 Proposed mechanism catalyzed by HFCD enzymes. FAD is utilized to oxidize a C-terminal Cys 
resulting in the formation of a thioaldehyde. This thioaldehyde serves as an electron sink and delocalizes the 
negative charge formed upon decarboxylation. During lanthipeptide biosynthesis, the enethiolate intermediate 
subsequently attacks a C-terminal dehydroamino acid forming the AviCys moiety. Dhx, dehydroalanine or 
dehydrobutyrine; AviCys, S-[(Z)-2-aminovinyl]-(3S)-D-cysteine; AviMeCys, S-[(Z)-2-aminovinyl]-(3S)-3-methyl-
D-cysteine.  
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Bioinformatic analysis of the microbisporicin biosynthetic gene cluster identified two 
genes coding for enzymes predicted to be responsible for the decarboxylation and halogenation 
of this peptide, respectively (6). One of the open reading frames (ORFs), mibD, codes for an 
enzyme that has sequence similarity to lanthipeptide decarboxylases (LanD) (7, 8). These 
enzymes belong to the homo-oligomeric flavin-containing Cys decarboxylase (HFCD) 
superfamily that employs a flavin cofactor (FAD or FMN) to catalyze the oxidative 
decarboxylation of C-terminal Cys-containing peptides. Decarboxylation proceeds via oxidation 
of a C-terminal Cys thiol to a thioaldehyde that subsequently serves to delocalize the negative 
charge developed at the former Cα upon decarboxylation (Figure 5.1) (9-13). Nucleophilic 
addition of the C-terminal enethiolate to a nearby dehydroamino acid within the core peptide 
yields the aforementioned AviCys moiety (Figure 5.1) (13). At present it is unclear whether this 
latter reaction is catalyzed by lanthipeptide decarboxylases, lanthipeptide cyclases or if it 
proceeds non-enzymatically. 
A second ORF, mibH, showed homology to flavin-dependent Trp halogenases (6). 
Members of this enzyme class catalyze Trp halogenations via the formation of a hypohalite. 
Reduced flavin is utilized by these halogenases to activate molecular oxygen, forming a 4a-flavin 
hydroperoxide intermediate. A halide ion performs a nucleophilic attack onto the distal oxygen 
atom of 4a-flavin hydroperoxide forming a hypohalite that subsequently transfers the halogen to 
a nearby conserved Lys residue within halogenases. This halogenated lysine is then believed to 
be responsible for the regiospecific halogenation of Trp (Figure 5.2) (14-16).  
 A separate enzyme supplies the reduced flavin needed by flavin-dependent halogenases. 
In some instances a gene coding for a flavin reductase is present near the halogenase gene. 
Within the microbisporicin biosynthetic gene cluster, mibS encodes a protein that showed 
sequence similarity to flavin reductases and it is presumably responsible for providing reduced 
flavin to MibH. Although bioinformatic analysis provided an initial description of these ORFs, 
the lack of biochemical characterization of MibD and MibH prevented their use in RiPP 
combinatorial biosynthesis. Fueled by the potential of these two enzymes to be used as tools for 
the generation of decarboxylated and halogenated peptide variants, I reconstituted both enzymes 
in vitro and characterized their substrate specificity using a variety of substrate analogs and 
bioinformatic approaches. 
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5.2. Results  
5.2.1. Characterization of MibD as a lanthipeptide Cys decarboxylase 
MibD was heterologously expressed in Escherichia coli as a hexahistidine (His6) tagged 
protein. Upon purification by Ni2+-NTA affinity chromatography, MibD exhibited a strong 
yellow color indicative of the presence of an oxidized flavin cofactor bound to the protein. To 
confirm the presence of bound flavin, ultraviolet-visible (UV/Vis) spectroscopy was performed 
on MibD after size exclusion chromatography. Indeed, the His6-MibD UV/Vis absorption 
spectrum revealed the presence of two absorption maxima at 380 nm and 452 nm characteristic 
of oxidized flavin (Figure 5.3a). HFCD enzymes are known to contain either FAD or FMN as 
cofactors (8, 11, 12). To identify the type of flavin cofactor present in His6-MibD, the purified 
protein was denatured, the flavin was purified by reversed phase solid phase extraction (RP-SPE) 
and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS). MALDI-TOF MS analysis indicated the presence of a species with an 
observed mass of 782.81 Da suggesting that FAD (theo. 785.56 Da) is the cofactor bound to 
His6-MibD (Figure 5.3b).  
 
 
Figure 5.3 Characterization of His6-MibD as an FAD containing enzyme. (a) UV/Vis absorption spectrum of 
MibD. Two absorption maxima, characteristic of oxidized flavin containing enzymes, are apparent. (b) MALDI-
TOF MS analysis of the cofactor isolated from MibD (top), or of an FAD standard solution (bottom). Average mass 
calc. [M+H]+ 786.56, obs. 783.81; average mass calc. [M+Na]+ 808.46, obs. 805.32. 
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To reconstitute the in vitro activity of MibD, enzyme assays were performed in the 
presence of the precursor peptide His6-MibA. Oxidative decarboxylation of His6-MibA was 
monitored by MALDI-TOF MS. Incubation of substoichiometric amounts of His6-MibD together 
with His6-MibA (10 fold excess) resulted in the appearance of a peak lower in mass (Figure 
5.4a). No starting material was observed after the reaction suggesting the reduced flavin formed 
upon decarboxylation must have been oxidized by O2 in order for MibD to be catalytically 
Figure 5.4 In vitro reconstitution of His6-MibD activity. (a-b) MALDI-TOF MS analysis of oxidative 
decarboxylation reactions after incubation with His6-MibD and either (a) precursor peptide His6-MibA, or (b) MibA 
core peptide. Top mass spectra represent a control reaction performed in the absence of His6-MibD. Bottom mass 
spectra represent an assay condition containing His6-MibD. M, starting material; OD, oxidative decarboxylation of 
starting material. (c) ESI-Q/TOF tandem MS/MS fragmentation analysis of MibA core peptide after modification by 
His6-MibD. Cys believed to be modified by MibD is shown in red. The presence of y ions carrying a difference of 
46 Da when compared to wt MibA suggests modification occurs at the C-terminus. For (a) M, average mass calc. 
[M+H]+ 8013, obs. 8022; OD, average mass calc. [M+H]+ 7967, obs. 7971. For (b) M, average mass calc. [M+H]+ 
2355, obs. 2356; OD, average mass calc. [M+H]+ 2309, obs. 2309. For (c) precursor parent ion monoisotopic mass 
calc. [M+H]+ 2307.90, obs. 2307.93. 
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competent. Enzyme activity was not dependent on the leader peptide since the MibA core 
peptide with its N-terminal leader peptide removed also displayed a loss of −46 Da when 
incubated with His6-MibD (Figure 5.4b). Tandem MS/MS analysis of the resulting product 
localized the modification to be at the C-terminus of the precursor peptide MibA (Figure 5.4c). 
Together these results suggest His6-MibD is responsible for catalyzing the oxidative 
decarboxylation of the precursor peptide MibA in a leader peptide independent manner. 
 
5.2.2. Characterization of the substrate specificity of MibD 
To determine the potential of MibD for RiPP combinatorial biosynthesis, its substrate 
specificity was assessed using several lanthipeptides containing a C-terminal Cys residue as 
substrates (Table 5.1). The extent of oxidative decarboxylation on these peptides was monitored 
by MALDI-TOF MS. His6-MibD was only active in the presence of its cognate substrate His6-
MibA. Even after long incubation periods His6-MibD was not active when using the different 
substrates shown in Table 5.1. This data suggests that His6-MibD does not tolerate substrates 
containing a different C-terminal amino acid sequence from the one present in the precursor 
peptide MibA (NCSFCC).  
 
 
Table 5.1 Substrates tested for decarboxylation by MibD. 
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5.2.3. Characterization of MibS as an NADH-dependent flavin reductase 
Flavin dependent halogenases require reduced flavin for activity. This cofactor can be 
obtained from the available cellular pool of reduced flavin or from a dedicated reductase forming 
a two-component halogenase system (14, 17). To probe whether MibS functions as a flavin 
reductase, the enzyme was heterologously expressed as a His6-tagged construct in E. coli. Initial 
expression attempts of the 20.9-kDa reductase resulted in insoluble protein. Co-expression 
experiments of MibS together with the E. coli chaperones GroES/EL afforded the production of 
enough soluble protein for further biochemical characterization. Upon purification by Ni2+-NTA 
chromatography, His6-MibS exhibited a strong yellow color characteristic of flavoproteins. The 
presence of flavin was corroborated when the His6-MibS UV/Vis absorption spectrum revealed 
the presence of two absorption maxima at 380 and 452 nm (Figure 5.5a). The bound flavin 
cofactor was isolated and identified as FAD by liquid chromatography electrospray ionization 
mass spectrometry (LC/ESI-Q/TOF MS) (Figure 5.5b). NAD(P)H oxidation assays, monitored 
by the decrease in absorbance at 340 nm, showed His6-MibS to be highly specific for NADH as 
an electron source with an apparent kcat of 198 min–1 and apparent Km for NADH of 80 µM 
(Figures 5.5c and 5.5d). The successful reconstitution of MibS as an NADH-dependent flavin 
reductase allowed the development of enzyme assays to study the halogenation reaction 
catalyzed by MibH. 
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Figure 5.5 Characterization of MibS as an NADH-dependent flavin reductase. (a) UV/Vis absorption spectrum 
of MibS. Two absorption maxima are apparent, which are characteristic of oxidized flavoproteins. (b) LC/ESI-
Q/TOF MS analysis of either an FMN standard solution (top), an FAD standard solution (middle), or the cofactor 
isolated from MibS (bottom). The presence of peaks corresponding to AMP and FAD suggests that the cofactor 
isolated from MibS is FAD. AMP, adenosine monophosphate, monoisotopic mass calc. [M+H]+ 348.22, obs. 
348.07; FMN, flavin mononucleotide, monoisotopic mass calc. [M+H]+ 457.34, obs. 457.08; FMN+Pi, flavin 
phospho-mononucleotide, monoisotopic mass calc. [M+H]+ 537.31, obs. 537.09; FAD, flavin adenine dinucleotide, 
monoisotopic mass calc. [M+H]+ 786.56, obs. 786.17. (c) Oxidation assays in the presence (red) or absence (black) 
of His6-MibS and NADH or in the presence of His6-MibS and NADPH (blue). Absorption at 340 nm was monitored 
to observe the extent of NAD(P)H consumption. (d) Kinetic characterization of His6-MibS. The initial rate of 
NADH consumption was monitored at 340 nm and plotted as a function of different NADH concentrations. The data 
was fit to the Michaelis–Menten equation to give the parameters shown, presented as the average ± standard error of 
three independent experiments. 
 122 
5.2.4. Chlorination of deschloromicrobisporicin by MibH in the presence of MibS 
Initial attempts to express MibH as a hexahistidine tagged protein in E. coli resulted in 
insoluble protein. Similar to His6-MibS, soluble protein was obtained after co-expression of his6-
mibH with the E. coli chaperones GroES/EL. Interestingly, during His6-MibH purification, the 
nickel column turned yellow, a color that is characteristic of flavoproteins. However after 
washing the column with low imidazole concentrations to remove non-specifically bound 
proteins, the yellow color was removed from the column while His6-MibH remained bound to 
the resin. This observation suggests that MibH has weak binding affinity for oxidized flavin 
cofactor. No observed flavin was present following purification of His6-MibH.  
Previous transcriptomic analysis of the microbisporicin native producer Microbispora sp. 
107891 revealed that microbisporicin biosynthesis commences with the production of deschloro-
deshydroxyl microbisporicin (a microbisporicin analog lacking hydroxylation and chlorination) 
(Figure 3.1b). Deschloro-deshydroxyl microbisporicin activates a dedicated sigma factor needed 
for the transcription of additional microbisporicin biosynthetic genes including mibH (18). Thus 
MibH presumably acts at a later stage of microbisporicin biosynthesis, chlorinating the modified 
(dehydrated, cyclized, and decarboxylated) MibA core (for further details into microbisporicin 
biosynthesis see Chapter 3). Initial MibH activity assays were performed using 
deschloromicrobisporicin as a substrate. This microbisporicin analog contains all post-
translational modifications characteristic of microbisporicin except 5-chlorotryptophan. 
Deschloromicrobisporicin was kindly provided by our collaborator Dr. Stefano Donadio 
(Ktedogen) as a mixture of bishydroxylated and monohydroxylated material. (Figure 5.6, peak 
1). LC/ESI-Q/TOF MS analysis of halogenation assays performed in the presence of MibH/MibS, 
FAD, NADH, NaCl and deschloromicrobisporicin revealed the formation of additional product 
peaks (Figure 5.6). Close inspection of the isotopic distribution of each peak (Figure 5.6, peaks 
2, 3, and 4) suggested successful chlorine incorporation into all of the observed products (Figure 
5.6). Analysis of peak 2 gave an [M+2H]2+ value of 1124.40 m/z and 1116.41 m/z, consistent 
with the formation of chlorinated bishydroxylated and monohydroxylated microbisporicin 
(Figure 5.6). The additional peaks 3 and 4 were mass adducts of +12 Da and +42 Da of the 
chlorinated final product, respectively, as observed for the characteristic isotopic distribution of 
chlorine containing compounds. The origin and identity of these adducts is still unknown and 
warrants further characterization.  
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5.2.5. Characterization of the substrate specificity of MibH 
The successful reconstitution of MibH activity in vitro allowed for the determination of 
its substrate specificity. All flavin dependent halogenases characterized to date are capable of 
halogenating either free Trp, Trp analogs or substrates bound to peptidyl carriers such as 
coenzyme A or peptidyl carrier proteins (PCP) (17, 19, 20). To determine if indeed MibH is 
capable of chlorinating free Trp, halogenation assays were performed using free Trp as a 
substrate. The extent of halogenation was assessed by MALDI-TOF MS analysis. Regardless of 
the conditions tested, halogenation activity was not detected (Table 5.2). This result suggests 
that MibH only recognizes Trp within the context of a peptide backbone thus making this 
enzyme the first characterized halogenase exhibiting specificity for Trp within a polypeptide.  
The potential of using MibH as a general peptide Trp halogenase was tested using several 
microbisporicin analogs containing a varying degree of post-translational modifications, 
including the A & B rings of microbisporicin (entry 10), provided by previous group member Dr. 
Figure 5.6 LC/ESI-MS analysis of halogenation reactions catalyzed by MibH. (left) Total ion chromatogram 
(TIC) of halogenation reactions preformed in the presence (bottom) or absence (top) of His6-MibH. The red number 
on top of each peak serves as an identifier. Expected chlorinated product (peak 2). Unidentified chlorinated products 
(peak 3 and 4). (right) ESI-Q/TOF MS analysis corresponding to each peak identified on the TIC. Black numbers on 
top of each family of peaks represent the [M+2H]2+ m/z value. Monohydroxylated, deschloromicrobisporicin 
monoisotopic mass calc. [M+2H]2+ 1099.41, obs. 1099.40; bishydroxylated deschloromicrobisporicin monoisotopic 
mass calc. [M+2H]2+ 1107.41, obs. 1107.39; monohydroxylated microbisporicin, monoisotopic mass calc. [M+2H]2+ 
1116.39, obs. 1116.41; bishydroxylated microbisporicin, monoisotopic mass calc. [M+2H]2+ 1124.39, obs. 1124.40; 
monohydroxylated microbisporicin +12 Da, monoisotopic mass obs. [M+2H]2+ 1122.38; bishydroxylated 
microbisporicin +12 Da, monoisotopic mass obs. [M+2H]2+ 1130.36; monohydroxylated microbisporicin +42 Da, 
monoisotopic mass obs. [M+2H]2+ 1137.35 m/z; bishydroxylated microbisporicin +42 Da, monoisotopic mass obs. 
[M+2H]2+ 1145.37. 
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Table 5.2 Substrates tested for halogenation by MibH 
Figure 5.7 Structural representation of the lanthipeptide analogs used as substrates to determine the 
substrate specificity of the halogenase MibH. Each bubble represents an amino acid. Each ring is labeled with an 
alphabet letter. 
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Subha Mukherjee  (Figure 5.7). Surprisingly MibH accepted none of the substrates tested (Table 
5.2). Additionally, halogenation assays using lanthipeptides like mutacin 1140 (entry 9) (kindly 
provided by Prof. Smith at Texas A&M University), which contains a Trp at the same location as 
microbisporicin, also resulted in no detectable halogenation.  
 
5.2.6. MibH crystallization attempts 
To obtain structural insights into the observed MibH substrate specificity, crystallization 
of MibH was attempted. Conditions suitable for protein crystal growth were identified from high 
throughput crystallization screening assays. One of the conditions that allowed crystal growth 
consisted of 0.08 M Tris HCl pH 8.5, 0.16 mM MgCl2, 20% glycerol, 24% PEG 4000 and 10 mg 
mL–1 His6-MibH. While the crystals obtained under this condition showed a good diffraction 
pattern, the size of the crystal prevented the acquisition of a full diffraction data set. Efforts 
aimed at increasing crystal size are needed to fully elucidate the crystal structure of MibH.  
 
5.3. Discussion 
The different post-translational modifications present in RiPPs endow these peptides with 
numerous biological activities such as antifungal, antibacterial and antiviral (21). This 
observation has led several research groups to utilize the different enzymes responsible for 
catalyzing RiPP post-translational modifications as tools to generate peptide variants with 
improved therapeutic properties. To demonstrate such potential Moll and coworkers were among 
the first to utilize the lanthipeptide biosynthetic machinery to introduce thioether crosslinks on 
non-cognate therapeutic peptides (1). Since then, only a limited set of RiPP post-translational 
modifications has been used for combinatorial biosynthesis (3, 22-24). The beneficial biological 
properties associated with compounds containing either AviCys rings or halogenated residues 
make the availability of these two post-translational modifications within the “chemical toolbox” 
for RiPP combinatorial biosynthesis highly desirable (25, 26). 
Activity assays demonstrated that the flavoprotein MibD is responsible for 
decarboxylation of Cys24 present in the microbisporicin precursor peptide. Decarboxylation is a 
prerequisite for AviCys formation. However the lack of activity observed for MibD when using 
different substrates containing a C-terminal Cys precluded the use of this enzyme for RiPP 
combinatorial biosynthesis. To obtain further insights into the type of substrates recognized by 
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these enzymes, the non-redundant protein database was searched for lanthipeptide 
decarboxylases. Close inspection of the precursor peptides associated with each lanthipeptide 
decarboxylase revealed that these LanAs can be classified into three different groups based on 
their putative ring topologies (Figure 5.8a). Irrespective of the group, each substrate peptide had 
a similar C-terminal ring topology with the consensus sequence S-F-N-(S/C)-S-(F/Y/W)-C-C   
(Figure 5.8a). The lack of variation within this sequence suggests that lanthipeptide 
decarboxylases have evolved to recognize this motif and not only the C-terminal Cys. All of the 
non-cognate substrates used in this study do not contain this motif, which explains the lack of 
activity observed for MibD.  
To provide information as to what residues within this sequence might be crucial for 
recognition by MibD, a structural homology model of MibD in complex with the pentapeptide 
DSYTC was generated based on the co-crystal structure of the lanthipeptide decarboxylase, 
Figure 5.8 Insights into the substrate specificity of lanthipeptide decarboxylases. (a) Sequence alignment of 
selected lanthipeptide precursor peptides from gene clusters containing lanthipeptide decarboxylases. Dehydratable 
residues are shown in blue while Cys residues are shown in red. Putative ring topologies are drawn on top of each 
group based on the topology of characterized lanthipeptides. (b) Structural homology model of the lanthipeptide 
decarboxylase MibD in complex with the pentapeptide DYSTC based on the available EpiD crystal structure (PDB 
ID 1G5Q). The pentapeptide DSYTC is shown as green sticks. The numbering used reflects microbisporicin core 
residues. The flavin cofactor is shown as yellow sticks. MibD surface representation is colored based on 
hydrophobicity. 
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EpiD in complex with the peptide DSYTC  (PDB ID 1G5Q)  (Figure 5.8b) (11). Within the 
model the pentapeptide substrate is bound to the enzyme mainly through hydrophobic 
interactions. While the five residues (DSYTC) make direct contact with MibD it is apparent that 
any additional amino acid extending towards the N-terminus would not contribute to binding 
since the rest of the peptide would be solvent exposed (Figure 5.8b). This provides an 
explanation as to why MibD does not require the leader peptide for catalysis since only the C-
terminal portion of the peptide is important for MibD binding. The pentapeptide’s C-terminal 
Cys (P24) is in close proximity to the C-4a of the flavin isoalloxazine ring. This observation is 
not surprising since this Cys residue undergoes an oxidization step before decarboxylation. In 
addition, the phenol ring of Tyr 22 is positioned within a hydrophobic pocket within MibD. It is 
noteworthy that all of the lanthipeptide precursor sequences associated with lanthipeptide 
decarboxylases contain an aromatic residue at this position, perhaps reflecting its importance for 
binding interactions between the substrate peptide and decarboxylase.  
To date two additional lanthipeptide decarboxylases have been characterized: EpiD and 
MrsD (7, 8, 11, 12, 27). EpiD and MrsD are involved in the oxidative decarboxylation of the 
lanthipeptides epidermin and mersacidin, respectively. Similar to MibD, MrsD did not 
demonstrated appreciable substrate tolerance. In contrast, EpiD was capable of decarboxylating a 
variety of substrates containing the C-terminal sequence (V/I/L/M/F/Y/W)-(A/S/V/T/C/I/L)-C 
making it a more attractive target for RiPP combinatorial biosynthesis compared to either MibD 
or MrsD (28). Although all three LanD enzymes are functionally similar, it is still not clear what 
elements confer the substrate tolerance of EpiD. Regardless, based on the results presented in 
this chapter, an alternative to employ MibD in RiPP combinatorial biosynthesis would be to 
incorporate the MibD recognition sequence, NSFCC, within the C-terminus of a target peptide. 
Similar to MibD, the halogenase MibH also exhibited high substrate specificity. While 
the lack of MibH activity on different substrate analogs prevents the use of this enzyme for RiPP 
combinatorial biosynthesis, this study helped to identify MibH as the first peptide halogenase 
characterized to date. MibH activity could only be reconstituted when using dehydrated and 
cyclized deschloromicrobisporicin containing a C-terminal AviCys ring. The lack of activity 
observed on substrates carrying a C-terminal lanthionine ring (lacking decarboxylation) or 
substrates carrying just the A and B rings of deschloromicrobisporicin (synthesized by previous 
group member Dr. Subha Mukherjee (29)) suggests MibH recognizes the C-terminal portion of 
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deschloromicrobisporicin. This result was not expected given that many of the RiPP biosynthetic 
enzymes that do not require the leader peptide for activity in general displayed high substrate 
tolerance (2, 30). Although mutacin 1140 has the same A and B rings as microbisporicin, as well 
as a C-terminal AviCys ring, MibH failed to halogenate this lanthipeptide as well. Since the N-
terminal sequence present in mutacin 1140 and deschloromicrobisporicin is different, it is not 
clear whether the lack of halogenation is due to this different amino acid sequence or due to the 
absence of an internal lanthionine ring in mutacin 1140 (Figure 5.7). Further experiments are 
needed to probe this observation. 
Phylogenetic reconstruction using Maximum likelihood methods (ML), of the different 
flavin-dependent halogenases that have been biochemically or structurally characterized to date 
reveals two main clades (Figure 5.9a). Upon closer inspection, the ML tree shows a strong 
correlation between the distribution of halogenases and their substrate specificity. One clade is 
formed by proteins known to halogenate pyrrole, phenyl, alkynyl and alkyl groups of substrates 
Figure 5.9 Insights into the substrate specificity of flavin-dependent Trp halogenases. (a) Maximum likelihood 
phylogenetic unrooted tree of various characterized flavin-dependent halogenases. Support for each clade is 
indicated by bootstrap percentage values. The name of each terminal branch corresponds to the name of the 
halogenase. Tree is colored based on substrate specificity. Green, halogenases that act on tethered substrates; blue, 
halogenases that act on peptides; red, halogenases that act on free Trp. Two flavin monooxygenases were used as 
outgroup. (b) Structural homology model of MibH based on the crystal structure of RebH (PDB ID 2OA1). α helices 
are shown in purple, β sheets are shown in green and flexible loops are shown in yellow. Predicted cavities are 
shown in red. 
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tethered to a bound carrier (either a protein or coenzyme A) (Figure 5.9a, Green) (19, 31-33). 
These halogenases are present within assembly lines like non-ribosomal peptide synthetases 
(NRPS) pathways and are responsible for halogenating a tethered building block that is 
subsequently incorporated into a final molecule (19, 31). MibH belongs to the same clade as Trp 
halogenases known to halogenate free Trp. This observation suggests MibH shares a closer 
evolutionary relationship with this type of halogenases. However the early divergence of MibH 
suggests that it is part of a separate subfamily, perhaps reflecting its ability to halogenate Trp 
embedded within a peptide substrate (Figure 5.9a, blue). The phylogenetic inference displayed 
by these enzymes could prove to be helpful at predicting the substrate specificities of 
uncharacterized halogenases. However, biochemical characterization of additional flavin 
halogenases is needed to further increase the reliability of this phylogenetic analysis. 
Structural studies of MibH in complex with its substrate peptide are needed to elucidate 
the major interactions responsible for determining MibH substrate specificity. While conditions 
have been identified suitable for protein crystal growth, MibH crystals were too small for 
structure elucidation. However, the sequence homology shared with additional Trp halogenases 
allowed for the generation of a MibH structural homology model based on the crystal structure 
of the flavin-dependent Trp halogenase RebH (PDB ID 2OA1) (34). RebH is responsible for the 
formation of 7-chlorotryptohan during the biosynthesis of the antitumor compound rebeccamycin 
(35). Two cavities are apparent in the homology model (Figure 5.9b). One of the cavities is 
present in all other flavin-dependent Trp halogenases structurally characterized to date and is 
mainly involved in accommodating the flavin cofactor (17, 31, 34, 36). Intriguingly a second 
cavity of ~ 150 Å3, near the predicted MibH active site, is apparent below a two-stranded 
antiparallel β sheet (Figure 5.9b). This additional cavity is not observed in other flavin-
dependent Trp halogenases known to halogenate free Trp. Presumably this cavity could serve to 
accommodate the A ring of deschloromicrobisporicin. The antiparallel β sheet seen in MibH 
could then position the N-terminus of deschloromicrobisporicin in an orientation suitable for 
catalysis via binding interactions with the C-terminal rings of this substrate. This could explain 
the lack of MibH activity observed when using substrates either lacking the microbisporicin’s A 
and B or the C-terminal rings. Future structural studies are needed to further corroborate this 
model.  
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Previously characterized flavin-Trp halogenases do not show appreciable relaxed 
substrate specificity. Several methodologies like directed evolution have been applied to expand 
the substrate scope of these enzymes (37-39). For example, RebH has been reprogrammed to 
halogenate unnatural substrates like plant alkaloid products (40). However this approach still 
relies on using Trp analogs or closely related compounds as substrates. This methodology results 
in the need of halogenating Trp building blocks rather than the final molecule containing Trp. 
While these methods indeed show promise for the halogenation of unnatural substrates, the 
methodology is limited by the capability of downstream biosynthetic enzymes recognizing the 
halogenated Trp building block. The characterization of MibH as a peptide halogenase opens the 
possibility of creating a catalyst capable of halogenating Trp embedded within peptides. MibH 
could be utilized as a starting point for selection experiments with the aim of increasing this 
enzyme’s substrate tolerance (39).  
In conclusion, while MibD and MibH showed high substrate specificities, hampering 
their use for combinatorial biosynthesis, the biochemical characterization presented herein sets 
the stage to engineer both catalysts to accept a wider range of substrates. 
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5.4. Methods 
General Methods 
Oligonucleotides used in this chapter were purchased from Integrated DNA Technologies 
Inc. (Coralville, IA). Reagents used for molecular biology were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Chemicals were purchased from Sigma-Aldrich (St. Louis, MO). E. coli DH5α 
and BL21 (DE3) strains were used for plasmid maintenance and protein overexpression 
respectively. For overexpression and coexpression experiments, plasmids were first purified 
using the QIAPrep Spin Miniprep kit (Qiagen, USA), from E. coli NEB-5 alpha cells and 50 ng 
of DNA was used to transform 50 µL of E. coli BL21 (DE3) or Rosetta2 cells using a 
MicroPulser Electroporator (BioRad, USA) in 0.1 cm cuvettes according to the manufacturer’s 
protocol. After transformation, cells were incubated in 950 µL of SOC media (20 g/L Bacto 
Tryptone, 5 g/L Bacto Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose) at 37 °C for 1 h. After the incubation period, 50 µL of cells were plated 
on Luria Bertani agar (LBA) supplemented with the appropriate antibiotics and incubated at 37 
°C overnight (O/N). PCRs were performed on a C1000TM thermal cycler (Bio-Rad). For primer 
sequences see Table 5.3. Plasmid inserts were sequenced at ACGT Inc. (Wheeling, IL). 
MALDI-TOF MS analysis was performed using a Bruker UltrafleXtreme MALDI TOF-TOF 
mass spectrometer (Bruker Daltonics) in reflective mode at The University of Illinois Mass 
Spectrometry laboratory unless otherwise noted. MS data was analyzed using the flexAnalysis 
software package from Bruker. Spectra were exported, normalized and plotted using Microsoft 
Excel. All biochemical assays were performed with hexahistidine tagged substrates and 
enzymes.  
 
Table 5.3 Primers used in this study 
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Cloning, overexpression and purification of His6-MibD 
The gene encoding MibD was amplified by PCR from a template provided by a previous 
group member Dr. Neha Garg, using a forward primer containing an NdeI restriction site 
(mibD.NdeI.F) and a reverse primer containing an XhoI restriction site (mibD.XhoI.R). PCR 
amplification reactions were performed in a 20 µL volume (1× HF Buffer, 0.2 mM DNTPs, 0.5 
µM forward and reverse primers each, 50 ng DNA template, 3% DMSO and 0.02 U µL–1 
Phusion high-fidelity DNA polymerase, NEB, USA). The PCR conditions consisted of an initial 
denaturation at 98 °C for 30 s followed by a cycle of 34 repetitions consisting of [98 °C for 10 s, 
61 °C for 30 s, 72 °C for 19 s] with a final extension period at 72 °C for 10 min. The amplified 
DNA was purified using the QIAGEN (QIAGEN, USA) gel extraction kit according to the 
manufacturer’s protocol. The PCR product and the vector pET28a were digested using restriction 
endonucleases NdeI and XhoI (NEB, USA) in a 50 µL reaction (1× NE Buffer 4, 1× BSA, 1 µg 
DNA, and 0.1 U µL–1 of each restriction endonuclease) for 2.5 h at 37 °C. After the incubation 
period, the digestion containing pET28a was dephosphorylated using 1 µL of calf intestine 
phosphatase (CIP) at 37 °C for 0.5 h. Products were run on a 1% agarose gel, purified by gel 
extraction and ligated in a 20 µL reaction (1× T4 DNA ligase Buffer, 40 ng pET28a, 1:3 vector: 
insert ratio, 1 µL of T4 DNA ligase, NEB, USA) overnight (O/N) at 16 °C. An aliquot of 5 µL of 
the ligation was used to transform 50 µL of chemically competent E. coli NEB-5 alpha cells 
according to the manufacturer’s protocol. The cells were then plated on Luria-Bertani agar 
(LBA) plates supplemented with kanamycin (kn, 50 µg mL–1) and incubated at 37 °C O/N. To 
confirm the presence of the correct insert, plasmids were purified as described above and sent for 
sequencing (ACGT Inc., USA). 
For heterologous overexpression, 50 µL of recombinant pET28a-his6-mibD was used to 
transform electrocompetent E. coli BL21 (DE3) Rosetta2 cells as described above. A single 
colony was used to inoculate a starter inoculum of 25 mL of LB supplemented with kanamycin 
(kan, 25 µg mL–1), chloramphenicol (cm, 12.5 µg mL–1) and glucose (50 mM, Sigma, USA) for 
12 h at 37 °C. Overexpression was performed in 2 L of TB supplemented with glycerol (4 mL L–
1 of TB), kan (25 µg mL–1), and cm (12.5 µg mL–1) with a starter OD600 of 0.025. Cultures were 
incubated at 37 °C, with shaking at 250 rpm and protein expression was induced with 0.3 mM 
IPTG at an OD600 of ~0.6. Induction was performed at 18 °C, 250 rpm for 16 h. 
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Cells were harvested by centrifugation (6976 × g, 25 min, 4 °C) and resuspended in 50 
mL of lysis buffer (20 mM Tris HCl pH 8.0, 150 mM NaCl, 5 mM imidazole) supplemented 
with one tablet of EDTA-free complete protease inhibitor (Roche) and lysed using an 
EmulsiFlex-C3 homogenizer (Avestin Inc., DE) with a pressure of less than 2.5 kbar. The lysed 
fraction was centrifuged (22,789 × g, 4 °C, 30 min) and the supernatant was clarified through a 
0.45 µm syringe-tip filter. The protein was purified by immobilized metal affinity 
chromatography (IMAC) using an ÄKTA purifier equipped with a 5 mL HisTrap column pre-
packed with Ni SepharoseTM according to the manufacturer’s protocol. After loading the 
supernatant into the column, the column was washed with lysis buffer until a stable baseline at 
280 nm was reached and the protein was eluted with a linear gradient from 0–100% v/v of 
elution buffer (20 mM Tris HCl pH 8.0, 500 mM NaCl, 250 mM imidazole and 10 % v/v 
glycerol) in lysis buffer over 30 min. Collected fractions were analyzed by SDS-PAGE and 
visualized by Coomassie staining. Fractions containing desired His6-MibD were collected and 
concentrated using an Amicon Ultra centrifuge tube of 30-kDa molecular weight cutoff 
(MWCO) (4,000 × g, 4 °C, 30 min). Imidazole was removed by size exclusion chromatography 
(SEC) using a HiLoad 16/60 column packed with Superdex 200 Prep Grade on an ÄKTA 
purifier at 4 °C eluting at 1 mL min–1 using SEC buffer (20 mM Tris HCl pH 8.0, 500 mM NaCl, 
and 10% glycerol). Protein was monitored at 280 nm, fractions were analyzed by SDS-PAGE, 
and visualized by Coomassie staining. Fractions containing protein of interest were pooled 
together and concentrated to 3.4 mg mL–1 using an Amicon Ultra centrifuge tube with a 10-kDa 
MWCO (4,000 × g, 30 min, 4 °C). Aliquots were frozen in liquid nitrogen and stored at  –80 °C  
for future use.  
 
Cloning, overexpression and purification of His6-MibA 
See Chapter 3 for a detailed description of the procedure. 
 
Characterization of the cofactor bound to His6-MibD 
The UV/Vis absorption spectrum of His6-MibD was recorded on a NanoDrop 2000c 
spectrophotometer (Thermo Scientific, USA) using a wavelength scan from 280 nm to 750 nm. 
To identify the flavin cofactor, an aliquot of 10 µL of a 140 µM solution of His6-MibD was 
denatured at 98 °C for 10 min. Precipitated protein was then removed by centrifugation (10,000 
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× g, 10 min, 25 °C) and the released flavin was purified by reversed phase solid phase extraction 
(RP-SPE) using a zip-tip concentrator (Millipore) following the manufacturer’s protocol. The 
purified flavin cofactor was mixed in a 1:1 ratio with α-cyano-4-hydroxycinnamic acid matrix 
and analyzed by MALDI-TOF MS using a Voyager-DE STR instrument. 
 
In vitro reconstitution of MibD activity and characterization of its substrate specificity 
For in vitro reconstitution experiments, His6-MibD (10 µM) was incubated with 150 µM 
linear His6-MibA at room temperature for 2 h in 100 µL of reaction buffer (20 mM Tris HCl pH 
8.0, and 3 mM DTT). The reaction was purified using a zip-tip concentrator to remove any 
excess salts, mixed in a 1:1 ratio with α-cyano-4-hydroxycinnamic acid and analyzed by 
MALDI-TOF MS using a Voyager-DE STR. To determine the importance of the N-terminal 
leader sequence for oxidative decarboxylation, 80 µM linear His6-MibA was incubated with 
trypsin (Worthington Biochemical Corp., USA) in a 1:10 ratio (trypsin:peptide) in 100 µL of 
trypsin buffer (100 mM Tris HCl pH 8.0, 5 mM TCEP, 2 mM MgCl2) and incubated for 3 h at 
room temperature. Removal of the N-terminal leader sequence was monitored by MALDI-TOF 
MS analysis as described above. After complete N-terminal leader sequence removal, His6-MibD 
(2 µM) was added to the reaction and the solution was incubated for 15 min at room temperature. 
Analysis of the reaction was performed by MALDI-TOF MS as described above. To determine 
the localization of the post-transitional modification an aliquot of 10 µL of the reaction mixture 
was injected into an Acquity UPLC Phenomenex Jupiter C18 column (5 µm, 0.1 × 150 mm) 
coupled to an electrospray ionization mass spectrometer (Q-TOF Synapt-G1 Waters in positive 
ion scan mode using manufacturer’s conditions for tandem MS/MS fragmentation). The sample 
was fractionated using a linear gradient from 2% v/v solvent A (0.1% v/v formic acid in 
acetonitrile) in 98% v/v solvent B (0.1% v/v formic acid in water) to 98% v/v solvent A over 20 
min.  
To characterize the substrate specificity of His6-MibD several lanthipeptide precursor 
peptides (Table 5.2) were used as substrates following the same reaction conditions as described 
above. Prochlorosin precursor peptides were provided by group member Dr. Gabrielle 
Thibodeaux. Oxidative decarboxylation was monitored by MALDI-TOF MS analysis using a 
Voyager-DE STR. 
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Cloning, overexpression and purification of His6-MibS 
The gene encoding MibS was amplified by PCR from a template (pET15-mibS), provided 
by a previous group member, Dr. Neha Garg, in a 20 µL reaction (1× HF Buffer, 0.2 mM DNTPs, 
0.5 µM forward and reverse primers each, 50 ng DNA template, 3% DMSO and 0.02 U µL–1 
Phusion high-fidelity DNA polymerase, NEB, USA) using a forward primer containing an NdeI 
restriction site (mibS.NdeI.F) and a reverse primer containing an XhoI restriction site 
(mibS.XhoI.R). The PCR conditions consisted of an initial denaturation step at 98 °C for 30 s 
followed by a cycle of 34 repetitions consisting of [98 °C for 10 s, 60 °C for 30 s, 72 °C for 18 s] 
with a final extension period at 72 °C for 10 min. The amplified DNA was purified using the 
QIAGEN (QIAGEN, USA) gel extraction kit according to the manufacturer’s protocol and 
cloned into pET28a using a similar procedure as described above but using appropriate 
restriction endonucleases.  
An aliquot of 50 ng of pET28a-MibS and pGro7 (arabinose inducible promoter 
containing E. coli chaperones groEL/ES, Takara, China) was used to co-transform 50 µL of 
electrocompetent E. coli BL21 (DE3) cells as described above. After the incubation period, cells 
were plated on LBA plates supplemented with kan (25 µg mL–1) and cm (12.5 µg mL–1) at 37 °C 
O/N. A single colony was used to inoculate a starter inoculum of 25 mL of LB supplemented 
with kan, cm, and glucose (50 mM, Sigma, USA) for 12 h at 37 °C. Overexpression was 
performed on 2 L of Terrific Broth (TB, Fisher Scientific, USA) containing glycerol (4 mL L–1 
of TB), kan, and cm with a starter OD600 of 0.025. Cultures were incubated at 37 °C, with 
shaking at 250 rpm until the OD600 reached ~0.6. At this OD, cultures were chilled on ice for 15 
min and protein expression was induced with 0.2 mM isopropyl-β-D-1-thiogalactopyranoside 
(IPTG, GoldBio, USA) and 0.4% w/v L(+)-arabinose. Overexpression was performed at 25 °C 
O/N. 
Protein purification was performed as described for His6-MibD but with different buffer 
conditions. The IMAC lysis buffer consisted of 20 mM Tris HCl pH 8.0, 500 mM NaCl, and 
10% v/v glycerol. The IMAC elution buffer consisted of 20 mM Tris HCl pH 8.0, 1 M NaCl, and 
500 mM imidazole). After IMAC purification His6-MibS was further purified by size exclusion 
chromatography using a similar procedure as described above. The buffer used for size exclusion 
chromatography consisted of 20 mM HEPES pH 7.5, 300 mM NaCl, and 10 % v/v glycerol. 
Protein was concentrated using a 10-kDa MWCO Amicon concentrator (4,000 × g, 20 min, 4 °C). 
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Final protein concentrations were determined on a NanoDrop 2000c spectrophotometer using an 
extinction coefficient at 280 nm of 22,710 M–1 cm–1 and a molecular weight of 20.773-kDa. 
Aliquots were frozen in liquid nitrogen and stored for future use. 
 
Identification of FAD as the flavin cofactor bound to MibS 
The UV/Vis absorption spectrum of His6-MibS was recorded on a NanoDrop 2000c 
spectrophotometer using a wavelength scan from 280 nm to 750 nm. His6-MibS was denatured at 
98 °C for 10 min to release bound flavin. Precipitated protein was removed by centrifugation and 
the released flavin was purified by RP-SPE as described above. Purified flavin (10 µL) was 
injected into an Acquity UPLC Phenomenex Jupiter C18 column (5 µm, 0.1 × 150 mm) coupled 
to an electrospray ionization mass spectrometer (Q-TOF Synapt-G1 Waters in positive ion scan 
mode using manufacturer’s conditions). The sample was fractionated using a linear gradient 
from 2% v/v solvent A (0.1% v/v formic acid in acetonitrile) in 98% v/v solvent B (0.1% v/v 
formic acid in water) to 98% v/v solvent A over 40 min. Similar conditions were used to analyze 
FMN and FAD standard solutions. 
 
Kinetic characterization of His6-MibS 
To determine the electron donor utilized by His6-MibS, NAD(P)H consumption assays 
were performed by measuring the decrease in absorbance at 340 nm (ε340 = 6,220 M–1 cm–1) on a 
Cary 4000 UV/Vis spectrophotometer (Agilent). Reaction conditions consisted of 1 µM MibS, 
20 mM sodium phosphate buffer pH 7.4, 10 mM NaCl, 50 µM FAD, and 0.16 mM NADH or 
NADPH. Kinetic characterization of His6-MibS was performed using continuous assays as 
described above. Reaction conditions consisted of 100 nM MibS, 20 mM sodium phosphate 
buffer pH 7.4, 10 mM NaCl, 50 µM FAD, and various concentrations of NADH that range from 
10–800 µM. Initial rates were calculated from the slope obtained within the portion of the graph 
where less than 10% of substrate was consumed. These initial rates were then plotted as a 
function of NADH concentration and fitted to the Michaelis–Menten equation. Kinetic 
experiments were performed in triplicates. 
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Cloning, overexpression and purification of His6-MibH 
The gene encoding MibH was amplified by PCR from a template provided by previous 
group member Dr. Neha Garg, using a forward primer containing an NdeI restriction site 
(mibH.NdeI.F) and a reverse primer containing an XhoI restriction site (mibH.XhoI.R). Cycle 
conditions used for the amplification were the same as described above using an annealing 
temperature of 55 °C for 30 s and an extension time of 51 s. The PCR product and the vector 
pET28a were digested using NdeI and XhoI restriction endonucleases and products were ligated 
and used to transform chemically competent E. coli cells as described before. Sequencing of the 
insert was performed by ACGT Inc. to verify sequence integrity. 
For heterologous overexpression, 50 ng of recombinant pET28a-his6-mibH and 50 ng of 
pGro7 (Takara, China) were used to co-transform electrocompetent E. coli BL21 (DE3) cells as 
described above. Conditions for protein overexpression and purification were similar to the ones 
already described above for the expression and purification of His6-MibS. 
 
Reconstitution of MibH activity in vitro and characterization of its substrate specificity 
MibH activity assays were performed using the following conditions: 20 mM sodium 
phosphate buffer pH 7.4, 10 mM NaCl, 5 µM FAD, 5 µM His6-MibS, 5 µM His6-MibH, and 50 
µM deschloromicrobisporicin. Reactions were initiated by the addition of 5 mM NADH. 
Halogenation assays were incubated at 30 °C for 2 h. After the incubation period, samples were 
centrifuged (13,000 × g, 10 min, 25 °C) to remove insoluble material and analyzed by LC/ESI-
MS on an Aquity UPLC system coupled to an electrospray ionization Q-TOF Synapt-G1 mass 
spectrometer (Waters). LC/ESI-Q/TOF MS conditions used were similar to the ones already 
described above. To characterize the substrate specificity of MibH, several substrates (Table 5.2) 
were tested for halogenation activity using similar reaction conditions as described above. 
Samples were then centrifuged to remove insoluble material and desalted using a C18 zip-tip 
concentrator following standard procedures. An aliquot of the sample was mixed in a 1:1 ratio 
with 2, 5-dihydroxybenzoic acid matrix and the extent of halogenation was analyzed using a 
Bruker UltrafleXtreme MALDI TOF-TOF mass spectrometer. Expression and purification of 
deschloromicrobisporicin analogs used is described in Chapter 3. The peptide containing the N 
terminal A and B rings of microbisporicin was chemically synthesized by previous group 
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member Dr. Subha Mukherjee (29). Mutacin 1140 was kindly provided by Prof. James Smith at 
Texas A&M University 
 
Phylogenetic analysis of flavin-dependent halogenases 
Amino acid sequences of selected, characterized halogenases (Table 5.4) were retrieved 
from the NCBI database and aligned using the PRALINE algorithm (41). The evolutionary 
history was inferred by using the Maximum Likelihood method based on the Whelan And 
Goldman model (42). The tree with the highest log likelihood (-15769.4650) is shown. Initial 
tree(s) for the heuristic search were obtained by applying the Neighbor-Joining method to a 
matrix of pairwise distances estimated using a Jones-Taylor-Thornton (JTT) model. A discrete 
Gamma distribution was used to model evolutionary rate differences among sites (5 categories 
(+G, parameter = 1.8946)). The rate variation model allowed for some sites to be evolutionarily 
invariable ([+I], 0.000% sites). The tree is drawn to scale, with branch lengths measured in the 
number of substitutions per site. The analysis involved 16 amino acid sequences. There were a 
total of 766 positions in the final dataset. Evolutionary analyses were conducted in MEGA6 (43). 
 
 
 
 
Table 5.4 Halogenases used for phylogenetic analysis. 
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Generation of structural homology models 
Structural homology models for MibD and MibH were generated using the I-TASSER 
suite (44) using EpiD (PDB 1G5Q) and RebH (2OA1) as templates. Visualization was performed 
using PymoL. 
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